

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/08401 A2

WO 02/08401 A2


Published:
without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guide
to the Patent Cooperation Treaty" appearing at the beginning
of each regular issue of the PCT Gazette.

- (51) International Patent Classification: C12N 9/00
- (21) International Application Number: PCT/US01/23259
- (22) International Filing Date: 24 July 2001 (24.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/624,670 24 July 2000 (24.07.2000) US
09/903,456 11 July 2001 (11.07.2001) US
- (71) Applicant: ABBOTT LABORATORIES [US/US];
D377 AP6D, 100 Abbott Park Road, Abbott Park, IL,
60064-6050 (US).
- (72) Inventors: MUKERJI, Pradip; 1069 Arceno Drive, Ga-
hanna, OH 43230 (US); DAS, Tapas; 936 Linkfield Drive,
Worthington, OH 43085 (US); HUANG, Yung-Sheng;
2462 Danvers Court, Upper Arlington, OH 43220 (US);
PARKER-BARNES, Jennifer, M.; 1311 Belms Drive,
New Albany, OH 43054 (US); LEONARD, Amanda,
TG).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GR, GT,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
ZD.
- (84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LI, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NI, SN, TD,
TG).

(54) Title: ELONGASE GENES AND USES THEREOF

[Continued on next page]



(57) Abstract: The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated fatty acids (i.e., "elongases") and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomo gamma linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as triolein acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, w6-docosapentaenoic acid or w3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

BEST AVAILABLE COPY

WO 02/08401 A2

ELONGASE GENES AND USES THEREOF

The subject application is a Continuation-In-Part of pending U.S. patent application Serial No. 09/624,670 filed on July 24, 2000, which is a Continuation-In-Part of pending U.S. patent application Serial No. 09/379,095 filed on August 23, 1999, which is a Continuation-In-Part of pending U.S. patent application Serial No. 09/145,828 filed on September 2, 1998, all of which are herein incorporated in their entirety by reference.

BACKGROUND OF THE INVENTION

Technical Field

The subject invention relates to the identification of several genes involved in the elongation of long-chain polyunsaturated fatty acids (i.e., "elongases") and to uses thereof. In particular, the elongase enzyme is utilized in the conversion of one fatty acid to another. For example, elongase catalyzes the conversion of gamma linolenic acid (GLA) to dihomo- γ -linolenic acid (DGLA, 20:3n-6) and the conversion of stearidonic acid (STA, 18:4n-3) to (n-3)-eicosatetraenoic acid (20:4n-3). Elongase also catalyzes the conversion of arachidonic acid (AA, 20:4n-6) to adrenic acid (ADA, 22:4n-6), the conversion of eicosapentaenoic acid (EPA, 20:5n-3) to ω 3-docosapentaenoic acid (22:5n-3), and the conversion of α -linolenic acid (ALA, 18:3n-3) to 20:3n-3. DGLA, for example, may be utilized in the production of other polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA) which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Background Information

The elongases which have been identified in the past differ in terms of the substrates upon which they act. Furthermore, they are present in both animals and plants. Those found in mammals have the ability to act on saturated, monounsaturated and polyunsaturated fatty acids. In contrast, those found in plants are specific for saturated or monounsaturated fatty acids. Thus, in order to generate polyunsaturated fatty acids in plants, there is a need for a PUFA-specific elongase.

In both plants and animals, the elongation process is believed to be the result of a four-step mechanism (Lassner et al., The Plant Cell 8:281-292 (1996)). CoA is the acyl carrier.

Step one involves condensation of malonyl-CoA with a long-chain acyl-CoA to yield carbon dioxide and a β -ketoacyl-CoA in which the acyl moiety has been elongated by two carbon atoms.

Subsequent reactions include reduction to β -hydroxyacyl-CoA, dehydration to an enoyl-CoA, and a second reduction to yield the elongated acyl-CoA. The initial condensation reaction is not only the substrate-specific step but also the rate-limiting step.

As noted previously, elongases, more specifically, those which utilize PUFAs as substrates, are critical in the production of long-chain polyunsaturated fatty acids which have many important functions. For example, PUFAs are important components of the plasma membrane of a cell where they are found in the form of phospholipids. They also serve as precursors to mammalian prostacyclins, eicosanoids, leukotrienes and prostaglandins. Additionally, PUFAs are necessary for the proper development of the developing infant brain as well as for tissue formation and repair. In view of the biological

significance of PUFAs, attempts are being made to produce them, as well as intermediates leading to their production, efficiently.

A number of enzymes are involved in PUFA biosynthesis including elongases (elo) (see Figure 1). For example, linoleic acid (LA, 18:2- Δ 9,12 or 18:2n-6) is produced from oleic acid (OA, 18:1- Δ 9 or 18:1n-9) by a Δ 12 desaturase. GLA (18:3- Δ 6,9,12) is produced from linoleic acid by a Δ 6-desaturase. AA (20:4- Δ 5,8,11,14) is produced from dihomo- γ -linolenic acid (DGLA, 20:3- Δ 8,11,14) by a Δ 5-desaturase. As noted above, DGLA is produced from GLA by an elongase.

It must be noted that animals cannot desaturate beyond the Δ 9 position and therefore cannot convert oleic acid into linoleic acid. Likewise, α -linolenic acid (ALA, 18:3- Δ 9,12,15 or 18:3n-3) cannot be synthesized by mammals, since they lack Δ 5 desaturase activity. However, α -linolenic acid can be converted to stearidonic acid (STA, 18:4- Δ 6,9,12,15) by a Δ 6-desaturase (see PCT publication WO 96/13591; see also U.S. Patent No. 5,552,306), followed by elongation to (n-3)-eicosatetraenoic acid (20:4- Δ 8,11,14,17 or 20:4n-3) in mammals and algae. This polyunsaturated fatty acid (i.e., 20:4- Δ 8,11,14,17) can then be converted to eicosapentaenoic acid (EPA, 20:5- Δ 5,8,11,14,17) by a Δ 5-desaturase. Other eukaryotes, including fungi and plants, have enzymes which desaturate at carbons 12 (see PCT publication WO 94/11516 and U.S. Patent No. 5,443,974) and 15 (see PCT publication WO 93/11245). The major polyunsaturated fatty acids of animals therefore are either derived from diet and/or from desaturation and elongation of linoleic acid or α -linolenic acid. In view of the inability of mammals to produce these essential long chain fatty acids, it is of significant interest to isolate

genes involved in PUFA biosynthesis from species that naturally produce these fatty acids and to express these genes in a microbial, plant or animal system which can be altered to provide production of commercial quantities of one or more PUFAs. Consequently, there is a definite need for the elongase enzyme, the gene encoding the enzyme, as well as recombinant methods of producing this enzyme. Additionally, a need exists for oils containing levels of PUFA beyond those naturally present as well as those enriched in novel PUFAs. Such oils can only be made by isolation and expression of the elongase gene.

One of the most important long chain PUFAs, noted above, is arachidonic acid (AA). AA is found in filamentous fungi and can also be purified from mammalian tissues including the liver and the adrenal glands. As noted above, AA production from DGLA is catalyzed by a Δ 5-desaturase, and DGLA production from γ -linolenic acid (GLA) is catalyzed by an elongase. However, until the present invention, no elongase had been identified which was active on substrate fatty acids in the pathways for the production of long chain PUFAs and, in particular, AA, eicosapentaenoic acid (EPA), adrenic acid, docosahexaenoic acid (DHA, 22:6n-3), ω 3-docosapentaenoic acid (22:5n-3) or ω 6-docosapentaenoic acid (22:5n-6).

Two genes appeared to be of interest in the present search for the elongase gene. In particular, the jojoba β -ketoacyl-coenzyme A synthase (KCS), or jojoba KCS (GenBank Accession # U37088), catalyzes the initial reaction of the fatty acyl-CoA elongation pathway (i.e., the condensation of malonyl-CoA with long-chain acyl-CoA (Lassner et al., The Plant Cell 8:281-292 (1996)). Jojoba KCS substrate preference is 18:0, 20:0, 20:1, 30 18:1, 22:1, 22:0 and 16:0. Saccharomycetes cerevisiae elongase

(ELO2) also catalyzes the conversion of long chain saturated and monounsaturated fatty acids, producing high levels of 22:0, 24:0, and also 18:0, 18:1, 20:0, 20:1, 22:0, 22:1, and 24:1 (Oh et al., The Journal of Biological Chemistry 272 (28):17376-17384 (1997); see also U.S. Patent No. 5,484,724 for a nucleotide sequence which includes the sequence of ELO2; see PCT publication WO 88/07577 for a discussion of the sequence of a glycosylation inhibiting factor which is described in Example V). The search for a long chain PUFA-specific elongase in Mortierella alpina began based upon a review of the homologies shared between these two genes and by expression screening for PUFA-elongase activity.

SUMMARY OF THE INVENTION

The present invention relates to an isolated nucleotide sequence corresponding to or complementary to at least about 50% of the nucleotide sequence shown in SEQ ID NO:1 (Figure 6). This isolated sequence may be represented by SEQ ID NO:1. The sequence encodes a functionally active elongase which utilizes a polyunsaturated fatty acid or a monounsaturated fatty acid as a substrate. In particular, the sequence may be derived from a fungus of the genus Mortierella and may specifically be isolated from Mortierella alpina.

The present invention also includes a purified protein encoded by the above nucleotide sequence as well as a purified polypeptide which elongates polyunsaturated fatty acids or monounsaturated fatty acids and has at least about 50% amino acid similarity to the amino acid sequence of the purified protein encoded by the above nucleotide sequence.

Additionally, the present invention encompasses a method of producing an elongase enzyme comprising the steps of: a)

isolating the nucleotide sequence represented by SEQ ID NO:1 (Figure 6); b) constructing a vector comprising: i) the isolated nucleotide sequence operably linked to ii) a promoter; and c) introducing the vector into a host cell under time and conditions sufficient for expression of the elongase enzyme.

The host cell may be a eukaryotic cell or a prokaryotic cell.

The prokaryotic cell may be, for example an E. coli cell, a cyanobacterial cell, or a B. subtilis cell. The eukaryotic cell may be, for example, a mammalian cell, an insect cell, a plant cell or a fungal cell. The fungal cell may be, for example, Saccharomyces spp., Candida spp., Lipomyces spp., Yarrowia spp., Kluyveromyces spp., Hansenula spp., Aspergillus spp., Penicillium spp., Neurospora spp., Trichoderma spp. or Pichia spp. In particular, the fungal cell may be a yeast cell such as Saccharomyces spp., in particular, Saccharomyces cerevisiae, Candida spp., Hansenula spp. or Pichia spp.

The invention also includes a vector comprising: a) a

nucleotide sequence as represented by SEQ ID NO:1 (Figure 6) operably linked to b) a promoter, as well as a host cell comprising this vector. The host may be a prokaryotic cell or a eukaryotic cell. Suitable examples of prokaryotic cells include E. coli, Cyanobacteria, and B. subtilis cells. Suitable examples of eukaryotic cells include a mammalian cell, an insect cell, a plant cell and a fungal cell. The fungal cell may be, for example, Saccharomyces spp., Candida spp., Lipomyces spp., Yarrowia spp., Kluyveromyces spp., Hansenula spp., Aspergillus spp., Penicillium spp., Neurospora spp., Trichoderma spp. and Pichia spp. In particular, the fungal cell may be, for example, a yeast cell such as, for example, Saccharomyces spp., in particular, Saccharomyces cerevisiae, Candida spp., Hansenula spp. and Pichia spp.

The present invention includes a plant cell, plant or plant tissue comprising the above-described vector, wherein expression of the nucleotide sequence of the vector results in production of at least one fatty acid selected from the group consisting of a monounsaturated fatty acid and a polyunsaturated fatty acid by the plant cell, plant or plant tissue. The polyunsaturated fatty acid may be, for example, dihomo- γ -linolenic acid (DGLA), 20:4n-3, and adrenic acid (ADA). The invention also includes one or more plant oils or fatty acids expressed by the plant cell, plant or plant tissue. Additionally, the present invention encompasses a transgenic plant comprising the above-described vector, wherein expression of the nucleotide sequence of the vector results in production of a polyunsaturated fatty acid in seeds of the transgenic plant.

Furthermore, the present invention includes a transgenic, non-human mammal whose genome comprises a DNA sequence encoding an elongase operably linked to a promoter. The DNA sequence may be represented by SEQ ID NO:1 (Figure 6). The present invention also includes a fluid (e.g., milk) produced by the transgenic, non-human wherein the fluid comprises a detectable level of at least one elongase or products thereof such as, for example, DGLA, ω 6-docosapentaenoic acid, ADA and/or 20:4n-3 (see Figure 1).

Additionally, the present invention includes a method for producing a polyunsaturated fatty acid comprising the steps of:

- isolating said nucleotide sequence represented by SEQ ID NO:1 (Figure 6);
- constructing a vector comprising the isolated nucleotide sequence; c) introducing the vector into a host cell under time and conditions sufficient for expression of elongase enzyme encoded by the isolated nucleotide sequence; and d) exposing the expressed elongase enzyme to a "substrate"

polyunsaturated fatty acid in order to convert the substrate to a "product" polyunsaturated fatty acid. The substrate polyunsaturated fatty acid may be selected from the group consisting of, for example, γ -linolenic acid (GLA), stearidonic acid (STA) and arachidonic acid (AA), and the product polyunsaturated fatty acid may be selected from the group consisting of, for example, DGLA, 20:4n-3, and ADA, respectively. The method may further comprise the step of exposing the product polyunsaturated fatty acid to at least one desaturase in order to convert the product polyunsaturated fatty acid to "another" polyunsaturated fatty acid. The product polyunsaturated fatty acid may be selected from the group consisting of, for example, DGLA, 20:4n-3, and ADA. The another polyunsaturated fatty acid may be selected from the group consisting of, for example, AA, eicosapentaenoic acid (EPA), ω 6-docosapentaenoic acid, respectively, and the at least one desaturase is Δ 5-desaturase, with respect to production of AA or EPA, and Δ 4-desaturase, with respect to production of ω 6-docosapentaenoic acid. The method may further comprise the step of exposing the another polyunsaturated fatty acid to one or more enzymes selected from the group consisting of at least one elongase and at least one additional desaturase in order to convert the another polyunsaturated fatty acid to a "final" polyunsaturated fatty acid. The final polyunsaturated fatty acid may be, for example, docosahexaenoic acid (DHA), AA, ω 6-docosapentaenoic acid, or ω 3-docosapentaenoic acid.

Also, the present invention includes a nutritional composition comprising at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the above-

described method, the another polyunsaturated fatty acid produced according to the above-described method, and the final polyunsaturated fatty acid produced according to the above-described method. The product polyunsaturated fatty acid may be selected from the group consisting of, for example, DGLA, 20:4n-3 and ADA. The another polyunsaturated fatty acid may be, for example, AA, EPA, or ω 6-docosapentaenoic acid. The final polyunsaturated fatty acid may be, for example, DHA, adrenic acid, ω 6-docosapentaenoic acid or ω 3-docosapentaenoic acid.

The nutritional composition may be, for example, an infant formula, a dietary supplement or a dietary substitute and may be administered to a human or an animal and may be administered enterally or parenterally. The nutritional composition may further comprise at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, monoglycerides, diglycerides, triglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, protein hydrolysates, sunflower oil, safflower oil, corn oil, and flax oil. It may also comprise at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex and at least one mineral selected from the group consisting of calcium magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium and iron.

Additionally, the present invention encompasses a pharmaceutical composition comprising 1) at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the above-described method, the another polyunsaturated fatty acid produced according to the above-described method, and the final

polyunsaturated fatty acid produced according to the above-described method and 2) a pharmaceutically acceptable carrier. The composition may be administered to a human or an animal. It may also further comprise at least one element selected from the group consisting of a vitamin, a mineral, a salt, a carbohydrate, an amino acid, a free fatty acid, a preservative, an excipient, an anti-histamine, a growth factor, an antibiotic, a diluent, a phospholipid, an antioxidant, and a phenolic compound. It may be administered enterally, parenterally, topically, rectally, intramuscularly, subcutaneously, intradermally, or by any other appropriate means.

The present invention also includes an animal feed comprising at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the above-described method, the another polyunsaturated fatty acid produced according to the above-described method, and the final polyunsaturated fatty acid produced according to the above-described method. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, and ADA. The another polyunsaturated fatty acid may be, for example, AA, EPA, or ω 6-docosapentaenoic acid. The final polyunsaturated fatty acid may be, for example, DHA, adrenic acid, ω 6-docosapentaenoic acid or ω 3-docosapentaenoic acid.

Moreover, the present invention also includes a cosmetic comprising a polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the above-described method, the another polyunsaturated fatty acid produced according to the above-described method, and the final polyunsaturated fatty acid produced according to the above-described method.

Additionally, the present invention includes a method of preventing or treating a condition caused by insufficient intake or production of polyunsaturated fatty acids comprising administering to the patient the above nutritional composition in an amount sufficient to effect prevention or treatment.

The present invention also includes an isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence shown in SEQ ID NO:2 (Figure 22).

This sequence may be represented by SEQ ID NO:2. The sequence encodes a functionally active elongase which utilizes a polyunsaturated fatty acid as a substrate. This sequence may also be derived, for example, from a fungus of the genus Mortierella. In particular, it may be derived from M. alpina.

Additionally, the present invention includes a purified protein encoded by the above nucleotide sequence as well as a purified polypeptide which elongates polyunsaturated fatty acids and has at least about 30% amino acid similarity to the amino acid sequence of the purified protein.

The present invention also includes a method of producing an elongase enzyme as described above. The sequence inserted in the vector is represented by SEQ ID NO:2 (Figure 22). The host cell may be prokaryotic or eukaryotic. Suitable examples are described above.

The present invention also includes a vector comprising: a) a nucleotide sequence as represented by SEQ ID NO:2 (Figure 22) operably linked to b) a promoter, as well as a host cell comprising this vector. Again, the host cell may be eukaryotic or prokaryotic. Suitable examples are described above.

The invention also includes a plant cell, plant or plant tissue comprising the above vector, wherein expression of the nucleotide sequence of the vector results in production of a

polyunsaturated fatty acid by the plant cell, plant or plant tissue. The polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, or ADA. Additionally, the invention includes one or more plant oils or fatty acids expressed by the plant cell, plant or plant tissue.

Furthermore, the present invention also includes a transgenic plant comprising the above vector, wherein expression of the nucleotide sequence (SEQ ID NO:2) of the vector results in production of a polyunsaturated fatty acid in seeds of the transgenic plant.

The invention also includes a transgenic, non-human mammal whose genome comprises a DNA sequence (SEQ ID NO:2) encoding an elongase operably linked to a promoter. The invention also includes a fluid produced by this transgenic, non-human mammal wherein the fluid comprises a detectable level of at least one elongase or products thereof.

The present invention also includes a method for producing a polyunsaturated fatty acid comprising the steps of: a)

isolating the nucleotide sequence represented by SEQ ID NO:2 (Figure 22); b) constructing a vector comprising the isolated nucleotide sequence; c) introducing the vector into a host cell under time and conditions sufficient for expression of an elongase enzyme encoded by the isolated nucleotide sequence; and d) exposing the expressed elongase enzyme to a substrate

a product polyunsaturated fatty acid. The substrate polyunsaturated fatty acid may be, for example, GLA, STA, or AA, the product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, or ω 6-docosapentaenoic acid, respectively.

The method may further comprise the step of exposing the expressed elongase enzyme to at least one desaturase in order to

convert the product polyunsaturated fatty acid to another polyunsaturated fatty acid. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, or ADA, the another polyunsaturated fatty acid may be, for example, AA, EPA, or ω6-docosapentaenoic acid, respectively, and the at least one desaturase is Δ5-desaturase with respect to production of AA or EPA, and Δ4-desaturase with respect to production of ω6-docosapentaenoic acid. The method may further comprise the step of exposing the another polyunsaturated fatty acid to one or more enzymes selected from the group consisting of at least one elongase and at least one additional desaturase in order to convert the another polyunsaturated fatty acid to a final polyunsaturated fatty acid. The final polyunsaturated fatty acid may be, for example, docosahexaenoic acid, AA, ω6-docosapentaenoic acid, or ω3-docosapentaenoic acid.

The invention also includes a nutritional composition comprising at least one polyunsaturated fatty acid selected from the product polyunsaturated fatty acid produced according to the method described with respect to SEQ ID NO:2, the another polyunsaturated fatty acid produced according to the method described with respect to SEQ ID NO:2, and the final polyunsaturated fatty acid produced according to the method described with respect to SEQ ID NO:2. The product polyunsaturated fatty acid may be selected from the group consisting of, for example, DGLA, 20:4n-3 and ADA. The another polyunsaturated fatty acid may be selected from the group consisting of, for example, AA, EPA, and ω6-docosapentaenoic acid. The final polyunsaturated fatty acid may be selected from the group consisting of, for example, DHA, AA, ω6-docosapentaenoic acid, and ω3-docosapentaenoic acid.

The other attributes of the composition are the same as those described above with respect to administration, characterization, components, etc.

The present invention also includes a pharmaceutical composition comprising 1) at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the method of noted above with respect to SEQ ID NO:2, the another polyunsaturated fatty acid produced according to the method described above with respect to SEQ ID NO:2, and the final polyunsaturated fatty acid produced according to the method described above with respect to SEQ ID NO:2, and 2) a pharmaceutically acceptable carrier. The characteristics of the above-described pharmaceutical composition (e.g., administration, components, etc.) also apply to this composition.

The present invention also includes an animal feed comprising at least one polyunsaturated fatty acid selected from the group consisting of: the product polyunsaturated fatty acid produced according to the method described with respect to SEQ ID NO:2, the another polyunsaturated fatty acid produced according to the method described above with respect to SEQ ID NO:2, and the final polyunsaturated fatty acid produced according to the method described with respect to SEQ ID NO:2. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3 or ADA. The another polyunsaturated fatty acid may be, for example, AA, EPA or ω6-docosapentaenoic acid. The final polyunsaturated fatty acid may be, for example, DHA, adrenic acid, ω6-docosapentaenoic acid or ω3-docosapentaenoic acid.

The invention also includes a cosmetic comprising a polyunsaturated fatty acid selected from the group consisting of: the product polyunsaturated fatty acid produced according to the method described above with respect to SEQ ID NO:2, the another polyunsaturated fatty acid produced according to the method described above with respect to SEQ ID NO:2, and the final polyunsaturated fatty acid produced according to the method described above with respect to SEQ ID NO:2.

Additionally, the present invention includes a method of preventing or treating a condition caused by insufficient intake or production of polyunsaturated fatty acids comprising administering to the patient the nutritional composition described directly above in an amount sufficient to effect the prevention or treatment.

Furthermore, the present invention includes an isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence shown in SEQ ID NO:3 (Figure 43). This sequence may be that represented by SEQ ID NO:3. This sequence encodes a functionally active elongase which utilizes a polyunsaturated fatty acid or a monounsaturated fatty acid as a substrate. The sequence is derived from a mammal such as, for example, a human.

The invention also includes a purified protein encoded by this nucleotide sequence. Also, the invention includes a purified polypeptide which elongates polyunsaturated fatty acids or monounsaturated fatty acids and has at least about 30% amino acid similarity to the amino acid sequence of this purified protein.

Additionally, the invention includes method of producing an elongase enzyme comprising the steps of: a) isolating the nucleotide sequence represented by SEQ ID NO:3 (Figure 43); b)

constructing a vector comprising: i) the isolated nucleotide sequence operably linked to ii) a promoter; and c) introducing said vector into a host cell under time and conditions sufficient for expression of the elongase enzyme. The host cell may be the same as that described above with respect to the corresponding methods utilizing SEQ ID NO:1 or 2.

The invention also includes a vector comprising: a) a nucleotide sequence as represented by SEQ ID NO:3 (Figure 43) operably linked to b) a promoter, as well as a host cell comprising this vector. The host cell may be the same as that described above.

The invention also includes a plant cell, plant or plant tissue comprising the above-described vector comprising SEQ ID NO:3, wherein expression of the nucleotide sequence of the vector results in production of at least one fatty acid selected from the group consisting of a monounsaturated fatty acid and a polyunsaturated fatty acid by said plant cell, plant or plant tissue. The polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3 or ADA. The invention also includes one or more plant oils or acids expressed by the plant cell, plant or plant tissue.

The invention also includes a transgenic plant comprising the vector comprising SEQ ID NO:3, wherein expression of the nucleotide sequence of the vector results in production of a polyunsaturated fatty acid in seeds of the transgenic plant.

Additionally, the present invention includes a transgenic, non-human mammal whose genome comprises a human DNA sequence encoding an elongase operably linked to a promoter. The DNA sequence is represented by SEQ ID NO:3 (Figure 43). The invention also includes a fluid produced by said transgenic,

non-human mammal wherein said fluid comprises a detectable level of at least one elongase or products thereof.

The invention also encompasses a method for producing a polyunsaturated fatty acid comprising the steps of: a) isolating the nucleotide sequence represented by SEQ ID NO:3 (Figure 43); b) constructing a vector comprising said nucleotide sequence; c) introducing the vector into a host cell under time and conditions sufficient for expression of elongase enzyme encoded by the isolated nucleotide sequence; and d) exposing the expressed elongase enzyme to a substrate polyunsaturated fatty acid in order to convert the substrate to a product polyunsaturated fatty acid. The substrate polyunsaturated fatty acid may be, for example, GLA, STA or AA, and the product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, or ADA, respectively. The method may further comprise the step of exposing the product polyunsaturated fatty acid to at least one desaturase in order to convert the product polyunsaturated fatty acid to another polyunsaturated fatty acid. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3 and ADA, the another polyunsaturated fatty acid may be, for example, AA, EPA, and $\omega 6$ -docosapentaenoic acid, respectively, and the at least one desaturase is $\Delta 5$ -desaturase with respect to production of AA or EPA and $\Delta 4$ -desaturase with respect to production of $\omega 6$ -docosapentaenoic acid. The method may further comprise the step of exposing the another polyunsaturated fatty acid to one or more enzymes selected from the group consisting of at least one elongase and at least one additional desaturase in order to convert the another polyunsaturated fatty acid to a final polyunsaturated fatty acid. The final polyunsaturated

fatty acid may be, for example, DHA, ADA, $\omega 6$ -docosapentaenoic acid, and $\omega 3$ -docosapentaenoic acid.

The nutritional composition comprising at least one polyunsaturated fatty acid which may be, for example, product polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:3, another polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:3, and the final polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:3. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, or ADA. The another polyunsaturated fatty acid may be selected from the group consisting of AA, EPA, or $\omega 6$ -docosapentaenoic acid. The final polyunsaturated fatty acid may be, for example, DHA, ADA, $\omega 6$ -docosapentaenoic acid, or $\omega 3$ -docosapentaenoic acid. The other properties or characteristic of the nutritional composition (e.g., administration, components, etc.) as the same as those recited above with respect to the other nutritional compositions.

Moreover, the present invention also includes a pharmaceutical composition comprising 1) at least one polyunsaturated fatty acid selected from the group consisting of: the product polyunsaturated fatty acid produced according to the method described above in connection with SEQ ID NO:3, the another polyunsaturated fatty acid produced according to the method described above in connection with SEQ ID NO:3, and the final polyunsaturated fatty acid produced according to the method described above in connection with SEQ ID NO:3 and 2) a pharmaceutically acceptable carrier. The other properties of the composition (e.g., administration, additional components,

etc.) are the same as those recited above with respect to the other pharmaceutical compositions.

The present invention also includes an animal feed comprising at least one polyunsaturated fatty acid selected from the group consisting of: the product polyunsaturated fatty acid produced according to the method recited above with respect to SEQ ID NO:3, the another polyunsaturated fatty acid produced according to the method recited above with respect to SEQ ID NO:3, and the final polyunsaturated fatty acid produced according to the method recited above with respect to SEQ ID NO:3. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, or ADA. The polyunsaturated fatty acid may be, for example, AA, EPA, or 06-docosapentaenoic acid. The final polyunsaturated fatty acid may be, for example, DHA, ADA, 06-docosapentaenoic acid or 03-docosapentaenoic acid.

Also, the present invention includes a cosmetic comprising a polyunsaturated fatty acid selected from the group consisting of: the product polyunsaturated fatty acid produced according to the method recited above with respect to SEQ ID NO:3, said another polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:3, and the final polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:3.

A method of preventing or treating a condition caused by insufficient intake of polyunsaturated fatty acids comprising administering to the patient the nutritional composition recited above in connection with SEQ ID NO:3 in an amount sufficient to effect the prevention or treatment.

Additionally, the present invention includes an isolated nucleotide sequence corresponding to or complementary to at

least about 35% of the nucleotide sequence shown in SEQ ID NO:4 (Figure 46). The sequence may be represented by SEQ ID NO:4.

It encodes a functionally active elongase which utilizes a polyunsaturated fatty acid as a substrate. The sequence may be derived or isolated from a nematode of the genus Caenorhabditis and, in particular, may be isolated from C. elegans.

The present invention includes a purified protein encoded by the nucleotide sequence above. The invention also includes a purified polypeptide which elongates polyunsaturated fatty acids and has at least about 30% amino acid similarity to the amino acid sequence of the purified protein.

Additionally, the present invention includes a method of producing an elongase enzyme comprising the steps of: a) isolating the nucleotide sequence represented by SEQ ID NO:4 (Figure 46); b) constructing a vector comprising: i) the isolated nucleotide sequence operably linked to ii) a promoter; and c) introducing the vector into a host cell under time and conditions sufficient for expression of the elongase enzyme. The properties of the host cell are the same as those described above in connection with SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.

The present invention also encompasses a vector comprising:

a) a nucleotide sequence as represented by SEQ ID NO:4 (Figure 46) operably linked to b) a promoter, as well as a host cell comprising this vector. The host cell has the same properties as those recited above in connection with the host cell recited above for SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

Moreover, the present invention includes a plant cell, plant or plant tissue comprising the above vector comprising SEQ ID NO:4, wherein expression of said nucleotide sequence of the vector results in production of a polyunsaturated fatty acid by

the plant cell, plant or plant tissue. The polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, or ADA. The invention also includes one or more plant oils or fatty acids expressed by this plant cell, plant or plant tissue.

5 The invention also includes transgenic plant comprising the above vector including the nucleotide sequence corresponding to SEQ ID NO:4, wherein expression of the nucleotide sequence of the vector results in production of a polyunsaturated fatty acid in seeds of the transgenic plant.

10 Additionally, the present invention includes a transgenic, non-human mammal whose genome comprises a C. elegans DNA sequence encoding an elongase operably linked to a promoter. The DNA sequence may be represented by SEQ ID NO:4 (Figure 46). The invention also includes a fluid produced by the transgenic, 15 non-human mammal, wherein the fluid comprises a detectable level of at least one elongase or products thereof.

The invention also includes a method for producing a polyunsaturated fatty acid comprising the steps of: a) isolating the nucleotide sequence represented by SEQ ID NO:4 (Figure 46); 20 b) constructing a vector comprising the isolated nucleotide sequence; c) introducing the vector into a host cell under time and conditions sufficient for expression of an elongase enzyme encoded by the isolated nucleotide sequence; and d) exposing the expressed elongase enzyme to a substrate polyunsaturated fatty acid in order to convert the substrate to a product 25 polyunsaturated fatty acid. The substrate polyunsaturated fatty acid may be, for example, GLA, STA, or AA, and the product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, or ADA, respectively. The method may further comprise the step 30 of exposing the expressed elongase enzyme to at least one desaturase in order to convert said product polyunsaturated

fatty acid to another polyunsaturated fatty acid. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3 or ADA, the another polyunsaturated fatty acid may be, for example, AA, EPA or ω -6-docosapentaenoic acid, respectively, and the at 5 least one desaturase is Δ 5-desaturase with respect to production of AA or EPA, and Δ 4-desaturase with respect to production of ω -6-docosapentaenoic acid. The method may further comprise the step of exposing the another polyunsaturated fatty acid to one or more enzymes selected from the group consisting of at least one elongase and at least one additional desaturase in order to 10 convert the another polyunsaturated fatty acid to a final polyunsaturated fatty acid. The final polyunsaturated fatty acid may be, for example, DHA, ADA, ω -6-docosapentaenoic acid, or ω -3-docosapentaenoic acid.

15 The invention also includes a nutritional composition comprising at least one polyunsaturated fatty acid selected from the group consisting of said the polyunsaturated fatty acid produced according to the method described above in connection with SEQ ID NO:4, the another polyunsaturated fatty acid 20 produced according to the method described above in connection with SEQ ID NO:4, and the final polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:4. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, or ADA. The another 25 polyunsaturated fatty acid may be, for example, AA, EPA, or ω -6-docosapentaenoic acid. The final polyunsaturated fatty acid may be, for example, DHA, ADA, ω -6-docosapentaenoic acid, or ω -3-docosapentaenoic acid. The other characteristics of the composition are the same as those recited for the nutritional 30 compositions present above.

Additionally, the present invention includes a pharmaceutical composition comprising 1) at least one polyunsaturated fatty acid selected from the group consisting of: the product polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:4, the another polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:4, and the final polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:4 and 2) a pharmaceutically acceptable carrier. The composition has the same properties (e.g., administration, added elements, etc.) as those described above with respect to the other pharmaceutical compositions.

The present invention also includes an animal feed comprising at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the method described above in connection with SEQ ID NO:4, the another polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:4, and the final polyunsaturated fatty acid produced according to the method described above in connection with SEQ ID NO:4. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3 or ADA. The another polyunsaturated fatty acid may be, for example, AA, EPA or ω -6-docosapentaenoic acid. The polyunsaturated fatty acid may be, for example, DHA, ADA, ω 6-docosapentaenoic acid or ω 3-docosapentaenoic acid.

Additionally, the present invention includes a cosmetic comprising a polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced

according to the method recited above in connection with SEQ ID NO:4, the another polyunsaturated fatty acid produced according to the method recited above in connection with SEQ ID NO:4 and the final polyunsaturated fatty acid produced according to the method described above in connection with SEQ ID NO:4.

Furthermore, the present invention encompasses a method of preventing or treating a condition caused by insufficient intake or production of polyunsaturated fatty acids comprising administering to the patient the nutritional composition recited with respect to SEQ ID NO:4 in an amount sufficient to effect the treatment or prevention.

The present invention also includes an isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence comprising SEQ ID NO:5 (Figure 54). Thus, the sequence may be that represented by SEQ ID NO:5. The sequence may encode a functionally active elongase which utilizes a polyunsaturated fatty acid as a substrate. It may also be derived from a mammal such as, for example, a mouse. The present invention also includes a purified protein encoded by the nucleotide sequence as well as a purified polypeptide which elongates polyunsaturated fatty acids and has at least about 30% amino acid similarity to the amino acid sequence of the protein.

Additionally, the invention also includes a method of producing an elongase enzyme, as described above, in which the nucleotide sequence isolated comprises either SEQ ID NO:5 or SEQ ID NO:6. The host cell utilized may be as described above.

The present invention also encompasses a vector comprising: a) a nucleotide sequence comprising SEQ ID NO:5 (Figure 54) (or a nucleotide sequence comprising SEQ ID NO:6 (Figure 58)) operably linked to b) a promoter, as well as a host cell comprising this

vector. Again, the host cell may be as described above for the related methods using the other nucleotide sequences of the present invention.

5 Additionally, the invention includes a plant cell, plant or plant tissue comprising the vector comprising SEQ ID NO:5 or 6, wherein expression of the nucleotide sequence of the vector results in production of a polyunsaturated fatty acid by the plant cell, plant or plant tissue. When the nucleotide sequence of the vector comprises SEQ ID NO:5, the polyunsaturated fatty acid is selected from the group consisting of AA, ADA, GLA and 10 STA. The invention also includes one or more plant oils or acids expressed by the plant cell, plant or plant tissue.

The present invention also includes a transgenic plant comprising the vector described above, wherein expression of the nucleotide sequence of the vector results in production of a polyunsaturated fatty acid in seeds of the transgenic plant.

15 Additionally, the present invention encompasses a transgenic, non-human mammal whose genome comprises a DNA sequence encoding an elongase, operably linked to a promoter, wherein the DNA sequence comprises SEQ ID NO:5 (Figure 54) (or SEQ ID NO:6 (Figure 58)). Also, the invention includes a fluid produced by this transgenic, non-human mammal, wherein the fluid comprises a detectable level of at least one elongase or products thereof.

25 The invention also includes a method for producing a polyunsaturated fatty acid, similar to the methods described above, except that the isolated nucleotide sequence comprises SEQ ID NO:5 (Figure 54). The substrate polyunsaturated fatty acid may be selected from the group consisting of GLA, STA, AA, 30 ADA and ALA, and the product polyunsaturated fatty acid may be

selected from the group consisting of DGLA, 20:4n-3, ADA, ω 6-docosapentaenoic acid and STA, respectively. The method may further comprise the step of exposing the expressed elongase enzyme to at least one desaturase in order to convert the product polyunsaturated fatty acid to another polyunsaturated fatty acid. The product polyunsaturated fatty acid may be 5 selected from the group consisting of DGLA, 20:4n-3, ADA and ω 6-docosapentaenoic acid, the another polyunsaturated fatty acid is selected from the group consisting of AA, EPA, ω 6-docosapentaenoic acid and docosahexaenoic acid respectively, and the at least one desaturase is Δ 5-desaturase with respect to production of AA or EPA, and Δ 4-desaturase with respect to 10 production of ω 6-docosapentaenoic acid, and Δ 19-desaturase with respect to production of docosahexaenoic acid. The method may further comprise the step of exposing the another polyunsaturated fatty acid to one or more enzymes selected from the group consisting of at least one elongase and at least one additional desaturase in order to convert the another polyunsaturated fatty acid to a final polyunsaturated fatty acid. The final polyunsaturated fatty acid may be selected from 20 the group consisting of ADA, ω 3-docosapentaenoic acid and docosahexaenoic acid.

The present invention also includes a nutritional composition comprising at least one polyunsaturated fatty acid 25 selected from the group consisting of the product polyunsaturated fatty acid produced according to the method above, the another polyunsaturated fatty acid is produced according to the method above, and the final polyunsaturated fatty acid produced according to the method above. The product polyunsaturated fatty acid may be selected from the group

consisting of DGLA, 20:4n-3, ADA, and ω 6-docosapentaenoic acid and STA. The another polyunsaturated fatty acid is selected from the group consisting of AA, EPA, ω 6-docosapentaenoic acid and docosahexaenoic acid. The final polyunsaturated fatty acid is selected from the group consisting of ADA, ω 3-docosapentaenoic acid and docosahexaenoic acid. The nutritional composition may be selected from the group consisting of an infant formula, a dietary supplement and a dietary substitute.

The present invention also includes a pharmaceutical composition comprising 1) at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the method above, the another polyunsaturated fatty acid produced according to the method above, and the final polyunsaturated fatty acid produced according to the method above and 2) a pharmaceutically acceptable carrier.

Additionally, the present invention includes an animal feed comprising at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the method above, the another polyunsaturated fatty acid produced according to the method above and the final polyunsaturated fatty acid produced according to the method above. The product polyunsaturated fatty acid may be selected from the group consisting of DGLA, 20:4n-3, ADA, ω 6-docosapentaenoic acid and STA. The another polyunsaturated fatty acid may be selected from the group consisting of AA, EPA, ω 6-docosapentaenoic acid and docosahexaenoic acid. The final polyunsaturated fatty acid may be selected from the group consisting of ADA, ω 3-docosapentaenoic acid and docosahexaenoic acid.

The invention includes a cosmetic comprising a polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the method above, the another polyunsaturated fatty acid produced according to the method above and the final polyunsaturated fatty acid produced according to the method above.

Additionally, a method of preventing or treating a condition caused by insufficient intake of polyunsaturated fatty acids comprising administering to the patient the nutritional composition above in an amount sufficient to effect the prevention or treatment.

The present invention includes an isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence comprising SEQ ID NO:6 (Figure 58). The isolated nucleotide sequence may comprise SEQ ID NO:6. The invention also includes a purified protein encoded by the nucleotide sequences.

Additionally, the present invention relates to an isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence shown in SEQ ID NO:7 (Figure 72). This isolated sequence may be represented by SEQ ID NO:7. The sequence encodes a functionally active elongase which utilizes a polyunsaturated fatty acid or a monounsaturated fatty acid as a substrate. In particular, the sequence may be derived from a fungus of the genus Thraustochytrium and may specifically be isolated from Thraustochytrium aureum.

The present invention also includes a purified protein encoded by the above nucleotide sequence as well as a purified polypeptide which elongates polyunsaturated fatty acids or monounsaturated fatty acids and has at least about 50% amino

acid similarity to the amino acid sequence of the purified protein encoded by the above nucleotide sequence.

Additionally, the present invention encompasses a method of producing an elongase enzyme comprising the steps of: a)

isolating the nucleotide sequence represented by SEQ ID NO:7

(Figure 72); b) constructing a vector comprising: i) the

isolated nucleotide sequence operably linked to ii) a promoter;

and c) introducing the vector into a host cell under time and

conditions sufficient for expression of the elongase enzyme.

The host cell may be a eukaryotic cell or a prokaryotic cell.

The prokaryotic cell may be, for example an E. coli cell, a

cyanobacterial cell, or a B. subtilis cell. The eukaryotic cell

may be, for example, a mammalian cell, an insect cell, a plant

cell or a fungal cell. The fungal cell may be, for example,

Saccharomyces spp., Candida spp., Lipomyces spp., Yarrowia spp.,

Kluyveromyces spp., Hansenula spp., Aspergillus spp.,

Penicillium spp., Neurospora spp., Trichoderma spp. or Pichia

spp. In particular, the fungal cell may be a yeast cell such as

Saccharomyces spp., in particular, Saccharomyces cerevisiae,

Candida spp., Hansenula spp. or Pichia spp.

The invention also includes a vector comprising: a) a nucleotide sequence as represented by SEQ ID NO:7 (Figure 72) operably linked to b) a promoter, as well as a host cell comprising this vector. The host may be a prokaryotic cell or a

eukaryotic cell. Suitable examples of prokaryotic cells include E. coli, Cyanobacteria, and B. subtilis cells. Suitable

examples of eukaryotic cells include a mammalian cell, an insect

cell, a plant cell and a fungal cell. The fungal cell may be,

for example, Saccharomyces spp., Candida spp., Lipomyces spp.,

Yarrowia spp., Kluyveromyces spp., Hansenula spp., Aspergillus

spp., Penicillium spp., Neurospora spp., Trichoderma spp. and

Pichia spp. In particular, the fungal cell may be, for example, a yeast cell such as, for example, Saccharomyces spp., in particular, Saccharomyces cerevisiae, Candida spp., Hansenula spp. and Pichia spp.

The present invention includes a plant cell, plant or plant

tissue comprising the above-described vector, wherein expression

of the nucleotide sequence of the vector results in production

of at least one fatty acid selected from the group consisting of

a monounsaturated fatty acid and a polyunsaturated fatty acid by

the plant cell, plant or plant tissue. The polyunsaturated

fatty acid may be, for example, dihomo- γ -linolenic acid (DGLA),

20:4n-3, and adrenic acid (ADA). The invention also includes

one or more plant oils or fatty acids expressed by the plant

cell, plant or plant tissue. Additionally, the present

invention encompasses a transgenic plant comprising the above-

described vector, wherein expression of the nucleotide sequence

of the vector results in production of a polyunsaturated fatty

acid in seeds of the transgenic plant.

Furthermore, the present invention includes a transgenic,

non-human mammal whose genome comprises a DNA sequence encoding

an elongase operably linked to a promoter. The DNA sequence may

be represented by SEQ ID NO:7 (Figure 72). The present

invention also includes a fluid (e.g., milk) produced by the

transgenic, non-human wherein the fluid comprises a detectable

level of at least one elongase or products thereof such as, for

example, DGLA, ω 6-docosapentaenoic acid, ADA and/or 20:4n-3 (see

Figure 1).

Additionally, the present invention includes a method for producing a polyunsaturated fatty acid comprising the steps of:

a) isolating said nucleotide sequence represented by SEQ ID NO:7

(Figure 72); b) constructing a vector comprising the isolated nucleotide sequence; c) introducing the vector into a host cell under time and conditions sufficient for expression of elongase enzyme encoded by the isolated nucleotide sequence; and d) exposing the expressed elongase enzyme to a "substrate" polyunsaturated fatty acid in order to convert the substrate to a "product" polyunsaturated fatty acid. The substrate polyunsaturated fatty acid may be selected from the group consisting of, for example, γ -linolenic acid (GLA), stearidonic acid (STA) and arachidonic acid (AA), and the product polyunsaturated fatty acid may be selected from the group consisting of, for example, DGLA, 20:4n-3, and ADA, respectively. The method may further comprise the step of exposing the product polyunsaturated fatty acid to at least one desaturase in order to convert the product polyunsaturated fatty acid to "another" polyunsaturated fatty acid. The product polyunsaturated fatty acid may be selected from the group consisting of, for example, DGLA, 20:4n-3, and ADA. The another polyunsaturated fatty acid may be selected from the group consisting of, for example, AA, eicosapentaenoic acid (EPA), ω -6-docosapentaenoic acid, respectively, and the at least one desaturase is Δ 5-desaturase, with respect to production of AA or EPA, and Δ 4-desaturase, with respect to production of ω -6-docosapentaenoic acid. The method may further comprise the step of exposing the another polyunsaturated fatty acid to one or more enzymes selected from the group consisting of at least one elongase and at least one additional desaturase in order to convert the another polyunsaturated fatty acid to a "final" polyunsaturated fatty acid. The final polyunsaturated fatty

acid may be, for example, docosahexaenoic acid (DHA), AA, ω -6-docosapentaenoic acid, or ω 3-docosapentaenoic acid.

Also, the present invention includes a nutritional composition comprising at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the above-described method, the another polyunsaturated fatty acid produced according to the above-described method, and the final polyunsaturated fatty acid produced according to the above-described method. The product polyunsaturated fatty acid may be selected from the group consisting of, for example, DGLA, 20:4n-3 and ADA. The another polyunsaturated fatty acid may be, for example, AA, EPA, or ω 6-docosapentaenoic acid. The final polyunsaturated fatty acid may be, for example, DHA, adrenic acid, ω 6-docosapentaenoic acid or ω 3-docosapentaenoic acid. The nutritional composition may be, for example, an infant formula, a dietary supplement or a dietary substitute and may be administered to a human or an animal and may be administered enterally or parenterally. The nutritional composition may further comprise at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, monoglycerides, diglycerides, triglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, protein hydrolysates, sunflower oil, safflower oil, corn oil, and flax oil. It may also comprise at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex and at least one mineral selected from the group consisting of calcium magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium and iron.

Additionally, the present invention encompasses a pharmaceutical composition comprising 1) at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the above-described method, the another polyunsaturated fatty acid produced according to the above-described method, and the final polyunsaturated fatty acid produced according to the above-described method, and 2) a pharmaceutically acceptable carrier.

The composition may be administered to a human or an animal. It may also further comprise at least one element selected from the group consisting of a vitamin, a mineral, a salt, a carbohydrate, an amino acid, a free fatty acid, a preservative, an excipient, an anti-histamine, a growth factor, an antibiotic, a diluent, a phospholipid, an antioxidant, and a phenolic compound. It may be administered enterally, parenterally, topically, rectally, intramuscularly, subcutaneously, intradermally, or by any other appropriate means.

The present invention also includes an animal feed comprising at least one polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the above-described method, the another polyunsaturated fatty acid produced according to the above-described method, and the final polyunsaturated fatty acid produced according to the above-described method. The product polyunsaturated fatty acid may be, for example, DGLA, 20:4n-3, and ADA. The another polyunsaturated fatty acid may be, for example, AA, EPA, or ω -6-docosapentaenoic acid. The final polyunsaturated fatty acid may be, for example, DHA, adrenic acid, ω -6-docosapentaenoic acid or ω -3-docosapentaenoic acid.

Moreover, the present invention also includes a cosmetic

comprising a polyunsaturated fatty acid selected from the group consisting of the product polyunsaturated fatty acid produced according to the above-described method, the another polyunsaturated fatty acid produced according to the above-described method, and the final polyunsaturated fatty acid produced according to the above-described method.

Additionally, the present invention includes a method of preventing or treating a condition caused by insufficient intake or production of polyunsaturated fatty acids comprising administering to the patient the above nutritional composition in an amount sufficient to effect prevention or treatment.

All U.S. patents and publications referred to herein are hereby incorporated in their entirety by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 represents various fatty acid biosynthesis pathways. The role of the elongase enzyme (elo) should be noted.

Figure 2 represents the percent similarity and percent identity between the amino acid sequences of jojoba KCS and ELO2.

Figure 3 represents the *S. cerevisiae* ELO2 sequence homologous to the jojoba KCS sequence (primer sequence underlined) of Figure 2.

Figure 4A shows the physical map of pRAE-2 containing the MAELO cDNA. Figure 4B represents the physical map of the constitutive expression vector, pRAE-5, used for elongase enzyme production in yeast.

Figure 5 represents a comparison of the nucleotide sequences of clones pRAE-5 and pRAE-6.

Figure 6 illustrates the complete nucleotide sequence of Mortierella alpina elongase (MAELO).

Figure 7 represents the amino acid sequence of the Mortierella alpina elongase translated from MAELO (see Figure 5 6).

Figure 8 represents an amino acid sequence alignment among 3 elongases: S. cerevisiae ELO2 (GNS1), S. cerevisiae ELO3 (SUR4) and the translated MAELO sequence as shown in Figure 7.

Figure 9 represents a comparison between the nucleotide sequence MAELO and the nucleotide sequence of ELO2 from S. cerevisiae.

Figures 10A and 10B represents the PUFA elongase activity of MAELO expressed in baker's yeast.

Figure 11 illustrates the PUFA elongase activity of MAELO 15 when co-expressed with the $\Delta 5$ -desaturase cDNA from M. alpina to produce AA.

Figure 12 compares the PUFA elongase activity of MAELO to the overexpression of ELO2 from S. cerevisiae in baker's yeast. Figures 13, 14 and 15 represent three separate comparisons of amino acid sequences derived from C. elegans nucleotide sequences in the GenEMBL database with the translated MAELO.

Figure 16 shows the comparison between amino acid translations of two different mammalian sequences in the GenEMBL database and the translated MAELO.

Figure 17 shows the comparison of a translated DNA sequence (see published PCT application WO 88/07577) with the amino acid sequence derived from MAELO, which was detected during a database search.

Figure 18 shows the complete nucleotide sequence of the $\Delta 5$ -desaturase from M. alpina.

Figure 19 represents the initial GC-FAME analysis of MAD708 pool. The detection of a DGLA (C20:3n-6) peak should be noted.

Figure 20 represents the PUFA elongase activity of the five MAD708 clones in yeast with GLA as substrate. All clones have 5 apparent elongase activity.

Figure 21 represents the DNA sequencing analysis of plasmid pRPB2. The analysis reveals an open reading frame of 957 bp in length.

Figure 22 shows the complete nucleotide sequence of the M. alpina cDNA, contained in the plasmid pRPB2, which is designated 10 GLELO for its GLA elongase activity.

Figure 23 represents the amino acid sequence of the M. alpina elongase translated from GLELO (see Figure 22).

Figure 24 illustrates the n-6 PUFA elongase activity in an 15 induced culture of 334 (pRPB2) when supplemented with GLA.

Figure 25 represents the n-3 and n-6 PUFA elongase activity in an induced culture of 334 (pRPB2) when supplemented with 25 μ M of other fatty acid substrates.

Figure 26A illustrates the elongase activity of GLELO with 20 GLA as a substrate when co-expressed with the M. alpina $\Delta 5$ -desaturase cDNA to produce AA. Figure 26B illustrates the elongase activity of GLELO with STA as a substrate when co-expressed with the M. alpina $\Delta 5$ -desaturase cDNA to produce EPA.

Figure 27 illustrates the comparison between the translated 25 GLELO sequence (see Figure 23) and the translated MAELO sequence (see Figure 7).

Figure 28 represents a comparison of the amino acid sequence of 4 elongases: the translated amino acid sequence of GLELO (see Figure 23), MAELO (see Figure 7), S. cerevisiae ELO2

37

(GNS1), and S. cerevisiae ELO3 (SUR4). The histidine box is underlined.

Figure 29 represents an alignment between translated MAELO sequence and translated putative human homologue HS1 sequence.

5 Figure 30 represents an alignment between the translated MAELO sequence and the translated putative human homologue HS2 sequence.

Figure 31 shows an alignment between the translated MAELO sequence and the translated putative mouse homologue MM2 sequence.

Figure 32 represents an alignment between the translated MAELO and the translated putative mouse homologue AI225632 sequence.

15 Figure 33 illustrates an alignment between the translated GLELO sequence and the translated human homologue AI815960 sequence.

Figure 34 shows an alignment between the translated GLELO sequence and the translated putative human homologue HS1 sequence.

20 Figure 35 represents an alignment between the translated GLELO sequence and the translated putative human homologue sequence from AC004050.

Figure 36 illustrates an alignment between the translated GLELO sequence and the translated putative mouse homologue MM2 sequence.

25 Figure 37 represents an alignment of the translated GLELO sequence and a translated putative mouse homologue AI225632 sequence.

Figure 38 illustrates an alignment of the translated GLELO sequence and a translated putative mouse homologue U97107.

38

Figure 39 represents an alignment of the translated GLELO sequence and a translated putative C. elegans U68749 (F56H11.4) homologue sequence.

5 Figure 40 shows an alignment between the translated MAELO sequence and a translated putative C. elegans U68749 (F56H11.4) homologue sequence.

Figure 41 represents an alignment between the translated GLELO sequence and a translated putative Drosophila melanogaster homologue sequence, DM1.

10 Figure 42 illustrates an alignment between the translated MAELO sequence and a translated putative Drosophila melanogaster homologue sequence, DM1.

Figure 43 illustrates the complete nucleotide sequence of a human elongase HSELO1.

15 Figure 44 represents the deduced amino acid sequence of the human elongase HSELO1.

Figure 45 illustrates the elongase activity (PUFA and others) of an induced culture of 334(PRAE-58-A1) when supplemented with GLA or AA.

20 Figure 46 shows the complete nucleotide sequence of the C. elegans elongase CEELO.

Figure 47 represents the deduced amino acid of C. elegans elongase CEELO.

25 Figure 48 illustrates the PUFA elongase activity of an induced culture of 334(pRET-21) and 334(pRET-22) when supplemented with GLA and AA.

Figure 49 represents the complete nucleotide sequence of the putative human elongase gene HS3.

30 Figure 50 illustrates the deduced amino acid sequence of the putative human elongase enzyme HS3.

Figure 51 represents the elongase activity (PUFA and others) of HSELO1 expressed in baker's yeast when supplemented with GLA, AA, STA, EPA, OA, or ALA.

Figure 52 represents the elongase activity (PUFA and others) of HSELO1 expressed in baker's yeast when supplemented with 25 mM or 100 mM of GLA, AA, or EPA.

Figures 53A, 53B, and 53C represent the elongase activity (PUFA and others) of HSELO1 expressed in baker's yeast when supplemented with PA, SA, ARA, BA, PTA, OA, EA, LA, GLA, DGLA, AA, ADA, ALA, STA, EPA, or DPA, or when no substrate is present.

Figure 54 represents the complete nucleotide sequence of mouse elongase MELO4.

Figure 55 represents the deduced amino acid sequence of the mouse elongase MELO4.

Figure 56 represents the PUFA elongase activity of MELO4 expressed in baker's yeast when supplemented with GLA, AA, ADA, STA, EPA, or DPA.

Figures 57A, 57B, and 57C represent the PUFA elongase activity of MELO4 expressed in baker's yeast when supplemented with PA, SA, ARA, BA, PTA, OA, EA, LA, GLA, DGLA, AA, ADA, ALA, STA, EPA, or DPA, or when no substrate is present.

Figure 58 represents the complete nucleotide sequence of mouse elongase MELO7.

Figure 59 represents the deduced amino acid sequence of the mouse elongase MELO7.

Figure 60 represents the elongase activity (PUFA and others) of MELO7 expressed in baker's yeast when supplemented with GLA, AA, ADA, STA, EPA, or DPA.

Figure 61 shows the activity of the *C. elegans* elongase when expressed in yeast when no substrate is present and with addition of AA or GLA.

Figure 62 illustrates the PUFA elongase activity of an induced culture of 334 (PRET22) when supplemented with 50 μ M of various substrates.

Figure 63 represents the PUFA elongase activity with GLA (Figure 63A) or STA (Figure 63B) as a substrate when co-expressed with the *M. alpina* Δ 5-desaturase cDNA to produce AA or EPA, respectively.

Figure 64 represents an amino acid sequence alignment among 4 elongases: HSELO1 (Figure 44), MELO4 (Figure 55), GLELO (Figure 23), and CELEO (Figure 47).

Figure 65 represents the consensus nucleotide sequence of the partial *Thraustochytrium aureum* (*T. aureum*) 7091 elongase gene.

Figure 66 represents the deduced amino acid sequence of the *T. aureum* 7091 elongase gene in Figure 65.

Figure 67 represents the complete nucleotide sequence of the *T. aureum* 7091 elongase TELO1, from plasmid PRAT-4-A1.

Figure 68 represents the complete nucleotide sequence of the *T. aureum* 7091 elongase TELO1, from plasmid PRAT-4-A2.

Figure 69 represents the complete nucleotide sequence of the *T. aureum* 7091 elongase TELO1, from plasmid PRAT-4-A3.

Figure 70 represents the complete nucleotide sequence of the *T. aureum* 7091 elongase TELO1, from plasmid PRAT-4-A4.

Figure 71 represents the complete nucleotide sequence of the *T. aureum* 7091 elongase TELO1, from plasmid PRAT-4-A6.

Figure 72 represents the complete nucleotide sequence of the *T. aureum* 7091 elongase TELO1, from plasmid PRAT-4-A7.

Figure 73 represents the complete nucleotide sequence of the *T. aureum* 7091 elongase TELO1, from plasmid PRAT-4-D1.

Figure 74 represents the deduced amino acid sequence of the T. aureum 7091 elongase TELO1, from plasmid PRAT-4-A1.

Figure 75 represents the deduced amino acid sequence of the T. aureum 7091 elongase TELO1, from plasmid PRAT-4-A2.

Figure 76 represents the deduced amino acid sequence of the T. aureum 7091 elongase TELO1, from plasmid PRAT-4-A3.

Figure 77 represents the deduced amino acid sequence of the T. aureum 7091 elongase TELO1, from plasmid PRAT-4-A4.

Figure 78 represents the deduced amino acid sequence of the T. aureum 7091 elongase TELO1, from plasmid PRAT-4-A6.

Figure 79 represents the deduced amino acid sequence of the T. aureum 7091 elongase TELO1, from plasmid PRAT-4-A7.

Figure 80 represents the deduced amino acid sequence of the T. aureum 7091 elongase TELO1, from plasmid PRAT-4-D1.

Figure 81 represents the elongase activity of TELO1 expressed in baker's yeast when supplemented with GLA or EPA.

Figure 82 represents an amino acid sequence alignment among the TELO1 elongases from the 7 plasmids: PRAT-4-A1 (Figure 74), PRAT-4-A2 (Figure 75), PRAT-4-A3 (Figure 76), PRAT-4-A4 (Figure 77), PRAT-4-A6 (Figure 78), PRAT-4-A7 (Figure 79), and PRAT-4-D1 (Figure 80).

Figure 83 represents an alignment between the translated TELO1 sequence and the translated HSELO1 sequence.

Figure 84 represents an alignment between the translated TELO1 sequence and the translated MELO4 sequence.

Figure 85 represents an alignment between the translated TELO1 sequence and the translated GLELO sequence.

Figure 86 represents an alignment between the translated TELO1 sequence and the translated CEELO sequence.

Figure 87 represents the elongase activity of TELO1 expressed in baker's yeast when supplemented with GLA, AA, STA, EPA, or no substrate.

Figure 88 represents the elongase activity of TELO1 expressed in baker's yeast when supplemented with LA, ALA, GLA, STA, DGLA, ETA, AA or EPA.

DETAILED DESCRIPTION OF THE INVENTION

The subject invention relates to nucleotide and corresponding amino acid sequences of two elongase cDNAs derived from Mortierella alpina, as well as to nucleotide and corresponding amino acid sequences of an elongase cDNA derived from a human, an elongase cDNA derived from C. elegans, two elongase cDNAs derived from a mouse, and an elongase cDNA derived from Thraustochytrium aureum. Furthermore, the subject invention also includes uses of the cDNAs and of the proteins encoded by the genes. For example, the genes and corresponding enzymes may be used in the production of polyunsaturated fatty acids and/or monounsaturated fatty acids such as, for example, DGLA, AA, ADA, EPA and/or DHA which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, cosmetics, and to other valuable products.

The Elongase Genes and Enzymes Encoded Thereby

As noted above, an elongase enzyme encoded by an elongase cDNA is essential in the production of various polyunsaturated fatty acids, in particular, 20-24 carbon PUFAs. With respect to the present invention, the nucleotide sequence of the isolated M. alpina elongase cDNA (MAELO) is shown in Figure 6, and the amino acid sequence of the corresponding purified protein or

enzyme encoded by this nucleotide sequence is shown in Figure 7. Additionally, the nucleotide sequence of the isolated GLA elongase cDNA (GLELO) is shown in Figure 22, and the amino acid sequence of the corresponding purified protein or enzyme encoded by this nucleotide sequence is shown in Figure 23. The nucleotide sequence of the isolated human sequence 1 (HSELO1) elongase is shown in Figure 43, and the amino acid sequence of the corresponding purified protein or enzyme encoded by this sequence is shown in Figure 44. Furthermore, the nucleotide sequence of the isolated C. elegans elongase cDNA (CEELO1) is shown in Figure 46, and the amino acid sequence of the corresponding purified protein or enzyme encoded thereby is shown in Figure 47. Additionally, the nucleotide sequence of the isolated mouse PUFA elongation enzyme (MELO4) is shown in Figure 54, and the amino acid sequence of the corresponding purified protein or enzyme encoded thereby is shown in Figure 55. Moreover, the nucleotide sequence of the second isolated mouse PUFA elongation enzyme (MELO7) is shown in Figure 58, and the amino acid sequence of the corresponding purified protein or enzyme encoded thereby is shown in Figure 59. Also, the nucleotide sequence of the isolated T. aureum elongase cDNA (TELO1) is shown in Figure 72, and the amino acid sequence of the corresponding purified protein or enzyme encoded thereby is shown in Figure 79.

As an example, several of the isolated elongases encoded by the cDNAs of the present invention elongate GLA to DGLA or elongate STA to 20:4n-3 or elongate AA to ADA. The production of arachidonic acid from DGLA, or EPA from 20:4n-3, is then catalyzed by, for example, a $\Delta 5$ -desaturase. Thus, neither AA (or EPA), nor DGLA (or 20:4n-3) nor ADA (or $\omega 3$ -docosapentaenoic

acid), can be synthesized without at least one elongase cDNA and enzyme encoded thereby.

It should be noted that the present invention also encompasses nucleotide sequences (and the corresponding encoded proteins) having sequences corresponding to (i.e., having identity to) or complementary to at least about 50%, preferably at least about 60%, and more preferably at least about 70% of the nucleotides in SEQ ID NO:1 (i.e., the nucleotide sequence of the MAELO cDNA described herein (see Figure 6)). Furthermore, the present invention also includes nucleotide sequences (and the corresponding encoded proteins) having sequences corresponding to (i.e., having identity to) or complementary to at least about 35%, preferably at least about 45%, and more preferably at least about 55% of the nucleotides in SEQ ID NO:2 (i.e., the nucleotide sequence of the GLELO cDNA described herein (see Figure 22)). Additionally, the present invention also includes nucleotide sequences (and the corresponding encoded proteins) having sequences corresponding to (i.e., having identity to) or complementary to at least about 35%, preferably at least about 45%, and more preferably at least about 55% of the nucleotides in SEQ ID NO:3 (i.e., the nucleotide sequence of the human sequence 1 (HSELO1) cDNA described herein (see Figure 43)). In addition, the present invention also includes nucleotide sequences (and the corresponding encoded proteins) having sequences corresponding to (i.e., having identity to) or complementary to at least about 35%, preferably at least about 45%, and more preferably at least about 55% of the nucleotides in SEQ ID NO:4 (i.e., the nucleotide sequence of the C. elegans cDNA, CEELO1, described herein (see Figure 46)). Further, the present invention also includes nucleotide sequences (and the corresponding encoded

proteins) having sequences corresponding to (i.e., having identity to) or complementary to at least about 35%, preferably at least about 45%, and more preferably at least about 55% of the nucleotides in SEQ ID NO:5 or SEQ ID NO:6 (i.e., the nucleotide sequence of the mouse PUFA elongases MELO4 and MELO7, described herein (see Figures 54 and 58, respectively)). Also, the present invention encompasses nucleotide sequences (and the corresponding encoded proteins) having sequences corresponding to (i.e., having identity to) or complementary to at least about 35%, preferably at least about 45%, and more preferably at least about 55% of the nucleotides in SEQ ID NO:7 (i.e., the nucleotide sequence of the *T. aureum* elongase gene TELO1, described herein (see Figure 72)). It should be noted that the "most preferable" range, referred to in each instance, may be increased by increments of ten percent. For example, if "at least 55%" is the most preferable range recited above, with respect to a particular sequence, such a range also naturally includes "at least 65% identity", "at least 75% identity", "at least 85% identity", and "at least 95% identity".

The corresponding or complementary sequences may be derived from non-*Mortierella* sources or sources other than from which the isolated, original sequences were derived (e.g., a eukaryote (e.g., *Thraustochytrium* spp. (e.g., *Thraustochytrium aureum* and *Thraustochytrium roseum*), *Schizochytrium* spp. (e.g., *Schizochytrium aggregatum*), *Conidiobolus* spp. (e.g., *Conidiobolus nanodes*), *Entomophthora* spp. (e.g., *Entomophthora exitalis*), *Saprolegnia* spp. (e.g., *Saprolegnia parasitica* and *Saprolegnia diclina*), *Leptomit* spp. (e.g., *Leptomit lacteus*), *Entomophthora* spp., *Pythium* spp., *Porphyridium* spp. (e.g., *Porphyridium cruentum*), *Conidiobolus* spp., *Phytophthora* spp., *Penicillium* spp., *Coidosporium* spp., *Mucor* spp. (e.g.,

Mucor circinelloides and *Mucor javanicus*), *Fusarium* spp., *Aspergillus* spp., *Rhodotorula* spp., *Amphidinium carteri*, *Chaetoceros calcitrans*, *Cricosphaera carterae*, *Cryptocodinium cohnii*, *Cryptomonas ovata*, *Euglena gracilis*, *Gonyaulax polyedra*, *Gymnodinium* spp. (e.g. *Gymnodinium nelsoni*), *Gyrodinium cohnii*, *Isochrysis* spp. (e.g. *Isochrysis galbana*), *Microalgae* MK8805, *Nitzschia frustulum*, *Pavlova* spp. (e.g. *Pavlova lutheri*), *Phaeodactylum tricornutum*, *Prorocentrum cordatum*, *Rhodomonas lens*, and *Thalassiosira pseudonana*), a Psychrophilic bacteria (e.g., *Vibrio* spp. (e.g., *Vibrio marinus*)), a yeast (e.g., *Dipodascopsis uninucleata*), a non-mammalian organism such as a fly (e.g., *Drosophila melanogaster*) or *Caenorhabditis* spp. (e.g., *Caenorhabditis elegans*), or a mammal (e.g., a human or a mouse). Such sequences may also be derived from a species within the genus *Mortierella*, other than the species *alpina*, for example, *Mortierella elongata*, *Mortierella exigua*, *Mortierella isabellina*, *Mortierella hygrophila*, and *Mortierella ramanniana*, va. *angulisporea*.

Furthermore, the present invention also encompasses fragments and derivatives of the nucleotide sequences of the present invention (i.e., SEQ ID NO:1 (MAELO), SEQ ID NO:2 (GLELO), SEQ ID NO:3 (HSELO1), SEQ ID NO:4 (CEELO1), SEQ ID NO:5 (MELO4), SEQ ID NO:6 (MELO7) and SEQ ID NO:7 (TELO1)) as well as of the corresponding sequences derived from non-*Mortierella* or non-mammalian sources, etc., as described above, and having the above-described complementarity or correspondence/identity to the 7 sequences. Functional equivalents of the above-sequences (i.e., sequences having elongase activity) are also encompassed by the present invention.

For purposes of the present invention, "complementarity" is defined as the degree of relatedness between two DNA segments. It is determined by measuring the ability of the sense strand of one DNA segment to hybridize with the antisense strand of the other DNA segment, under appropriate conditions, to form a double helix. In the double helix, wherever adenine appears in one strand, thymine appears in the other strand. Similarly, wherever guanine is found in one strand, cytosine is found in the other. The greater the relatedness between the nucleotide sequences of two DNA segments, the greater the ability to form hybrid duplexes between the strands of two DNA segments.

"Identity" between two nucleotide sequences is defined as the degree of sameness, correspondence or equivalence between the same strands (either sense or antisense) of two DNA segments. The greater the percent identity, the higher the correspondence, sameness or equivalence between the strands.

"Similarity" between two amino acid sequences is defined as the presence of a series of identical as well as conserved amino acid residues in both sequences. The higher the degree of similarity between two amino acid sequences, the higher the correspondence, sameness or equivalence of the two sequences. ("Identity" between two amino acid sequences is defined as the presence of a series of exactly alike or invariant amino acid residues in both sequences.)

The definitions of "complementarity", "identity", and "similarity" are well known to those of ordinary skill in the art.

The invention also includes a purified polypeptide which elongates polyunsaturated and monounsaturated fatty acids and has at least about 50%, preferably at least about 70%, and more preferably at least about 90% amino acid similarity to the amino

acid sequences of the above-noted proteins (see, e.g., Figure 7 (WAELO)) and which are, in turn, encoded by the above-described nucleotide sequences. Additionally, the present invention includes a purified polypeptide which elongates polyunsaturated fatty acids and has at least about 30%, preferably at least about 60%, and more preferably at least about 90% amino acid similarity to the amino acid sequences of the above-noted proteins (see, e.g., Figure 23 (GLELO)) and which are, in turn, encoded by the above-described nucleotide sequences.

Furthermore, the invention also includes a purified polypeptide which elongates polyunsaturated and monounsaturated fatty acids and has at least about 30%, preferably at least about 60%, and more preferably at least about 90% amino acid similarity to the amino acid sequences of the above-noted proteins (see, e.g., Figure 44 (HSELO1)) and which are, in turn, encoded by the above-described nucleotide sequences. Also, the present invention includes a purified polypeptide which elongates polyunsaturated fatty acids and has at least about 30%, preferably at least about 60%, and more preferably at least about 90% amino acid similarity to the amino acid sequences of the above-noted proteins (see, e.g., Figure 47 (CHELO1)) and which are, in turn, encoded by the above-described nucleotide sequences. The present invention also includes a purified polypeptide which elongates polyunsaturated fatty acids and has at least about 30%, preferably at least about 60%, and more preferably at least about 90% amino acid similarity to the amino acid sequences of the above-noted proteins (see, e.g., Figure 55 (MELO4) and Figure 58 (MELO7)) and which are, in turn, encoded by the above-described nucleotide sequences. Also, the present invention includes a purified polypeptide which elongates polyunsaturated fatty acids and has at least about 30%,

preferably at least about 60%, and more preferably at least about 90% amino acid similarity to the amino acid sequences of the above noted proteins (see, e.g., Figure 79 (TELO1)) and which are, in turn, encoded by the above-described nucleotide sequences.

The present invention also encompasses an isolated nucleotide sequence which encodes PUFA elongase activity and that is hybridizable, under moderately stringent conditions, to a nucleic acid having a nucleotide sequence corresponding or complementary to the nucleotide sequence represented by SEQ ID NO:1 shown in Figure 6 (WAELO) and/or SEQ ID NO:2 shown in Figure 22 (GLELO) and/or SEQ ID NO:3 (HSELO1) shown in Figure 43 and/or SEQ ID NO:4 (CEELO1) shown in Figure 46 and/or SEQ ID NO:5 (WEL04) shown in Figure 54 and/or SEQ ID NO:6 (WEL07) shown in Figure 58 and/or SEQ ID NO:7 (TELO1) shown in Figure 72. A nucleic acid molecule is "hybridizable" to another nucleic acid molecule when a single-stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and ionic strength (see Sambrook et al., "Molecular Cloning: A Laboratory Manual, Second Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York)). The conditions of temperature and ionic strength determine the "stringency" of the hybridization.

"Hybridization" requires that two nucleic acids contain complementary sequences. However, depending on the stringency of the hybridization, mismatches between bases may occur. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementarity. Such variables are well known in the art.

More specifically, the greater the degree of similarity or homology between two nucleotide sequences, the greater the value

of T_m , melting temperature, for hybrids of nucleic acids having those sequences. For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived (see Sambrook et al., supra). For hybridization with shorter nucleic acids, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., supra).

Production of the Elongase Enzyme

Once the gene encoding the elongase has been isolated, it may then be introduced into either a prokaryotic or eukaryotic host cell through the use of a vector, plasmid or construct.

The vector, for example, a bacteriophage, cosmid or plasmid, may comprise the nucleotide sequence encoding the elongase as well as any promoter which is functional in the host cell and is able to elicit expression of the elongase encoded by the nucleotide sequence. The promoter is in operable association with or operably linked to the nucleotide sequence.

(A promoter is said to be "operably linked" with a coding sequence if the promoter affects transcription or expression of the coding sequence.) Suitable promoters include, for example, those from genes encoding alcohol dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglucoisomerase, phosphoglycerate kinase, acid phosphatase, T7, TPI, lactase, metallothionein, cytomegalovirus immediate early, whey acidic protein, glucoamylase, and promoters activated in the presence of galactose, for example, GAL1 and GAL10. Additionally, nucleotide sequences which encode other proteins,

oligosaccharides, lipids, etc. may also be included within the vector as well as other regulatory sequences such as a polyadenylation signal (e.g., the poly-A signal of SV-40T-

antigen, ovalalbumin or bovine growth hormone). The choice of sequences present in the construct is dependent upon the desired expression products as well as the nature of the host cell.

As noted above, once the vector has been constructed, it may then be introduced into the host cell of choice by methods known to those of ordinary skill in the art including, for example, transfection, transformation and electroporation (see Molecular Cloning: A Laboratory Manual, 2nd ed., Vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press (1989)).

The host cell is then cultured under suitable conditions permitting expression of the PUFA which is then recovered and purified.

It should also be noted that one may design a unique triglyceride or oil if one utilizes one construct or vector comprising the nucleotide sequences of two or more cDNAs (e.g., MAELO, GLELO, HSELO1, CELO1 and/or TELO1). This vector may then be introduced into one host cell. Alternatively, each of the sequences may be introduced into a separate vector. These vectors may then be introduced into two host cells, respectively, or into one host cell.

Examples of suitable prokaryotic host cells include, for example, bacteria such as Escherichia coli, Bacillus subtilis as well as cyanobacteria such as Spirulina spp. (i.e., blue-green algae). Examples of suitable eukaryotic host cells include, for example, mammalian cells, plant cells, yeast cells such as Saccharomyces spp., Lipomyces spp., Candida spp. such as Yarrowia (Candida) spp., Kluyveromyces spp., Pichia spp., Trichoderma spp. or Hansenula spp., or fungal cells such as filamentous fungal cells, for example, Aspergillus, Neurospora and Penicillium. Preferably, Saccharomyces cerevisiae (baker's yeast) cells are utilized.

Expression in a host cell can be accomplished in a transient or stable fashion. Transient expression can occur from introduced constructs which contain expression signals functional in the host cell, but which constructs do not replicate and rarely integrate in the host cell, or where the host cell is not proliferating. Transient expression also can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest, although such inducible systems frequently exhibit a low basal level of expression. Stable expression can be achieved by introduction of a construct that can integrate into the host genome or that autonomously replicates in the host cell. Stable expression of the gene of interest can be selected for through the use of a selectable marker located on or transfected with the expression construct, followed by selection for cells expressing the marker. When stable expression results from integration, the site of the construct's integration can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination with the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.

A transgenic mammal may also be used in order to express the enzyme of interest (i.e., the elongase) encoded by one or both of the above-described nucleotide sequences. More specifically, once the above-described construct is created, it may be inserted into the pronucleus of an embryo. The embryo may then be implanted into a recipient female. Alternatively, a nuclear transfer method could also be utilized (Schnieke et al., Science 278:2130-2133 (1997)). Gestation and birth are then

permitted to occur (see, e.g., U.S. Patent No. 5,750,176 and U.S. Patent No. 5,700,671). Milk, tissue or other fluid samples from the offspring should then contain altered levels of PUFAs, as compared to the levels normally found in the non-transgenic

5 animal. Subsequent generations may be monitored for production of the altered or enhanced levels of PUFAs and thus incorporation of the gene or genes encoding the elongase enzyme into their genomes. The mammal utilized as the host may be selected from the group consisting of, for example, a mouse, a rat, a rabbit, a pig, a goat, a sheep, a horse and a cow.

However, any mammal may be used provided it has the ability to incorporate DNA encoding the enzyme of interest into its genome.

For expression of an elongase polypeptide, functional transcriptional and translational initiation and termination regions are operably linked to the DNA encoding the elongase polypeptide. Transcriptional and translational initiation and termination regions are derived from a variety of nonexclusive sources, including the DNA to be expressed, genes known or suspected to be capable of expression in the desired system, expression vectors, chemical synthesis, or from an endogenous locus in a host cell. Expression in a plant tissue and/or plant part presents certain efficiencies, particularly where the tissue or part is one which is harvested early, such as seed, leaves, fruits, flowers, roots, etc. Expression can be targeted to that location with the plant by utilizing specific regulatory sequence such as those of U.S. Patent Nos. 5,463,174, 4,943,674, 5,106,739, 5,175,095, 5,420,034, 5,188,958, and 5,589,379. Alternatively, the expressed protein can be an enzyme which produces a product which may be incorporated, either directly or upon further modifications, into a fluid fraction from the host plant. Expression of an elongase gene or genes, or antisense

elongase transcripts, can alter the levels of specific PUFAs, or derivatives thereof, found in plant parts and/or plant tissues.

The elongase polypeptide coding region may be expressed either by itself or with other genes, in order to produce tissues

5 and/or plant parts containing higher proportions of desired PUFAs or in which the PUFA composition more closely resembles that of human breast milk (Prieto et al., PCT publication WO 95/24494). The termination region may be derived from the 3' region of the gene from which the initiation region was obtained or from a different gene. A large number of termination regions are known to and have been found to be satisfactory in a variety of hosts from the same and different genera and species. The termination region usually is selected as a matter of convenience rather than because of any particular property.

15 As noted above, a plant (e.g., Glycine max (soybean) or Brassica napus (canola)), plant cell, plant tissue, corn, potatoe, sunflower, safflower or flax may also be utilized as a host or host cell, respectively, for expression of the elongase enzyme(s) which may, in turn, be utilized in the production of polyunsaturated fatty acids. More specifically, desired PUFAs can be expressed in seed. Methods of isolating seed oils are known in the art. Thus, in addition to providing a source for PUFAs, seed oil components may be manipulated through the expression of the elongase genes, as well as perhaps desaturase genes, in order to provide seed oils that can be added to nutritional compositions, pharmaceutical compositions, animal feeds and cosmetics. Once again, a vector which comprises a DNA sequence encoding the elongase operably linked to a promoter, will be introduced into the plant tissue or plant for a time and under conditions sufficient for expression of the elongase gene. 30 The vector may also comprise one or more genes which encode

other enzymes, for example, $\Delta 4$ -desaturase, $\Delta 5$ -desaturase, $\Delta 6$ -desaturase, $\Delta 8$ -desaturase, $\Delta 9$ -desaturase, $\Delta 10$ -desaturase, $\Delta 12$ -desaturase, $\Delta 13$ -desaturase, $\Delta 15$ -desaturase, $\Delta 17$ -desaturase and/or $\Delta 19$ -desaturase. The plant tissue or plant may produce the relevant substrate (e.g., DGLA, GLA, STA, AA, ADA, EPA, 20:4n-3, etc.) upon which the enzymes act or a vector encoding enzymes which produce such substrates may be introduced into the plant tissue, plant cell, plant, or host cell of interest. In addition, substrate may be sprayed on plant tissues expressing the appropriate enzymes. Using these various techniques, one may produce PUFAs (e.g., n-6 unsaturated fatty acids such as DGLA, AA or ADA, or n-3 fatty acids such as EPA or DHA) by use of a plant cell, plant tissue, plant, or host cell of interest. It should also be noted that the invention also encompasses a transgenic plant comprising the above-described vector, wherein expression of the nucleotide sequence of the vector results in production of a polyunsaturated fatty acid in, for example, the seeds of the transgenic plant.

The substrates which may be produced by the host cell either naturally or transgenically, as well as the enzymes which may be encoded by DNA sequences present in the vector, which is subsequently introduced into the host cell, are shown in Figure 1.

In view of the above, the present invention also encompasses a method of producing one of the elongase enzymes described above comprising the steps of: 1) isolating the desired nucleotide sequence of the elongase cDNA; 2) constructing a vector comprising said nucleotide sequence; and 3) introducing said vector into a host cell under time and conditions sufficient for the production of the elongase enzyme.

The present invention also encompasses a method of producing polyunsaturated fatty acids comprising exposing an acid to the elongase(s) produced as above such that the elongase converts the acid to a polyunsaturated fatty acid. For example, when GLA is exposed to elongase, it is converted to DGLA. DGLA may then be exposed to $\Delta 5$ -desaturase which converts the DGLA to AA. The AA may then be converted to EPA by use of $\Delta 17$ -desaturase which may be, in turn, converted to DHA by use of elongase and a $\Delta 4$ -desaturase. Alternatively, elongase may be utilized to convert 18:4n-3 to 20:4n-3 which may be exposed to $\Delta 5$ -desaturase and converted to EPA. Elongase may also be used to convert 18:3n-3 to 20:3n-3, which may be, in turn, converted to 20:4n-3 by a $\Delta 8$ -desaturase. Thus, elongase may be used in the production of polyunsaturated fatty acids which may be used, in turn, for particular beneficial purposes. (See Figure 1 for an illustration of the many critical roles the elongase enzyme plays in several biosynthetic pathways.)

Uses of the Elongase Gene and Enzyme Encoded Thereby

As noted above, the isolated elongase cDNAs and the corresponding elongase enzymes (or purified polypeptides) encoded thereby have many uses. For example, each cDNA and corresponding enzyme may be used indirectly or directly in the production of polyunsaturated fatty acids, for example, DGLA, AA, ADA, 20:4n-3 or EPA. ("Directly" is meant to encompass the situation where the enzyme directly converts the acid to another acid, the latter of which is utilized in a composition (e.g., the conversion of GLA to DGLA)). "Indirectly" is meant to encompass the situation where a fatty acid is converted to another fatty acid (i.e., a pathway intermediate) by elongase

(e.g., GLA to DGLA) and then the latter fatty acid is converted to another fatty acid by use of a non-elongase enzyme (e.g., DGLA to AA by $\Delta 5$ -desaturase)). These polyunsaturated fatty acids (i.e., those produced either directly or indirectly by activity of the elongase enzyme) may be added to, for example, nutritional compositions, pharmaceutical compositions, cosmetics, and animal feeds, all of which are encompassed by the present invention. These uses are described, in detail, below.

10 Nutritional Compositions

The present invention includes nutritional compositions. Such compositions, for purposes of the present invention, include any food or preparation for human consumption including for enteral or parenteral consumption, which when taken into the body (a) serve to nourish or build up tissues or supply energy and/or (b) maintain, restore or support adequate nutritional status or metabolic function.

The nutritional composition of the present invention comprises at least one oil or acid produced by use of at least one elongase enzyme, produced using the respective elongase gene, and may either be in a solid or liquid form. Additionally, the composition may include edible macronutrients, vitamins and minerals in amounts desired for a particular use. The amount of such ingredients will vary depending on whether the composition is intended for use with normal, healthy infants, children or adults having specialized needs such as those which accompany certain metabolic conditions (e.g., metabolic disorders).

30 Examples of macronutrients which may be added to the composition include but are not limited to edible fats,

carbohydrates and proteins. Examples of such edible fats include but are not limited to coconut oil, soy oil, and mono- and diglycerides. Examples of such carbohydrates include but are not limited to glucose, edible lactose and hydrolyzed starch. Additionally, examples of proteins which may be utilized in the nutritional composition of the invention include but are not limited to soy proteins, electrodialysed whey, electrodialysed skim milk, milk whey, or the hydrolysates of these proteins.

10 With respect to vitamins and minerals, the following may be added to the nutritional compositions of the present invention: calcium, phosphorus, potassium, sodium, chloride, magnesium, manganese, iron, copper, zinc, selenium, iodine, and Vitamins A, E, D, C, and the B complex. Other such vitamins and minerals may also be added.

15 The components utilized in the nutritional compositions of the present invention will be of semi-purified or purified origin. By semi-purified or purified is meant a material which has been prepared by purification of a natural material or by synthesis.

20 Examples of nutritional compositions of the present invention include but are not limited to infant formulas, dietary supplements, dietary substitutes, and rehydration compositions. Nutritional compositions of particular interest include but are not limited to those utilized for enteral and parenteral supplementation for infants, specialist infant formulae, supplements for the elderly, and supplements for those with gastrointestinal difficulties and/or malabsorption.

25 The nutritional composition of the present invention may also be added to food even when supplementation of the diet is not required. For example, the composition may be added to food

of any type including but not limited to margarines, modified butters, cheeses, milk, yogurt, chocolate, candy, snacks, salad oils, cooking oils, cooking fats, meats, fish and beverages.

In a preferred embodiment of the present invention, the

5 nutritional composition is an enteral nutritional product, more preferably, an adult or pediatric enteral nutritional product. This composition may be administered to adults or children

experiencing stress or having specialized needs due to chronic or acute disease states. The composition may comprise, in

10 addition to polyunsaturated fatty acids produced in accordance with the present invention, macronutrients, vitamins and minerals as described above. The macronutrients may be present

in amounts equivalent to those present in human milk or on an energy basis, i.e., on a per calorie basis.

15 Methods for formulating liquid or solid enteral and parenteral nutritional formulas are well known in the art. (See also the Examples below.)

The enteral formula, for example, may be sterilized and subsequently utilized on a ready-to-feed (RTF) basis or stored in a concentrated liquid or powder. The powder can be prepared by spray drying the formula prepared as indicated above, and reconstituting it by rehydrating the concentrate. Adult and pediatric nutritional formulas are well known in the art and are commercially available (e.g., Similac®, Ensure®, Jevity® and Alimientum® from Ross Products Division, Abbott Laboratories, Columbus, Ohio). An oil or fatty acid produced in accordance with the present invention may be added to any of these formulas.

The energy density of the nutritional compositions of the present invention, when in liquid form, may range from about 0.6 Kcal to about 3 Kcal per ml. When in solid or powdered form,

the nutritional supplements may contain from about 1.2 to more than 9 Kcals per gram, preferably about 3 to 7 Kcals per gm. In general, the osmolality of a liquid product should be less than 700 mOsm and, more preferably, less than 660 mOsm.

5 The nutritional formula may include macronutrients, vitamins, and minerals, as noted above, in addition to the PUFAs produced in accordance with the present invention. The presence of these additional components helps the individual ingest the minimum daily requirements of these elements. In addition to the provision of PUFAs, it may also be desirable to add zinc, copper, folic acid and antioxidants to the composition. It is believed that these substance boost a stressed immune system and will therefore provide further benefits to the individual receiving the composition. A pharmaceutical composition may also be supplemented with these elements.

15 In a more preferred embodiment, the nutritional composition comprises, in addition to antioxidants and at least one PUFA, a source of carbohydrate wherein at least 5 weight % of the carbohydrate is indigestible oligosaccharide. In a more preferred embodiment, the nutritional composition additionally comprises protein, taurine, and carnitine.

20 As noted above, the PUFAs produced in accordance with the present invention, or derivatives thereof, may be added to a dietary substitute or supplement, particularly an infant formula, for patients undergoing intravenous feeding or for preventing or treating malnutrition or other conditions or disease states. As background, it should be noted that human breast milk has a fatty acid profile comprising from about 0.15% to about 0.36% as DHA, from about 0.03% to about 0.13% as EPA, from about 0.30% to about 0.88% as AA, from about 0.23% to about 0.67% as DGLA, and from about 0.27% to about 1.04% as GLA. Thus,

fatty acids such as DGLA, AA, EPA and/or docosahexaenoic acid (DHA), produced in accordance with the present invention, can be used to alter, for example, the composition of infant formulas in order to better replicate the PUFA content of human breast milk or to alter the presence of PFAs normally found in a non-human mammal's milk. In particular, a composition for use in a pharmacologic or food supplement, particularly a breast milk substitute or supplement, will preferably comprise one or more of AA, DGLA and GLA. More preferably, the oil blend will comprise from about 0.3 to 30% AA, from about 0.2 to 30% DGLA, and/or from about 0.2 to about 30% GLA.

Parenteral nutritional compositions comprising from about 2 to about 30 weight percent fatty acids calculated as triglycerides are encompassed by the present invention. The preferred composition has about 1 to about 25 weight percent of the total PUFA composition as GLA (U.S. Patent No. 5,196,198). Other vitamins, particularly fat-soluble vitamins such as vitamin A, D, E and L-carnitine can optionally be included. When desired, a preservative such as alpha-tocopherol may be added in an amount of about 0.1% by weight.

In addition, the ratios of AA, DGLA and GLA can be adapted for a particular given end use. When formulated as a breast milk supplement or substitute, a composition which comprises one or more of AA, DGLA and GLA will be provided in a ratio of about 1:19:30 to about 6:1:0.2, respectively. For example, the breast milk of animals can vary in ratios of AA:DGLA:GLA ranging from 1:19:30 to 6:1:0.2, which includes intermediate ratios which are preferably about 1:1:1, 1:2:1, 1:1:4. When produced together in a host cell, adjusting the rate and percent of conversion of a precursor substrate such as GLA and DGLA to AA can be used to precisely control the PUFA ratios. For example, a 5% to 10%

conversion rate of DGLA to AA can be used to produce an AA to DGLA ratio of about 1:19, whereas a conversion rate of about 75% to 80% can be used to produce an AA to DGLA ratio of about 6:1. Therefore, whether in a cell culture system or in a host animal, regulating the timing, extent and specificity of elongase expression, as well as the expression of other desaturases, can be used to modulate PUFA levels and ratios. The PUFAs/acids produced in accordance with the present invention (e.g., AA and DGLA) may then be combined with other PUFAs/acids (e.g., GLA) in the desired concentrations and ratios.

Additionally, PUFA produced in accordance with the present invention or host cells containing them may also be used as animal food supplements to alter an animal's tissue or milk fatty acid composition to one more desirable for human or animal consumption.

Pharmaceutical Compositions

The present invention also encompasses a pharmaceutical composition comprising one or more of the fatty acids and/or resulting oils produced using at least one of the elongase cDNAs (i.e., MAELO, GLELO, HSELO1, CELO, MELO4 and MELO7), in accordance with the methods described herein. More specifically, such a pharmaceutical composition may comprise one or more of the acids and/or oils as well as a standard, well-known, non-toxic pharmaceutically acceptable carrier, adjuvant or vehicle such as, for example, phosphate buffered saline, water, ethanol, polyols, vegetable oils, a wetting agent or an emulsion such as a water/oil emulsion. The composition may be in either a liquid or solid form. For example, the composition may be in the form of a tablet, capsule, ingestible liquid or

powder, injectible, or topical ointment or cream. Proper fluidity can be maintained, for example, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. It may also be desirable to include

5 isotonic agents, for example, sugars, sodium chloride and the like. Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents and perfuming agents.

10 Suspensions, in addition to the active compounds, may comprise suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these

15 substances.

Solid dosage forms such as tablets and capsules can be prepared using techniques well known in the art. For example, PUFAs produced in accordance with the present invention can be tableted with conventional tablet bases such as lactose,

20 sucrose, and cornstarch in combination with binders such as acacia, cornstarch or gelatin, disintegrating agents such as potato starch or alginic acid, and a lubricant such as stearic acid or magnesium stearate. Capsules can be prepared by incorporating these excipients into a gelatin capsule along with antioxidants and the relevant PUFA(s). The antioxidant and PUFA

25 components should fit within the guidelines presented above.

For intravenous administration, the PUFAs produced in accordance with the present invention or derivatives thereof may be incorporated into commercial formulations such as

30 Intralipids™. The typical normal adult plasma fatty acid profile comprises 6.64 to 9.46% of AA, 1.45 to 3.11% of DGLA,

and 0.02 to 0.08% of GLA. These PUFAs or their metabolic precursors can be administered alone or in combination with other PUFAs in order to achieve a normal fatty acid profile in a patient. Where desired, the individual components of the

5 formulations may be provided individually, in kit form, for single or multiple use. A typical dosage of a particular fatty acid is from 0.1 mg to 20 g (up to 100 g) daily and is preferably from 10 mg to 1, 2, 5 or 10 g daily.

Possible routes of administration of the pharmaceutical compositions of the present invention include, for example, enteral (e.g., oral and rectal) and parenteral. For example, a liquid preparation may be administered, for example, orally or rectally. Additionally, a homogenous mixture can be completely dispersed in water, admixed under sterile conditions with

15 physiologically acceptable diluents, preservatives, buffers or propellants in order to form a spray or inhalant.

The route of administration will, of course, depend upon the desired effect. For example, if the composition is being utilized to treat rough, dry, or aging skin, to treat injured or

20 burned skin, or to treat skin or hair affected by a disease or condition, it may perhaps be applied topically.

The dosage of the composition to be administered to the patient may be determined by one of ordinary skill in the art and depends upon various factors such as weight of the patient,

25 age of the patient, immune status of the patient, etc.

With respect to form, the composition may be, for example, a solution, a dispersion, a suspension, an emulsion or a sterile powder which is then reconstituted.

The present invention also includes the treatment of various disorders by use of the pharmaceutical and/or

30 nutritional compositions described herein. In particular, the

compositions of the present invention may be used to treat restenosis after angioplasty. Furthermore, symptoms of inflammation, rheumatoid arthritis, asthma and psoriasis may also be treated with the compositions of the invention.

5 Evidence also indicates that PUFAs may be involved in calcium metabolism; thus, the compositions of the present invention may, perhaps, be utilized in the treatment or prevention of osteoporosis and of kidney or urinary tract stones.

10 Additionally, the compositions of the present invention may also be used in the treatment of cancer. Malignant cells have been shown to have altered fatty acid compositions. Addition of fatty acids has been shown to slow their growth, cause cell death and increase their susceptibility to chemotherapeutic agents. Moreover, the compositions of the present invention may also be useful for treating cachexia associated with cancer.

15 The compositions of the present invention may also be used to treat diabetes (see U.S. Patent No. 4,826,877 and Horrobin et al., Am. J. Clin. Nutr. Vol. 57 (Suppl.) 732S-737S). Altered fatty acid metabolism and composition have been demonstrated in diabetic animals.

20 Furthermore, the compositions of the present invention, comprising PUFAs produced either directly or indirectly through the use of the elongase enzyme(s), may also be used in the treatment of eczema, in the reduction of blood pressure, and in the improvement of mathematics examination scores.

25 Additionally, the compositions of the present invention may be used in inhibition of platelet aggregation, induction of vasodilation, reduction in cholesterol levels, inhibition of proliferation of vessel wall smooth muscle and fibrous tissue (Brenner et al., Adv. Exp. Med. Biol. Vol. 83, p.85-101, 1976), reduction or prevention of gastrointestinal bleeding and other

side effects of non-steroidal anti-inflammatory drugs (see U.S. Patent No. 4,666,701), prevention or treatment of endometriosis and premenstrual syndrome (see U.S. Patent No. 4,758,592), and treatment of myalgic encephalomyelitis and chronic fatigue after viral infections (see U.S. Patent No. 5,116,871).

5 Further uses of the compositions of the present invention include use in the treatment of AIDS, multiple sclerosis, and inflammatory skin disorders, as well as for maintenance of general health.

10 Additionally, the composition of the present invention may be utilized for cosmetic purposes. It may be added to pre-existing cosmetic compositions such that a mixture is formed or may be used as a sole composition.

15 Veterinary Applications

It should be noted that the above-described pharmaceutical and nutritional compositions may be utilized in connection with animals (i.e., domestic or non-domestic), as well as humans, as animals experience many of the same needs and conditions as humans. For example, the oil or acids of the present invention may be utilized in animal feed supplements, animal feed substitutes, animal vitamins or in animal topical ointments.

20 The present invention may be illustrated by the use of the following non-limiting examples:

Example I

Determination of Codon Usage in *Mortierella alpina*

30

The 5' end of 1000 random cDNA clones were sequenced from *Mortierella alpina* cDNA library. The sequences were translated in six reading frames using GCG (Genetics Computer Group (Madison, Wisconsin)) with the FastA

algorithm (Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444-2448 (1988)) to search for similarity between a query sequence and a group of sequences of the same type (nucleic acid or protein), specifically with the

Swissprot database (GeneBio, Geneva, Switzerland). Many

of the clones were identified as a putative housekeeping gene based on protein sequence homology to known genes.

Twenty-one *M. alpina* cDNA sequences which matched with known, housekeeping genes in the database were selected (see Table 1 below). *M. alpina* codon bias table (see

Table 2) was generated based on these 21 sequences as well as the full length *M. alpina* Δ5- (see Figure 18),

Δ6-, and Δ12-desaturase sequences. Since the FastA

alignment between the putative protein coded by the *M.*

alpina cDNA sequence and the known protein sequence was

weak in some areas, only the codons from areas of strong homology were used.

Table 1

Clone #	Match	# of bp	# of
193	Elongation factor 1-alpha	426	14
143	60S ribosomal protein L17	417	14
235	Actin I	360	14
299	40S ribosomal protein YS11	387	12
390	Ras-related protein rab-1a	342	11
65	40S ribosomal protein RP10	366	14
289	Ubiquitin-conjugating enzyme E2-16 KD	294	9
151	Ubiquitin-cytochrome C reductase	375	14
80	Initiation factor 5A-2	183	6
33	60S ribosomal protein L15	252	8

132	60S ribosomal protein L3-2	300	14
198	Histone H3	285	9
286	6-phosphogluconate dehydrogenase, decarboxylating	363	14
283	40S ribosomal protein S22	261	8
127	Elongation factor 2	231	7
197	Actin, gamma	252	8
496	40S ribosomal protein S16	270	9
338	Histone H4	219	7
262	Ubiquitin	228	7
188	Guanine nucleotide-binding protein beta subunit-like protein	213	7
81	Ubiquitin	228	7
21	TOTAL	6252	20

Table 2

Amino acid	Codon Bias	% used	Amino acid	Codon Bias	% used
Ala	GCC	63%	Lys	AAG	98%
Arg	CGC	50%	Met	ATG	100%
Asn	AAC	97%	Pro	TTC	78%
Asp	GAC	85%	Ser	CCC	88%
Cys	TGC	87%	Thr	TCC	46%
Gln	CAG	78%	Trp	ACC	78%
Glu	GAG	85%	Tyr	TGG	100%
Gly	GGT	47%	Val	TAC	95%
His	CAC	91%	Stop	GTC	72%
Ile	ATC	72%		TAA	50%
Leu	CTC	49%			

20

of

of bp

Clone #

25

Example II
Cloning of a Full-length Elongase-like cDNA from *M. alpina*

The β -ketoacyl-coenzyme A synthase (KCS) from *Jojoba* and the *Saccharomyces cerevisiae* elongase (ELO2) were aligned to determine an area of amino acid homology (see Figure 2). The codon bias was applied to the area of

sequence corresponding to the homologous amino acids between the two elongases, and primers were designed based on this biased sequence (see Figure 3). The cDNA was excised from the M11 M. alpina cDNA library (Knutzon et al., J. Biol. Chem. 273:29360-29366 (1998)), which contains approximately 6 X 10⁵ clones with an average insert size of 1.1 Kb. The excised cDNA was amplified with internal primer R0339 (5' -TTG GAG AGG AGG CCA CCG AAG ATG ATG- 3') and a vector forward primer CCA CCG AAG ATG ATG- 3') and a vector forward primer R0317 (5' -CAC ACA GGA AAC AGC TAT GAC CAT GAT TAC G - 3'). Polymerase Chain Reaction (PCR) was carried out in a 100 µl volume containing: 300 ng of excised M. alpina cDNA library, 50 pmole each primer, 10 µl of 10X buffer, 1 µl 10 mM PCR Nucleotide Mix (Boehringer Mannheim Corp., Indianapolis, IN) and 1.0 U of Taq Polymerase.

Thermocycler conditions in Perkin Elmer 9600 (Norwalk, CT) were as follows: 94°C for 2 mins., then 30 cycles of 94°C for 1 min., 58°C for 2 mins., and 72°C for 3 mins. PCR was followed by an additional extension at 72°C for 7 minutes.

The PCR amplified product was run on a gel, an amplified fragment of approximately 360 bp was gel purified, and the isolated fragment was directly sequenced using ABI 373A DNA Sequencer (Perkin Elmer, Foster City, CA). The sequence analysis package of GCG was used to compare the obtained sequence with known sequences. The sequence was translated in all six reading frames in the GCG Analysis Program using the Fasta algorithm (Pearson and Lipman, supra). The Swissprot database (GeneBio, Geneva, Switzerland) of proteins was

searched. This translated cDNA fragment was identified as a part of a putative elongase based on the homology of the putative protein sequence to the G. cerevisiae ELO2 (GNS1), having 41.3% identity in 63 amino acids.

New primers were designed based on the putative elongase sequence and the vector, pZLI1 (Life Technologies, Inc., Gaithersburg, MD) sequence used to construct M. alpina cDNA library. The M. alpina excised cDNA library was PCR amplified again using primers R0350 (5' -CAT CTC ATG GAT CCG CCA TGG CCG CCG CAA TCT TG- 3'), which has an added BamHI restriction site (underlined), and the vector reverse primer R0352 (5' -ACG CGT ACG TAA AGC TTG- 3') to isolate the full length M. alpina elongase cDNA, using previously described conditions.

The termini of the approximately 1.5 Kb PCR amplified fragment was filled-in with T4 DNA polymerase (Boehringer Mannheim Corp., Indianapolis, IN) to create blunt ends and cloned into the PCR-blunt vector (Invitrogen Corp., Carlsbad, CA). This resulted in two clones, pRAE-1 and pRAE-2 (see Figure 4A). (Plasmid DNA pRAE-2 was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, on August 28, 1998, under the terms of the Budapest Treaty, and was accorded deposit number ATCC 203166.) The elongase cDNAs from these vectors were cut out as an EcoRI fragment and cloned into the EcoRI digested pYX242 (Novagen, Madison, WI) vector. The clones pRAE-5 and pRAE-6 (see Figure 4B) have the elongase cDNAs from pRAE-1 and pRAE-2, respectively. (Plasmid DNA pRAE-5 was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-

2209, on August 28, 1998, under the terms of the Budapest Treaty, and was accorded deposit number ATCC 203167.) The sequencing of pRAE-5 and pRAE-6 revealed that 5' untranslated region of the elongase gene in pRAE-5 is 16 bp shorter than that in pRAE-6 (see Figure 5). The complete M. alpina elongase cDNA sequence, designated MAELO was obtained from pRAE-2 (see Figure 6). Figure 7 is the amino acid sequence obtained from the translation of MAELO. The Swissprot database (GeneBio, Geneva, Switzerland) was searched again, as previously described, with the translated MAELO: MAELO has 44.3% identity in 317 amino acids with S. cerevisiae GNS1(ELO2) and 44.7% identity in 318 amino acids with S. cerevisiae SUR4(ELO3). The FastA alignment among the three elongases is shown in Figure 8. At the nucleotide level (see Figure 9), MAELO has 57.4% identity in 549 bp overlap with S. cerevisiae GNS1(ELO2) (GenBank Accession # S78624). However, the identity between the complete MAELO gene of 954 bp and S. cerevisiae GNS1(ELO2) is 33.0%.

Example III

Expression of M. alpina Elongase cDNA in Baker's Yeast

The constructs pRAE-5, and pRAE-6 were transformed into S. cerevisiae 334 (Hoveland et al., Gene 83:57-64 (1989)) and screened for elongase activity. The plasmid pCGN7875 (Calgene LLC, Davis, CA) containing jojoba KCS gene in pYES2 vector (Invitrogen Corp., Carlsbad, CA) was used as a positive control. The substrate used to detect elongase activity in M. alpina elongase (MAELO) was GLA

and that in jojoba KCS was oleic acid (OA). The negative control strain was S. cerevisiae 334 containing pYX242 vector. The cultures were grown for 40-48 hours at 25°C, in selective media (Ausubel et al., Short Protocols in Molecular Biology, Ch. 13, p. 3-5 (1992)), in the presence of a particular substrate. The expression of the jojoba KCS gene cloned in pYES2 was under the control of GAL1 promoter, while the promoter in pYX242 is TP1, which is constitutive. Hence, the 334(pCGN7875) and 334(pYES2) cultures were induced with galactose. The GC-FAME analysis of the lipid fraction of each cell pellet was performed as previously described (Knutzon et al., supra).

The elongase activity results from different experiments are provided in Figure 10A and 10B. The jojoba KCS elongates long chain monounsaturated fatty acids 18:1n-9 to 20:1n-9. The amino acid homology between the M. alpina elongase (MAELO) and the S. cerevisiae ELO2 and ELO3 suggested that the proteins encoded by these genes may have similar substrate specificity. The activity of the M. alpina elongase, elongation (MAELO) of long chain monounsaturated and saturated fatty acids, is seen in the conversion of 18:1n-9 to 20:1n-9 and also in the synthesis of 24:0. The control strain, 334(pYX242) has very little or no detectable amount of 20:1 and 24:0 (see Figure 10A). M. alpina elongase (MAELO) also acts on at least one PUFA, converting 18:3n-6(GLA) to 20:3n-6(DGLA). The percentage of the 20:3n-6 in total lipid is higher in the strain 334(pRAE-5) and 334(pRAE-6) with the M. alpina elongase (MAELO) cDNA when compared to that in the control

334 (pYX242). The percentages of 20:3n-6 produced were 0.092% for 334 (pYX242) vs. 0.324% for 334 (pRAE-5) and 0.269% for 334 (pRAE-6) (shown in parenthesis in Figures 10A and 10B). This difference in the fatty acid profile is also seen in the total amount of 20:3n-6 produced. Only 0.226 μ g of 20:3n-6 was produced by 334 (pYX242) while 334 (pRAE-5) and 334 (pRAE-6) produced 2.504 μ g of 20:3n-6 and 1.006 μ g of 20:3n-6, respectively. Also, when no substrate is added, the level of 20:3n-6 is not detectable.

Once 20:3n-6 is generated by the *M. alpina* elongase (MAELO), the $\Delta 5$ -desaturase can convert it to AA in the desired expression system. To test this hypothesis, the constructs pRAE-5 and pCGR-4 (a $\Delta 5$ -desaturase containing plasmid) were co-transformed into *S. cerevisiae* 334 and screened for AA production. The substrate used was 25 μ M GLA (18:3n-6). If the *M. alpina* elongase (MAELO) is active in yeast, then the substrate will be converted to DGLA (20:3n-6), which the $\Delta 5$ -desaturase will convert to AA (20:4n-6). The results in Figure 11 confirm the production of AA and therefore, the activity of the *M. alpina* elongase (MAELO).

The expression of $\Delta 5$ -, $\Delta 6$ -, and $\Delta 12$ -desaturases, in yeast, along with the elongase, should result in the production of AA (see Figure 1) without the need for an exogenous supply of fatty acids.

Example IV

A Comparison of the Expression of *M. alpina* Elongase cDNA MAELO and *S. cerevisiae* Elongase ELO2 in Baker's Yeast

The ELO2 gene encoding for the yeast elongase was cloned from an *S. cerevisiae* genomic library (Origene, Rockville, MD) using the primers R0514 (5' -GGC TAT GGA TCC ATG AAT TCA CTC GTT ACT CAA TAT G-3') and R0515 (5' -CCT GCC AAG CTT TTA CCT TTT TCT TCT GTG TTG AG-3') incorporating the restriction sites (underlined) *Bam*HI and *Hind*III (respectively). The ELO2 gene was cloned into the vector pYX242 at the *Bam*HI and *Hind*III sites, designated pRELO, transformed into the *S. cerevisiae* host 334 (Hoveland et al., *supra*) and screened for PUFA elongase activity. The vector plasmid was used as a negative control and 334 (pRAE-5) was grown to compare the PUFA elongase activity. The cultures were grown as previously described with no galactose in the media and 25 μ M GLA added as a substrate. Figure 12 shows that amount of 20:3n-6 or DGLA produced (elongated from 18:3n-6 or GLA) by 334 (pRAE-5) was approximately 4 times the negative control containing the unaltered vector pYX242, while the two individual clones 334 (pRELO-1) and 334 (pRELO-2) were only twice the negative control. Additionally, when DGLA produced is expressed as a percent of the total lipids (shown in parenthesis, Figure 12), the clones 334 (pRELO-1) and 334 (pRELO-2) produced 0.153% and 0.2% DGLA respectively, while 334 (pYX242) produced 0.185% DGLA. Hence all these strains produced comparable percentages of DGLA. The strain 334 (pRAE-5), however, produced 0.279% DGLA, an increase of 50.8% over 334 (pYX242) (negative control). These data show that the *S. cerevisiae* elongase gene ELO2, even when overexpressed in yeast, does not elongate GLA to DGLA effectively. The *M. alpina* PUFA elongase activity is specific for this conversion as evidenced by the higher amount of DGLA produced compared to the control, 334 (pYX242).

Example V

Identification of Elongases from Other Sources Using MAELO

The TFasta algorithm (Pearson and Lipman, supra) is used to search for similarity between a query peptide sequence and the database DNA sequence translated in each of the six reading frames. Translated MAELO was used as the query for a TFasta search in GCG with the GenEBL database (6/98) from GCG to identify other potential elongase sequences based on their amino acid similarity comparisons to translated MAELO. For example, in Figures 13 and 14, two alignments are shown between translations of two different C. elegans sequences from chromosome III and MAELO. C. elegans DNA sequence (GenBank accession # 268749) was annotated denoting similarity with GNS1 (ELO2), while the additional C. elegans DNA sequence (GenBank accession # U61954) was noted as similar to both GNS1 and SUR4 (ELO3). These are spliced DNA fragments in which the introns have been removed from the genomic sequence, and the exons assembled and translated. The amount of amino acid identity between the putative PUFA elongases from C. elegans and translated MAELO are around 30%. This would point towards a common function in the fatty acid metabolism, e. g., a PUFA elongase. Figure 15 is another example of a translated C. elegans sequence (GenBank accession # AF003134) from chromosome III. The DNA sequence was identified that had DNA homology to the S. cerevisiae ELO2. Further inspection of this DNA sequence and its amino acid translation determined that there was homology to translated MAELO. C. elegans, therefore, may contain a PUFA elongase.

Figure 16 shows the alignments of translated DNA sequences from mouse and human, respectively, with translated MAELO. The

mouse sequence CIG30, GenBank accession # U97107, was isolated from brown adipose tissue and reported as being "similar to yeast SUR4 protein". As shown in Figure 16, amino acids numbered 130 to 152 in the U97107 translation contain a high degree of similarity to the translated MAELO. The human sequence, GenBank accession # AC004050, from chromosome 4 was from an HTGS (High Throughput Genome Sequence). There were no annotations contained with this sequence. However, translated AC004050 had 28.7% identity in 150 amino acids with translated MAELO. This gene fragment could be a fragment of a human PUFA elongase based on its amino acid similarity to translated MAELO.

Figure 17 shows the amino acid alignment of translated MAELO and a mammalian sequence (GenBank accession # I05465, PCT# WO 88/ 07577) which claims that the protein derived from expression of this sequence is a glycosylation inhibition factor. The amino acid identities between the two proteins, signifying that there could be related function, such as PUFA elongase activity.

These examples of other translated DNA sequences and their homology to the translated MAELO illustrate that any of the above examples could potentially be a PUFA elongase. These examples are not inclusive of all the possible elongases. However, use of MAELO or its amino acid translation as a query for database searches can identify other genes which have PUFA elongase activities.

Example VI

M. alpina cDNA Library Screening Using A Plaque Hybridization Method

In an effort to isolate additional PUFA elongase genes from M. alpina, a conventional plaque hybridization method was used to screen an M. alpina cDNA library made in a lambda vector. The DNA probe was generated based on MAELO nucleotide sequence and was used to screen the M7+8 M. alpina cDNA library made in a λ Ziplox vector (Knutzon et al., J. Biol. Chem. 273:29360-29366 (1998)).

To make the DNA probe for screening the library, the MAELO cDNA was digested with *Nsp*I and *Pvu*II restriction endonucleases. Three small DNA fragments, with an average size of approximately 300 bp, were produced and used as probes. The rationale for using a mixture of fragmented MAELO cDNA was based on the assumption that there might be a common region or domain in the amino acid sequence which is conserved among various PUFA elongases present in M. alpina. Using MAELO DNA probes, the cDNA library was screened by a plaque hybridization technique according to standard protocol (Sambrook et al., Molecular Cloning, 2nd Ed., Cold Spring Harbor, 1989).

Briefly, 50,000 primary clones were plated and transferred to nylon membranes. The membranes were denatured and hybridized with alpha ³²P-dCTP-labelled MAELO DNA probes overnight in the hybridization buffer which contained 20% formamide, 0.2% PVP, BSA, Ficoll, 0.1% SDS and 0.5 M NaCl. The filters were washed with 0.5X SSC at 37 °C and exposed to X-ray film for autoradiography. This procedure was repeated three times. Four clones (designated as F1, F2, F3, and F4) which hybridized repeatedly were picked and suspended in SM buffer (Sambrook et al., supra) containing 7% DMSO.

The largest open reading frame of each candidate was subcloned into yeast expression vector pYX242 (Novagen, Inc., Madison, Wisconsin). The cDNA clones F1 and F3 were subcloned

into pYX242 at the *Eco*RI site while F2 and F4 were subcloned at *Nco*I/*Hind*III sites. The recombinant pYX242 containing each candidate was transformed into SC334 (Hoveland et al., supra) for expression in yeast. To determine the elongase activity, as well as substrate specificity, SC334 containing each cDNA clone was grown in minimal media lacking leucine in the presence of 25 μ M of GLA substrate as described in Example III. The fatty acid analysis was performed as described in Knutzon et al. (J. Biol. Chem. 273:29360-29366 (1998)). The results indicated that none of these four cDNA clones showed any significant activity in converting GLA to DGLA. Thus, the hybridization approach appeared to be unsuccessful in identifying additional PUFA elongases.

Example VII

Construction of Direct cDNA Expression Library of M. alpina in Yeast

To identify PUFA elongase genes other than MAELO, a different approach was taken to screen the M. alpina cDNA library. In particular, since Baker's yeast is incapable of producing long chain PUFAs due to the absence of respective desaturases and elongases, an attempt was made to construct an expression cDNA library of M. alpina in Saccharomyces cerevisiae. The vector pYES2 (Novagen, Inc., Madison, Wisconsin), containing the GAL1 promoter, was chosen for the expression of cDNA library in S. cerevisiae.

The conventional way by which a cDNA library is made (i.e. transformation of cDNA/vector ligated DNA mixture into host cells) is difficult in yeast because the transformation efficiency by direct electroporation of ligated DNA mix is very

low compared to the efficiency of purified supercoiled plasmid DNA. However, the major advantage of this method is to avoid amplification of primary clones which happens when the library is made in E. coli as an intermediate. Due to the limitation in the number of colonies to be screened, it was decided to first optimize the efficiency of transformation in different S. cerevisiae strains using cDNA/vector ligated mix. The best results were obtained with a yield of $4-5 \times 10^5$ transformants per μ g of ligated DNA in S. cerevisiae strain SC334 (Hoveland et al., supra).

To make a direct M. alpina cDNA expression library in yeast total RNA was isolated from the fungus. M. alpina fungus (ATCC # 32221) was plated onto cornmeal agar (Difco Laboratories, Detroit, MI) and grown at room temperature for 3-4 days. Once fungus growth was visible, it was inoculated into 50 ml of potato dextrose broth and shaken at room temperature very slowly to formulate spores. Once spores were visible, the 50 ml culture was inoculated into a 1 liter culture of potato dextrose, and spores were grown for 72 hours. After filtering through sterile gauze, the cells were immediately frozen into liquid nitrogen for future RNA extraction. Total RNA was prepared from 36 g of cell pellet using the hot phenol/LiCl extraction method (Sambrook et al., supra). The cell pellets were homogenized in a 10 mM EDTA, 1% SDS and 200 mM sodium acetate, pH 4.8 solution. Phenol and chloroform were added to the homogenates, and the aqueous layer was extracted. The aqueous layer was back extracted one more time with phenol and chloroform. Then an equal volume of 4 M lithium chloride was added. The samples were ethanol precipitated on ice for 3 hours, and pellets were obtained by centrifugation. The RNA pellets were washed with 70% ethanol and resuspended in DEPC

treated water. Total RNA was quantitated by spectrophotometry and visualized by agarose gel electrophoresis to confirm the presence of 28S and 18S ribosomal bands. Approximately, 15 mg of total RNA were obtained from 36 gram of cell pellet.

The library was constructed according to the standard protocol (Sambrook et al., Molecular Cloning, 2nd Ed., Cold Spring Harbor, 1989). Messenger RNA was prepared from the total RNA using oligo dT cellulose affinity purification. Messenger RNA was reverse transcribed with oligo dT primer containing a XhoI restriction site using AMV reverse transcriptase.

Following first strand cDNA synthesis, the second strand of cDNA was synthesized by adding E. coli DNA polymerase, E. coli DNA ligase and RNase H.

The EcoRI adaptor was ligated into the blunt-ended cDNA by T4 DNA ligase. The cDNA sample was kinased using T4 polynucleotide kinase and digested with XhoI, diluted with column buffer and passed through a Sephacryl S-400 column. The DNA samples were eluted by high salt buffer. Samples containing DNA from 400-5,000 bps were pooled and used for ligation into a pYES2 vector (Invitrogen Corp., Carlsbad, CA). The cDNA was ligated into the EcoRI/XhoI digested pYES2 vector using T4 DNA ligase. A large scale ligation reaction was carried out since a large amount of the ligated DNA (2-3 μ g) is required in direct transformation of yeast.

To transform yeast cells directly with the cDNA/pYES2 ligated mixture, competent SC334 cells were prepared using the LiAc TRAF0 method (Gietz et al., Mol. Cell. Biol., 5: 255-269, 1995). Briefly, fresh culture of SC334 from the plate was inoculated into 50 ml YPD medium. The culture was grown at 30 °C with shaking until the OD at 600 had reached 1.0. Thirty ml of this starter was inoculated into 300 ml of YPD liquid medium and

incubated with shaking until the cell number of the culture reached $\sim 3.5 \times 10^6$ cell/ml (approximately 3-4 h). The cells were harvested and washed with sterile water. The entire cell pellet was resuspended in 1.5 ml of freshly prepared 1X TE/LiAc (0.1M LiAc). These cells were used immediately for the transformations.

Seven hundred and fifty microliters of competent SC334 cells were aliquoted into 15 ml falcon tubes. Approximately 2 μ g of cDNA/pYES2 ligated DNA were added to the cells along with carrier DNA and mixed gently. Three milliliters of sterile 40% PEG/LiAc was added to the cells and mixed gently but thoroughly. The cells were incubated at 30 °C for 30 min with shaking and subsequently given heat shock at 42 °C for 15 min. The cells were cooled, pelleted, and resuspended in 5 ml of 1X TE. A 100 μ l aliquot of the above cells was plated onto fifty 150 mm selective agar plates lacking uracil (Ausubel et al., *supra*) and incubated at 30 °C for 3 days. A total of 8×10^5 primary clones were obtained. Five colonies were pooled in 1 ml minimal media lacking uracil (Ausubel et al., *supra*) and glycerol added to prepare stocks. A total of 5,000 pools were made for screening.

Example VIII

MAD (M. alpina Direct) Screening in Yeast

The quality of the library was analyzed by determining the average size of the cDNAs in the library. Since the screening of the library was based on the expression of the cDNA, it was important to determine the average size of the cDNA present in the library. The expression library containing the longest cDNAs would be the best appropriate choice to isolate full-length cDNAs of interest. To this end, randomly selected pools

were plated onto selective agar plates, as described in Example VII, to obtain individual colonies. Forty different yeast colonies were randomly picked, and each colony was inoculated into 5 ml of selective liquid medium lacking uracil (as described in Example VII) and grown, while shaking, for 24 hours at 30 °C. Plasmid DNA was extracted from these colonies by the bead beating method (Hoffman et al., *Gene* 57:267 (1987)) adapted as follows:

Pellets from 5 ml of culture were lysed in 0.5 ml of a 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA and 0.1% SDS solution.

Sterile 0.5 mm glass beads of equal volume were added and manually vortexed for 3 minutes. Two hundred microliters of the same buffer were added, and the mixture was vortexed for an additional minute. The samples were centrifuged on high for 2 minutes, and cytoplasmic extract was then transferred to a fresh tube. An equal volume of phenol/CHCl₃ was added to the sample, vortexed and centrifuged again for 2 minutes. The aqueous layer was re-extracted twice and precipitated with 0.3 M sodium acetate and approximately 2.5 volumes of ethanol for 30 minutes at -20 °C. The precipitates were washed with 70% ethanol and resuspended in water. To eliminate RNA and any protein contamination, the plasmid DNAs isolated from 40 different samples were further purified using the QIAprep Spin Miniprep Kit according to the manufacturer's protocol (Qiagen Inc., Valencia, CA). The plasmid DNA samples were then restricted with EcoRI and XhoI restriction endonucleases to release the cDNA fragment, and the digest was analyzed on 1% agarose gel. The results indicated that the majority of the cDNAs of the direct library varied in length from 0.8 Kb to 1.5 Kb.

To screen the library, the glycerol stocks were thawed and approximately 0.5 ml was added to 5 ml of liquid selective media

lacking uracil (Ausubel et al., supra) and grown at 30°C for 24 hours. The culture was then transferred into 50 ml of liquid selective medium lacking uracil with 2% galactose and 25 μ M GLA (substrate for the elongase enzyme) for 24 hours at 25 °C with shaking. The GC-FAME analysis of the lipid content in the cell pellet of each induced culture was performed as previously described (Knutzon et al., supra). The MAELO (pRAE-5 in pYX242 grown in selective media lacking leucine) was used as a positive control in each batch run. MAELO had consistently been able to convert 1.5% of GLA to DGLA (see Example III).

Example IX

Identification of a cDNA Encoding a Potential PUFA Elongase

After screening and analyzing approximately 750 individual pools by GC-FAME analysis, as described in Example VIII, one pool of five colonies (i.e., MAD708) appeared to have significant enzymatic activity in converting GLA to DGLA. This activity was found to be approximately 5 fold higher than the M. alpina elongase activity (MAELO) in terms of DGLA/GLA ratio (Figure 19). This pool was tested again under identical assay conditions to confirm the initial findings. The repeat experiment showed 9.5% conversion of GLA to DGLA and was again around 5 fold higher than M. alpina elongase activity (MAELO). These results strongly indicated that the MAD708 pool contained an elongase candidate which was specific for GLA as substrate. Since MAD708 was a pool of five different clones, it was necessary to isolate the individual cDNA clone which encoded for elongase activity from this pool. To do this, the original MAD708 glycerol stock was plated onto a selective media agar

plate lacking uracil (Ausubel et al., supra). Thirty individual colonies were picked and grown in liquid selective medium, lacking uracil with 2% galactose, as previously described in Example VIII, in the presence of GLA. The cell pellet obtained from each culture was then subjected to fatty GC-FAME analysis (Knutzon et al., supra) along with a positive control of 334 (pRAE-5) (MAELO in pYX242). The fatty acid analysis from the 30 individual clones from the MAD708 expression pool in yeast revealed that 5 of the 30 clones showed elongase activity in converting GLA to DGLA. The fatty acid profiles of the active clones MAD708-2, MAD708-10, MAD708-18, MAD708-19 and MAD708-30 are shown in Figure 20. As shown in this Figure, MAD708-2, 10, and 30 produced the most DGLA, approximately 25 fold more than MAELO (pRAE-5). These 3 converted in the range of 41% to 49% of GLA to DGLA. Other clones, MAD708-18 and MAD708-19, converted 8% and 21% of GLA to DGLA, respectively. All MAD708 clones converted a higher percentage of GLA to DGLA with respect to MAELO encoded elongase (3.4%).

Example X

Characterization of cDNAs Encoding Elongase

Plasmid DNA was extracted from SC334 yeast clones (MAD708 pool) that showed significant GLA specific elongase activity by the bead beating method, as described in Example VIII. To determine the size of the cDNA insert, PCR was performed using each plasmid DNA obtained from positive elongase clones as a template. The forward primer R0541 (5'- GAC TAC TAG CAG CTG TAA TAC -3') and the reverse primer R0540 (5'- GTG AAT GTA AGC GTG ACA TAA -3') are in the multicloning site of the pYES2 vector

and were used to amplify the cDNA insert within the *EcoRI* and *XhoI* sites. PCR reaction was performed in a 50 μ l volume containing 4 μ l of plasmid DNA, 50 pmole of each primer, 5 μ l of 10X buffer, 1 μ l 10 μ M PCR Nucleotide Mix (Boehringer Mannheim Corp., Indianapolis, IN) and 0.5 μ l of High Five Taq polymerase (Boehringer Mannheim, Indianapolis, IN). The amplification was carried out as follows: 2 mins. denaturation at 94 $^{\circ}$ C, then 94 $^{\circ}$ C for 1 min, 55 $^{\circ}$ C for 2 mins., and 72 $^{\circ}$ C for 3 mins. for 30 cycles, and 7 mins. extension at 72 $^{\circ}$ C at the end of the amplification. Analysis of PCR amplified products on a 1% agarose gel showed the sizes of the elongase cDNAs to be around 1.0 - 1.2 Kb. The plasmid DNAs, containing the potential elongase cDNAs, were designated as pRPB2, pRPB10, pRPB18, pRPB19, and pRPB30. Since the cDNA library was made in the pYES2 vector at the *EcoRI* and *XhoI* sites, the size of the cDNA present in each plasmid was further confirmed by digesting the above plasmids with *EcoRI* and *XhoI*.

The plasmid DNAs isolated from yeast were re-amplified in *E. coli* for long-term storage of the cDNA clones as well as for DNA sequencing. *E. coli* TOP10 (Invitrogen Corp., Carlsbad, CA) cells were transformed with the pRPB recombinant plasmids according to the manufacturer's protocol. The transformants obtained from each plasmid DNA were inoculated into LB containing ampicillin (50 μ g/ml) and grown overnight at 37 $^{\circ}$ C with shaking. Plasmid DNAs were isolated from these cultures by using QIAprep Spin Miniprep (Qiagen Inc., Valencia, CA) according to the manufacturer's protocol. The purified plasmid DNAs were then used for sequencing from both 5' and 3' ends. The DNA sequencing was performed by using a 373A Stretch ABI automated DNA sequencer (Perkin Elmer, Foster City, CA) according to the manufacturer's protocol. Primers used for

sequencing were the forward primer RO541 (5'- GAT TAC TAG CAG CTG TAA TAC -3') and the reverse primer RO540 (5'- GTG AAT GTA AGC GTG ACA TAA -3') contained in the multicloning sites of the pYES2 vector. The obtained nucleotide sequences were

transferred to Sequencher software program (Gene Codes Corporation, Ann Arbor, MI) for analysis. The DNA sequence

analysis revealed that all five elongase cDNAs contained the identical nucleotide sequence with a common overlap of 301 nucleotides. Each DNA sequence contains a putative start site at the beginning of the 5' end and a stop codon with poly A tail at the end of the 3' site. To further confirm the DNA sequence, internal forward primers RO728 (5'- GAG ACT TTG AGC GGT TCG -3') and RO730 (5'- TCT CTG CTG TGA ACT CG -3'),

along with reverse primers RO729 (5'- AAA GCT CTT GAC CTC GAA C -3') and RO731 (5'- AAC TTG ATG AAC GAC ACG TG -3') were designed within the cDNA, and used for sequencing of pRPB2,

since this candidate possessed the highest elongase activity. The entire nucleotide sequence was analyzed by the Sequencher

program (Figure 21), and the longest open reading frame deduced from the entire cDNA sequence in pRPB2 appeared to be 957 bp in length (Figure 22). The deduced open reading frame was then translated into the corresponding amino acid sequence, and the predicted sequence is shown in Figure 23. The elongase encoded by the cDNA (pRPB2) identified from *M. alpina* appears to be a 318 amino acid long protein which is nearly identical in size with translated MABLO. This new elongase cDNA was designated as "GLBLO" and its encoded protein has been named "GLA elongase".

Plasmid DNA pRPB2 was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 on July 22, 1999 under the terms of the Budapest Treaty. It was accorded ATCC Deposit # PTA-402.

Example XI

Biochemical Characterization of GLA Elongase (GLELO)

A. Confirmation of GLA Elongase Activity

To further confirm the activity of the GLA elongase encoded by the pRPB2 recombinant plasmid, elongase activity screening was repeated on the yeast clone SC334 containing pRPB2 plasmid. This experiment was also conducted to assure consistent lipid extraction and to detect the activity of GLA elongase by averaging four independent experiments. The *S. cerevisiae* 334 glycerol stock containing pRPB2 was plated onto minimal media agar plates lacking uracil. Individual colonies were randomly picked and grown in minimal medium lacking uracil, as described in Example VIII. The four independent cultures were combined, and a 5 ml aliquot was used as an inoculum for four separate 50 ml cultures. The cultures were then grown in the presence of GLA and were subjected to fatty acid analysis along with a negative control of *S. cerevisiae* 334 containing pYES2, as described in Example VIII. The average elongase activity from four independent cultures of 334 (pRPB2) with 25 μ M GLA is shown in Figure 24. The GLA elongase activity of each of the four independent samples of 334 (pRPB2) appeared to be consistent with an average conversion of 62% GLA to DGLA.

B. Determination of GLELO Substrate Specificity for GLA Elongase

To analyze the substrate specificity of the GLA elongase, the culture of 334 (pRPB2) was tested with different fatty acid substrates besides GLA (e.g., SA(18:0), OA(18:1), LA(18:2n-6), AA(20:4n-6), ADA(22:4n-6), ALA(18:3n-3), STA(18:4n-3), and EPA(20:5n-3)). Under identical assay conditions, the only other substrate utilized by the elongase enzyme was STA, a fatty acid

from the n-3 pathway. GLA elongase was able to convert 73% of STA to 20:4n-3 (Figure 25). From these experiments, it can be concluded that the GLA elongase has substrate specificity for both GLA and STA, indicating that it possesses elongase activity along both the n-6 and n-3 pathways.

C. Co-expression of Fungal GLELO and Δ 5-Desaturase Gene in Yeast

Once DGLA (20:3n-6) is produced by the GLA elongase, the Δ 5-desaturase can convert it to AA (20:4n-6) in a desired co-expression system. This scheme, as depicted in Figure 1, can be tested by co-transforming *S. cerevisiae* 334 with plasmids pRPB2 and pRPB31 (the recombinant plasmid pYK242 containing a Δ 5-desaturase cDNA (Figure 18) cloned at the *EcoRI* site. The co-transformed yeast cultures were supplemented with 25 μ M GLA and analyzed for AA synthesis. If both elongase and Δ 5-desaturase enzymes are expressed, the GLA substrate will be converted to DGLA, which will then be converted to AA. The results in Figure 26A indicate that the sequential action of GLA elongase and Δ 5-desaturase on GLA substrate resulted in an average conversion of 27% GLA to AA. Therefore, the GLA elongase has the ability to work with other enzymes in the n-6 PUFA synthetic pathway to produce desirable fatty acids.

To determine whether the above conversion is also true in n-3 pathways, the similar co-expression experiments were carried out in the presence of 25 μ M STA. Again, if both enzymes are expressed, the STA substrate will be converted to 20:4n-3 which will then be converted to EPA (20:5n-3) by the Δ 5-desaturase. Figure 26B shows the results in which the production of EPA (approx. 40%) is observed. Once again, the GLA elongase

demonstrates its ability to work with $\Delta 5$ -desaturase in the n-3 pathway to produce desirable fatty acids.

Example XII

5 Sequence Comparison Between GLELO and Other Fungal Elongases

The sequence analysis package of GCG (see Example I) was used to compare the GLELO sequence with known protein sequences. The nucleotide sequence of GLELO open reading frame was first translated into amino acid sequence that was used as a query sequence to search Swissprot database (see Example I) using the FastA algorithm (see Example I). Based on amino acid sequence similarity, the best matches were found with S. cerevisiae YJT6 (an EST with unknown annotation) with 33.9% identity in 189

15 amino acid overlap, S. cerevisiae ELO2 (GNS1) with 25.8% identity in 295 amino acid overlap, and S. cerevisiae ELO3 (SUR4) with 25.2% identity in 313 amino acid overlap. The FastA alignment of GLELO with MAELO showed 30.9% identity in 275 amino acids (Figure 27). GCG Pileup program creates a multiple

20 sequence alignment from a group of related sequences using progressive, pairwise alignments (see Example I), and was used with the elongases described above. The Pileup results indicate that there are many conserved regions among the elongases including a putative histidine box, which is underlined (Knutzon et. al., J. Biol. Chem. 273: 29360-29366, 1998) (Figure 28).

Thus, although GLELO has similarity with MAELO, the difference in their encoded elongases may presumably be due to their substrate preference. GLA elongase can convert a higher percentage of GLA to DGLA than M. alpina elongase. In addition, MAELO expression in S. cerevisiae showed elongation of saturated

30

and monounsaturated fatty acids in addition to GLA elongation to DGLA (see Example III).

Example XIII

5 Identification of M. alpina MAELO Homologues in Mammals

The MAELO translated sequence was used to search the Unified Human Transcript Database of Abbott Laboratories, 100 Abbott Park Rd., Abbott Park, Illinois 60064. This database was searched using Basic Local Alignment Search Tool (BLAST) (Altschul et al., Nuc. Acids Res. 25:3389-3402 (1997)) which "is a set of similarity search programs designed to explore all of the available sequence databases regardless of whether the query is a protein or DNA." Specifically, the tblastn algorithm was used (i.e., a protein query search to a nucleotide database translated in six reading frames). The contig (CC) sequences in the Unified Human Transcript Database are consensus sequences representing groups of expressed sequence tags (EST) cDNAs derived from the public domain and from the Incyte LIFESEQ™ database of ESTs (Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304) that are clustered together on the basis of defined sequence homology, and assembled on the basis of sequence overlap. Two sequences from this database,

25 CC067284R1 and CC1484548T1 had 28% identity in 242 amino acid overlap and 28.6% identity in 266 amino acid overlap, respectively, with the translated MAELO sequence. The two derived and edited sequences were designated as ha1 and ha2, respectively, and copied into the sequence analysis software package of GCG (see Example I). The translated MAELO sequence was aligned with translated HS1 (28.5% identity in 242 amino

30

91

acids) and HS2 (28.2% identity in 266 amino acids) cDNA sequences using the FastA algorithm, as shown in Figures 29 and 30, respectively. HS1 cDNA nucleotide sequence also had 86.9% identity in 844 bp with the I05465 nucleotide sequence (see Example V). The translated HS2 cDNA sequence had 100% identity with the amino acid sequence from GenBank with accession number W74824 (see published PCT application WO9839448).

The National Center for Biotechnology Information (NCBI at <http://www.ncbi.nlm.nih.gov/>) was used to conduct database searches using tblastn with the 28 amino acid sequence

(DTFTILRKQKLIFLHWYHHITVLLYSW) translated from AC004050 (a human sequence identified in a TFASTA search, see Example V). This amino acid sequence contains a histidine box (underlined), which has a noted motif of desaturases (Knutzon et al., *supra*), and both PUFA elongases, MAELO and GLELO (see Figure 28). A translated mouse sequence shown previously in Example V (GenBank Accession #U97107) and a translated *C. elegans* sequence (GenBank Accession # U41011) had the highest matches with this 28 amino acid query. The NCBI mouse EST database was searched again with tblastn, using translated U41011 as a query. An additional mouse sequence was identified (GenBank Accession #AF014033.1), annotated as "putative involvement in fatty acid elongation."

Three longer sequences (GenBank Accession #'s AA591034, AA189549, and AA839346) were identified through a tblastn search of the mouse EST database with translated AF014033.1 and combined into one sequence designated as mm2. The FastA alignment (see Example I) of translated mm2 and MAELO is shown in Figure 31. Another related, but not identical mouse sequence (GenBank Accession #AI225632), was also identified in a tblastn search of the mouse EST database with AF014033.1. The FastA alignment with translated AI225632 to MAELO is shown in Figure

92

32. The percent identity for both translated MM2 and AI 225632 with translated MAELO is 30.4% in 191 and 115 amino acid overlap, respectively. The level of amino acid identity with translated MAELO with these two translated mouse sequences identifies them as putative homologues of PUFA elongases.

Example XIV

Identification of M. alpina GLELO Homologues in Mammals

The TFASTA algorithm, which compares a protein sequence to the database DNA sequence translated in each of the six reading frames, was used with translated GLELO as the query. The GenEMBL database from GCG was used to identify other potential elongase sequences based on their amino acid similarity to translated GLELO. Three human sequences were found to have matches with the GLELO amino acid sequence. These sequences have GenBank accession numbers 1) AI815960, 2) AL034374, and 3) AC004050. AI815960, a *Homo sapiens* EST sequence, has 40.3% identity in 144 amino acid overlap with translated GLELO (see Figure 33). A translated region of the human genomic sequence AL034374, derived from chromosome VI has 46.7% identity in a 60 amino acid overlap with translated GLELO. This homologous region in AL034374 appeared to be a part of the HS1 amino acid sequence which was shown to have homology with translated MAELO (see Example XIII). Therefore, HS1 sequence has similarity with both MAELO (see Figure 29) as well as GLELO (see Figure 34). A translated region of a human genomic sequence AC004050 from chromosome IV has 34.8% identity in 89 amino acid overlap with translated GLELO (see Figure 35). The amino acid identities between GLELO and these human sequences indicate that the

proteins derived from these human sequences could have related function, such as PUFA elongase activity.

To identify a mouse cDNA similar to GLELO, TFASTA searches were performed with the GenEMBL database using translated GLELO as a query. From the TFASTA searches, the three mouse sequences with the highest matches to translated GLELO were identified:

(GenBank accession numbers 1) AF104033, 2) AI595258, and 3)

U97107). AF104033 is annotated as "MUEL protein having putative fatty acid elongase with homology to yeast ELO3 (SUR4)" and is a part of the sequence of MM2. The MM2 sequence was initially

derived from AF104033 mouse sequence, but the entire MM2 sequence was finally obtained through further mouse EST database searches and also shown to have homology with translated MAELO (see Example XIII and Figure 31). When this MM2 amino acid

sequence was aligned with translated GLELO sequence using Fasta, a 34.6% identity in 211 amino acid overlap was found (see Figure 36) indicating that MM2 also has homology with GLELO. AI595258 is a mouse cDNA clone having 5' similarity with yeast ELO3

elongase and is part of mouse EST cDNA AI225632. The AI225632

mouse sequence, which is a longer sequence than AI595258, was shown to have similarity with translated MAELO (see Figure 32).

The AI225632 was also aligned with the translated GLELO, and the Fasta alignment is shown in Figure 37. A 35.3% identity in 199 amino acid overlap has been found. The third sequence, U97107,

a mouse sequence, was annotated as "similar to yeast ELO3 (SUR4) gene." The Fasta alignment of translated GLELO with U97107 is shown in Figure 38 where a 23.7% identity in 279 amino acid overlap was found. Previously, a region of U97107 was also found to have a high degree of homology with MAELO based on a Fasta alignment (see Example V and Figure 16).

The above searches clearly indicate that the same human and mouse sequences were obtained by using either MAELO or GLELO as a query.

Example XV

5 Identification of M. alpina GLELO and MAELO Homologues in Other PUFA Producing Organisms

A) Caenorhabditis elegans:

10 A putative amino acid sequence deduced from a chromosomal sequence of C. elegans (GenBank Accession # U41011) was able to identify a partial sequence contained in the mouse MM2 putative PUFA elongase which has amino acid similarity with both GLA elongase (GLELO) and M. alpina elongase (MAELO). It was

15 therefore conceivable that C. elegans homologues of GLELO or MAELO might be present in the nematode database. The putative amino acid sequences derived from GLELO and MAELO sequences were used as queries independently to search the nematode databases.

A BLAST search (see Example XIII) was performed on wormpep16

20 (blastp compares an amino acid query sequence against a nucleotide sequence database) and wormpep 16cDNAs (tblastn) databases which are predicted proteins and cDNAs obtained from the C. elegans genome sequencing project or EST's and their corresponding cDNA sequences, respectively. These sequence data were produced by the C. elegans Sequencing group, carried out jointly by the Sanger Centre and Genome Sequencing Center, and can be obtained from ftp://ftp.sanger.ac.uk/pub/

databases/wormpep/. At least seven putative C. elegans

translated sequences were identified by their amino acid

30 sequence homology to the translated amino acid sequence of both GLELO and MAELO. The GenBank Accession #'s of those genomic

sequences containing the deduced amino acids were identified as Z19154, U68749 (2 deduced proteins (F56H11.4 and F56H11.3 (wormpep Accession #'s)), U41011, U61954 (2 deduced proteins (F41H10.7 and F41H10.8 (wormpep Accession #'s)), and Z81058. Those underlined were identified in a previous search using translated MAELO as query (see Example V). As an example, the FASTA amino acid alignments of translated U68749 (F56H11.4) with translated GLELO and MAELO are shown in Figures 39 and 40. Translated U68749 (F56H11.4) has 25-30% identity with both M. alpina elongase and GLA elongase in approximately a 200 amino acid overlap (see Figures 39 and 40). For all seven translated putative C. elegans cDNAs, the FASTA alignments to translated GLELO was between 25-30% identity in a 200 amino acid overlap, while the identity was 26-34% in at least a 188 amino acid overlap for translated MAELO. The alignment similarities indicate that either translated GLELO or MAELO can be used to identify potential genes from C. elegans with elongase activity.

B) Drosophila melanogaster:

The translated deduced cDNA from the genomic sequence U41011 (C. elegans) had its highest match with a Drosophila melanogaster EST, accession number A1134173 in a blastn search (compares a nucleotide query sequence against a nucleotide database) of the "other ESTs" database through NCBI (see Example XIII) and was assembled with an overlapping DNA EST fragment, accession number A1517255. The translated DNA fragment DM1, derived from the two overlapping sequences was aligned with translated GLELO as well as MAELO (see Figures 41 and 42) using FASTA in GCG (see Example I). The alignments showed 27.2% identity with GLA elongase in a 206 amino acid overlap and 30% identity with M. alpina elongase in a 237 amino acid overlap.

Thus, based on amino acid similarity, the DM1 could be a potential homologue to GLELO or MAELO having PUFA elongase-like activity. Moreover, using DNA sequences of GLELO and MAELO as queries for database searches, homologues with PUFA elongase activity from Drosophila can be identified.

Example XVI

Cloning and Expression of A Human PUFA Elongase Homologue

Many potential PUFA elongase sequences were identified based on their amino acid similarities to translated GLELO and/or MAELO. To determine the potential elongase activities of these sequences, the cDNA encoding the full-length protein is then identified, cloned, and expressed, as demonstrated in the present example.

Primers R0719 (5' -GGT TCT CCC ATG GAA CAT TTT GAT GCA TC- 3') and R0720 (5' -GGT TTC AAA GCT TTG ACT TCA ATC CTT CCG- 3') were designed based on the putative HSI sequence, and used to amplify the human liver Marathon-Ready cDNA (Clontech Laboratories, Inc., Palo Alto, California). The polymerase Chain Reaction (PCR) was carried out in a 50 μ l volume containing: 5 μ l of human liver Marathon-Ready cDNA, 50 pmole each primer, 1 μ l 10 mM PCR Nucleotide Mix (Boehringer Mannheim Corp., Indianapolis, IN), 5 μ l 10 X buffer and 1.0 U of Advantage KlenTaq Polymerase Mix (Clontech Laboratories, Inc., Palo Alto, CA). Thermocycler conditions in Perkin Elmer 9600 (Norwalk, CT) were as follows: 94 °C for 2 mins, then 30 cycles of 94 °C for 1 min., 58 °C for 2 mins, and 72 °C for 3 mins. PCR was followed by an additional extension cycle at 72 °C for 7 minutes.

The PCR amplified product was run on a gel, an amplified fragment of approximately 960 bp was gel purified, the termini of the fragment filled-in with T4 DNA polymerase (Boehringer Mannheim, Corp., Indianapolis, IN), and cloned into pCR-BLunt Vector (Invitrogen Corp., Carlsbad, CA) following manufacturer's protocol. The new plasmid was designated as pRAE-52, and the putative PUFA elongase cDNA in this clone was sequenced using ABI 373A Stretch DNA Sequencer (Perkin Elmer, Foster City, CA). The putative PUFA elongase cDNA sequence in plasmid pRAE-52 is shown in Figure 43, and the translated sequence is shown in Figure 44.

The putative PUFA elongase cDNA from plasmid pRAE-52 was then digested with *NcoI/HindIII*, gel purified, and ligated into pYX242(*NcoI/HindIII*). The new plasmid was designated as pRAE-58-A1. (Plasmid 58-A1 was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 on August 19, 1999, under the terms of the Budapest Treaty and was accorded deposit number PTA-566.)

The construct pRAE-58-A1 was transformed into *S. cerevisiae* 334 (Hoveland et al., *supra*) and screened for elongase activity. The negative control strain was *S. cerevisiae* 334 containing pYX242 vector. The cultures were grown for 24 hours at 30°C, in selective media (Ausubel et al., *supra*), in the presence of 25 µM of GLA or AA. In this study, DGLA or adrenic acid (ADA, 22:4n-6), respectively, was the predicted product of human elongase activity. When GLA was used as a substrate, the yeast cells containing the human elongase cDNA contained elevated levels of DGLA compared to control cells, 2.75% vs. 0.09% of total fatty acids, respectively (see Figure 45). When AA was used as a substrate, the yeast cells containing the human elongase cDNA contained elevated levels of ADA compared to control cells, none

detected vs. 1.21% of total fatty acids, respectively. Thus, the human elongase converts both 18 and 20 carbon chain long PUFAs to their respective elongated fatty acids.

The yeast cells containing the human elongase cDNA also had elevated levels of monounsaturated fatty acids including 18:1n-7, 20:1n-7, 20:1n-9, and 18:1n-5, compared to the control strain. Therefore, these results indicate that the identified human elongase is capable of utilizing PUFAs as well as monounsaturated fatty acids as substrates. Thus, this human sequence HSELO1, and its encoded protein (HSELO1p), possesses elongase activity independent of substrate specificity.

To further confirm the substrate specificity of the human elongation enzyme, described above and referred to herein as HSELO1, the recombinant yeast strain 334(pRAE-58-A1) was grown in minimal media containing n-6 fatty acids GLA, AA, or n-3 fatty acids ALA, STA, or EPA. The lipid profiles of these yeast cultures, when examined by GC and GC-MS, indicated that there were accumulations of DGLA, ADA, ω3-eicosatrienoic acid (ETra, C20:3n-3), ETA, and DPA, respectively (Figure 51). The levels of these fatty acids were 7.29% (DGLA), 6.26% (ADA), 6.15% (ETra), 10.06% (ETA), and 6.66% (DPA), respectively, of the total fatty acids in the strain containing the pRAE-58-A1 sequence. These represented 78.3%, 42.7%, 30.4%, 79.2%, and 71.7% conversions of the substrate fatty acids, respectively, to the products elongated by two carbon atoms.

The yeast cells expressing the recombinant HSELO1 sequence, compared to the control cells, also contained significantly elevated levels of C18:1n-7 and C20:1n-7, and to a lesser extent, eicosenoic acid (EA, C20:1n-9) (Figure 45). This finding suggested that the recombinant HSELO1 protein (HSELO1p) might also be involved in the elongation of monounsaturated

fatty acids of 16 or 18 carbon lengths. To confirm this hypothesis, 25 μ M of exogenous OA was added as a substrate to the recombinant yeast strain 334(pRAE-58-A1). After incubation, the accumulation of EA at 2.25% of the total fatty acids demonstrated that the expressed HSELO1 enzyme could elongate monounsaturated fatty acids (Figure 51). However, the conversion of OA to EA by recombinant HSELO1p was only 8.9%; this conversion was significantly lower than the endogenous conversion of C16:1n-7 (to C18:1n-7) or C18:1n-7 (to C20:1n-7), which was 20.4% and 58.1%, respectively.

To determine whether the substrate concentration affects the conversion of 18 and 20 carbon fatty acids to the respective elongated products, two different concentrations of GLA, AA, and EPA were examined (Figure 52). When 25 μ M of the substrates GLA, AA, and EPA were added exogenously, the levels of the fatty acids produced by two carbon elongation were 3.95% (DGLA), 2.91% (ADA), and 4.82% (DPA), respectively, of the total fatty acids in the lysates of 334(pRAE-58-A1). These represented 62.4%, 27.5%, and 70.3% conversions of the substrate fatty acids, respectively, to the products elongated by two carbon atoms. When 100 μ M of the substrates GLA, AA, and EPA were added, the levels of the fatty acids produced by two carbon elongation were 9.56% (DGLA), 3.90% (ADA), and 11.50% (DPA), respectively, of the total fatty acids in the lysates of 334(pRAE-58-A1). These represented 39.8%, 15.7%, and 45.7% conversions of the substrate fatty acids, respectively, to the products elongated by two carbon atoms. Although the addition of more substrates led to higher percentages of the two carbon elongated products, the overall conversion rate decreased by at least 35%.

To further confirm the substrate specificity of HSELO1p, the recombinant yeast strain 334(pRAE-58-A1) was grown in minimal media containing 25 μ M of saturated, monounsaturated, or PUFAs. The lipid profiles of these various substrates revealed that HSELO1p is not involved in the elongation of saturated fatty acids such as palmitic acid (PA, C16:0), stearic acid (SA, C18:0), arachidic acid (ARA, C20:0), behenic acid (BA, C22:0) (Figure 53A). HSELO1p is also not involved in the elongation of monounsaturated fatty acids OA and EA. When PTA was added as a substrate, 12.76% of the total fatty acids was OA. However, this is not an increase in the level of OA compared to the samples where PTA was not added, as OA was 25-31% of the total fatty acids in all samples. HSELO1p is involved in the elongation of n-6 PUFAs LA, GLA, and AA, but not DGLA or ADA (Figure 53B). The lipid profiles of these yeast cultures indicated that there were accumulations of C20:2n-6, DGLA, and ADA, respectively, but not C22:3n-6 or C24:4n-6. The levels of these fatty acids were 0.74% (C20:2n-6), 2.46% (DGLA), and 2.14% (ADA), respectively, of the total fatty acids in the lysates of 334(pRAE-58-A1). These represented 13.2%, 51.4%, and 27.1% conversions of the substrate fatty acids, respectively, to the products elongated by two carbon atoms. HSELO1p is also involved in the elongation of n-3 PUFAs ALA, STA, and EPA, but not DPA (Figure 53C). The lipid profiles of these yeast cultures indicated that there were accumulations of ETrA, ETA, and DPA, respectively, but not C24:5n-3. The levels of these fatty acids were 1.03% ETrA, 2.24% (ETA), and 3.19% (DPA), respectively, of the total fatty acids in the strain containing the pRAE-58-A1 sequence. These represented 22.2%, 61.9%, and 39.5% conversions of the substrate fatty acids, respectively, to the products elongated by two carbon atoms. All results

confirmed that the expression of HSEL01 from human liver in yeast resulted in the elongation of various long-chain PUFAs in n-6 and n-3 fatty acid pathways.

Example XVII

Cloning, Expression and Characterization of a C. elegans PUFA Elongase

Several putative *C. elegans* elongases were identified with amino acid homology to both translated GLELO and MAELO. As with the human cDNA sequence, cloning of a cDNA and expression in yeast was used to determine if indeed it was a PUFA elongase. Primers RO738 (5' -AAT CAG GAA TTC ATG GCT CAG CAT CCG CTC GTT CAA C -3') and RO739 (5' -CCG CTT GTC GAC TTA GTT CTT CTT CTT TGG CAC -3') with restriction sites *EcoRI* and *Sall* (underlined), respectively, were based on the putative cDNA sequence contained in the genomic sequence U68749 (wormpep cDNA accession #F56H11.4.) A PCR amplification was performed in a 100 μ l volume containing: 250 ng excised *C. elegans* library cDNA (Origene Technologies Inc., Rockville, MD), 50 pmole each primer, 10 μ l 10X reaction buffer (Boehringer Mannheim Corp., Indianapolis, IN), 1 μ l 10 mM PCR Nucleotide mix (Boehringer Mannheim Corp., Indianapolis, IN), and 2.5 U Taq polymerase (Boehringer Mannheim Corp., Indianapolis, IN). Thermocycler conditions in a Perkin Elmer 9600 (Norwalk, CT) were as follows: 95 °C for 5 mins, then 25 cycles of 94 °C for 30 secs, 55 °C for 2 mins, and 72 °C for 2 mins. PCR was followed by an additional cycle of 72 °C for 7 minutes.

The PCR amplified product was purified from an agarose gel, cut with *EcoRI* and *Sall*, ligated to pXX242 (Invitrogen Corp., Carlsbad, CA) (linearized with *EcoRI* and *Sall*) using the Rapid

Ligation kit (Boehringer Mannheim Corp., Indianapolis, IN), according to the manufacturer's protocol and transformed into *E. coli* Top10 cells (Invitrogen Corp., Carlsbad, CA). The new plasmids, designated pRET-21 and pRET-22 (two individual clones from the ligation), were sequenced with the 373A Stretch DNA sequencer ABI (Perkin Elmer, Foster City, CA), and the cDNA sequences were identical. The 867 base cDNA nucleotide sequence of the plasmid pRET-22 containing the putative elongase is shown in Figure 46 and the translated sequence of 288 amino acids is shown in Figure 47. (Plasmid pRET-22 was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 on August 19, 1999, under the terms of the Budapest Treaty and was accorded deposit number PTA-565.)

The plasmids pRET-21 and -22 were transformed into *S. cerevisiae* 334 as previously described (see Example III) and the resulting yeast cultures (334(pRET-21) and 334(pRET-22)) grown in 100 ml of selective media without leucine (Ausubel et al., *supra*) for 48 hours at 20 °C in the presence of 50 μ M GLA and AA. The cell pellets were collected and subjected to fatty acid analysis and the results shown in Figure 48. DGLA, the predicted product from GLA elongation, was found to be an average of 1.79% of the total lipid in the two samples, versus 0.13% for the negative control (334 containing plasmid pXX242) indicating that the enzyme encoded by both pRET-21 and pRET-22 possessed GLA elongase activity. The percent conversion of GLA to DGLA by 334(pRET-21) and 334(pRET-22) was 11.1% and 19.4% respectively with an average of 15.25%. Interestingly, almost no elongation of AA or any endogenous fatty acid was observed (Fig. 48). These results indicate that the elongase encoded by this newly identified *C. elegans* cDNA, CEELO1, is able to

specifically elongate GLA to DGLA, suggesting that it may be a C. elegans homologue of GLA elongase.

To further confirm the GLA elongation activity of CEEL01, the experiment described in the paragraphs above was repeated with the exception that GLA and AA were added to cultures of 334 (pRET-22) separately. Again, GLA was elongated to DGLA with a 38.2% conversion rate. No elongation activity of AA was detected as shown in Figure 61. In this case, the percent conversion appears to be double that described in previous results (see Figure 48) and may either be due to the absence of the additional substrate (AA) or the subculturing of the yeast. CEEL01 has the additional activity of elongating endogenous 16:1n-7 to 18:1n-7 with a 9.12% conversion rate compared to 3.9% control culture 334 (pYX242) under identical conditions. Thus, the C. elegans elongation enzyme possesses a major elongation activity for a C18 polyunsaturated fatty acid and a minor activity for a C16 monounsaturated fatty acid.

Additionally, to further determine the substrate specificity of CEEL01, 50 μ M of each substrate besides GLA (e.g., SA (18:0), OA (18:1), LA (18:2n-6), DGLA (20:3n-9), AA (20:2n-6), ADA (22:4n-6), ALA (18:3n-3), PA (18:0), EPA (20:5n-3) and STA (18:4n-2)) was added individually to cultures of 334 (pRET-22) and grown for 48 hours at 20 °C, as described in Example XVII. STA was the only exogenously added substrate that was elongated. The CEEL01 elongated 13% of STA incorporated to ETA (20:4n-3) (see Figure 62).

Parallel to Examples III and XI, the C. elegans CEEL01 gene in the plasmid pRET22 and M. alpina Δ 5 desaturase (pCGR-4; see Example III) were co-expressed in yeast to determine if AA or EPA could be produced from exogenously added GLA or STA, respectively. When a yeast culture containing both pRET22 and

pCGR4 plasmids was grown in the presence of 50 μ M GLA or STA in media lacking leucine and uracil, the percent conversion to the final products of AA and EPA, respectively, appeared identical (27% conversion) (see Figure 63). Thus, simultaneous heterologous expression of CEEL01 and a Δ 5 desaturase results in the biosynthesis of AA and EPA from GLA and STA, respectively in yeast.

Example XVIII

Isolation of a Putative Human Elongase cDNA Based on AC004050 Sequence

To isolate the full length putative elongase cDNA based on the AC004050 sequence, primers RP735 (5' -CCT CCT GAA TTC CAQA CAC TAT TCA GCT TTC -3') and RO73 (5' -TAA TAC GAC TCA CTA TAG GG -3') were used to PCR amplify the human liver Marathon-Ready cDNA (Clontech Laboratories, Inc., Palo Alto, CA). The PCR was carried out using the Advantage™ cDNA PCR Kit (Clontech Laboratories, Inc., Palo Alto, CA) with 5 μ l of human liver Marathon-Ready cDNA and 50 pmole each primer following manufacturer's instructions. Thermocycler conditions in Perkin Elmer 9600 (Norwalk, CT) were as follows: 94 °C for 2 mins, then 30 cycles of 94 °C for 1 min., 58 °C for 2 mins., and 72 °C for 3 mins. PCR was followed by an additional extension at 72 °C for 7 mins.

The PCR amplified product was run on a gel, an amplified fragment of approximately 1 Kb was gel purified, the termini of the fragment were filled in with T4DNA polymerase (Boehringer Mannheim, Corp., Carlsbad, CA) following manufacturer's instructions. The new plasmid was designated as pRAE-59, and

the putative PUFA elongase cDNA in this plasmid, designated as HS3, was sequenced using the ABI 373A Stretch Sequencer (Perkin Elmer, Foster City, CA). The putative PUFA elongase cDNA sequence HS3 is shown in Figure 49, and the translated sequence is shown in Figure 50.

Example XIX Cloning and Expression of a Mouse PUFA Elongation Enzyme

The National Center for Biotechnology Information (NCBI at <http://www.ncbi.nlm.nih.gov>) was used to conduct database searches using blastn with the mouse EST sequence AI225632 (see Example XIII). Three mouse EST sequences were identified (GenBank Accession #'s AI428130, AI595258, and AA061089), and assembled to generate a putative full-length elongation enzyme sequence, designated as MELO4. Primers RO819 (5' -ATG ATG CCA TGG AGC AGC TGA AGG CCT TTG- 3') and RO820 (5' -CAG TCT CTG CTT TAA AAC AAG CTC GTC- 3') were designed based on the putative full length mouse elongation enzyme sequence, and used to amplify the mouse brain Marathon-Ready cDNA (Clontech Laboratories, Inc., Palo Alto, California). The Polymerase Chain Reaction (PCR) was carried out as previously described (Example XVI). The PCR amplified product was run on a gel, an amplified fragment of approximately 1,000 bp was gel purified, the termini of the fragment were digested with NcoI and DraI (Boehringer Mannheim, Corp., Indianapolis, IN), and the fragment was cloned into pYX242 (NcoI/HindIII). The new plasmid was designated as pRAE-84, and the putative PUFA elongation enzyme cDNA in this clone was sequenced using ABI 373A Stretch DNA Sequencer (Perkin Elmer, Foster City, CA). The putative PUFA

elongation enzyme cDNA sequence in plasmid pRAE-84 is shown in Figure 54, and the translated sequence is shown in Figure 55.

The construct pRAE-84 was transformed into *S. cerevisiae* 334 (Hoveland et al., supra) and screened for elongase activity. The negative control strain was *S. cerevisiae* 334 containing pYX242 vector. The cultures were grown for 42-48 hours at 30°C, in selective media (Ausubel et al., supra), in the presence of 25 µM of GLA, AA, ADA, STA, EPA, or DPA. The lipid profiles of these yeast cultures indicated that GLA was not elongated to the expected product of DGLA. However, there were accumulations of ADA, ω6-tetracosatetraenoic acid (TTA, C24:4n-6), ETA, DPA, and ω3-tetracosapentaenoic acid (TPA, C24:5n-3), respectively (Figure 56). The n-6 fatty acid substrate AA was converted to ADA, which was subsequently converted to TTA, and the n-3 fatty acid EPA was converted to DPA, which was subsequently converted to TPA. The levels of these fatty acids were 0.64% (ADA), 1.07% (TTA), 1.47% (DPA), and 7.06% (TPA), respectively, of the total fatty acids in the strain containing the pRAE-84 sequence. These represented 10.4%, 62.6%, 32.7%, and 82.8% conversions of the substrate fatty acids, respectively, to the products elongated by two carbon atoms. The C22 substrates ADA and EPA were elongated to 2.4% (TTA) and 3.82% (TPA) of the total fatty acids. These represented 9.2% and 43.9% conversions of the substrate fatty acids, respectively. The expression of MELO4 in yeast results in the conversion of C20 and C22 fatty acids to the respective elongated products. The conversion rate of C22 to C24 fatty acids is much greater when the exogenously added substrate is C20 fatty acid.

To further confirm the substrate specificity of MELO4 protein (MELO4), the recombinant yeast strain 334 (pRAE-84) was

grown in minimal media containing 25 μ M of saturated, monounsaturated, or polyunsaturated fatty acids. The lipid profiles of these various substrates revealed that MELO4p is not involved in the elongation of saturated fatty acids such as PA, SA, ARA, or BA (Figure 57A). MELO4p is also not involved in the elongation of monounsaturated fatty acids PTA, OA, or EA. MELO4p is involved in the elongation of n-6 PUFAs AA and ADA, but not LA or DGLA (Figure 57B). The lipid profiles of these yeast cultures indicated that there were accumulations of ADA and TTA, but not C20:2n-6 or C22:3n-6. When AA was added exogenously, the levels of product fatty acids were 0.5% (ADA) and 0.39% (TTA), and when ADA was added exogenously, the level of product fatty acid was 1.3% (TTA) of the total fatty acids in the strain containing the pRAE-84 sequence. These represented 8.7%, 43.8%, and 7.3% conversions of the substrate fatty acids, respectively, to the products elongated by two carbon atoms. MELO4p is also involved in the elongation of GLA to DGLA. The lipid profile of the strain containing the pRAE-84 sequence, in presence of GLA, had 0.43% of DGLA, which represented 14.7% conversion of GLA to DGLA. MELO4p is also involved in the elongation of n-3 PUFAs EPA and DPA (Figure 53C). The lipid profiles of these yeast cultures indicated that there were accumulations of DPA and TPA. When EPA was added, the levels of these fatty acids were 1.21% (DPA) and 3.38% (TPA), and when DPA was added, the level of the product fatty acid was 3.09% (TPA) of the total fatty acids in the strain containing the pRAE-84 sequence. These represented 24.0%, 73.6%, and 46.4% conversions of the substrate fatty acids, respectively, to the products elongated by two carbon atoms. MELO4p is also involved in the elongation of STA to C22:4n-3. When STA was added, the levels of fatty acids produced by two-carbon elongation were 0.3% ETA

and 0.23% C22:4n-3. These represented 11.1% and 43.4% conversions of substrate fatty acids to the products elongated by two carbon atoms. MELO4p also appeared to be involved in the elongation of ALA; however, the small amount of the fatty acid produced by two-carbon elongation (0.16% of ETrA) may not be significant. All results confirmed that the expression of MELO4 from mouse brain in yeast resulted in the elongation of C20 and C22 long-chain PUFAs in n-6 and n-3 fatty acid pathways.

10

Example XX

Identification, Cloning, and Expression of HSELO1 Homologue from Mouse

The National Center for Biotechnology Information (NCBI at <http://www.ncbi.nlm.nih.gov>) was used to conduct database searches using blastn with the HSELO1 sequence. Two human EST sequences were identified (GenBank Accession #'s AI787925 and AI746838) and the respective cDNA clones (I.M.A.G.E. Consortium Clone ID's 2076831 and 206182) were purchased through Research Genetics (Huntsville, AL). Primers R0833 (5' -GGT TTT ACC ATG GAA CAT TTC GAT GCG TCA C- 3') and R0832 (5' -CGA CCT GCA GCT CGA GCA CA- 3') were designed based on 5' sequence of the putative mouse elongation enzyme, and the cDNA clone vector, respectively. Primers R0833 and R0832 were used to amplify the mouse cDNA clone 2076182. The Polymerase Chain Reaction (PCR) was carried out as previously described (Example XVI). The termini of the PCR amplified product were filled-in with T4 DNA polymerase (Boehringer Mannheim, Corp., Indianapolis, IN) and the 5' region was digested with NcoI. The modified fragment was run on a gel, an amplified fragment of approximately 2.4 Kp was gel purified, and the fragment was cloned into pYX242

25

30

(NcoI/EcoRV). The new plasmid was designated as pRAE-87, and the putative PUFA elongation enzyme cDNA in this clone, MELO7, was sequenced using ABI 373A Stretch DNA Sequencer (Perkin Elmer, Foster City, CA). The putative PUFA elongation enzyme cDNA sequence in plasmid pRAE-87 (MELO7) is shown in Figure 58, and the translated sequence is shown in Figure 59.

The construct pRAE-87 was transformed into *S. cerevisiae* 334 (Hoveland et al., supra) and screened for elongase activity. The negative control strain was *S. cerevisiae* 334 containing pYX242 vector. The cultures were grown for 42-48 hours at 30°C, in selective media (Ausubel et al., supra), in the presence of 25 μ M of GLA, AA, STA, EPA, DPA, or ADA. The lipid profiles of the yeast cultures expressing MELO7 indicated that there were accumulations of DGLA, ADA, and ETA, respectively (Figure 60). The levels of these fatty acids were 4.1% (DGLA), 6.33% (ADA), 3.4% (ETA), and 6.18% (DPA), respectively, of the total fatty acids in the strain containing the pRAE-87 sequence. These substrate fatty acids, respectively, to the products elongated by two carbon atoms. MELO7 protein (MELO7) was not involved in the elongation of ADA. MELO7p also appeared to be involved in further elongation of the fatty acid DPA produced by two-carbon elongation to TPA when EPA was the added substrate, and when DPA was added. However, the small amounts of the product fatty acids (0.27% and 0.25% of TPA) may not be significant.

The yeast cells expressing the recombinant MELO7 sequence, compared to the control cells, also contained significantly elevated levels of C18:1n-7 and C20:1n-7. All results confirmed that the expression of MELO7 from mouse embryo in yeast resulted in the elongation of various long-chain PUFAs in n-6 and n-3 fatty acid pathways, and that MELO7 was a homologue of HSELO1.

Example XXI

Cloning and Expression of a Fungal PUFA Elongation Enzyme

The translated amino acid sequences of the four elongases, HSELO1, MELO4, GLELO, and CEELO, were aligned to identify areas of homology (Figure 64). A primer was designed based on a block of sequences that showed similarities (underlined). Primer

RO895 (5' -GTA GTA WGA GTA CAT GAT WAC GTG GAT RAA WGA GTT WAG-3') and vector primer RO898 (5' -CCC AGT CAC GAC GTT GTA AAA CGA CGG CCA G-3') were used to amplify the cDNA from *Thraustochytrium aureum* 7091 (T7091). PCR was carried out in a 50 μ l volume containing: 1 μ l of T7091 cDNA, 0.2 μ M dNTP mix, 50 pM each primer, 5 μ l of 10 X buffer, 1.5 μ l of 50 mM MgSO₄, and 0.5 U of Taq DNA Polymerase. Thermocycler conditions in Perkin Elmer 9600 were as follows: 94°C for 3 min, then 30 cycles of 95°C for 45 sec., 55 °C for 30 sec., and 68°C for 2 min. The PCR amplified mixture was run on a gel, an amplified fragment of approximately 750 bp was gel purified, and the isolated fragment was cloned into the PCR-blunt vector (Invitrogen, Co., Carlsbad, CA).

Twelve clones were prepared and sequenced. All twelve clones had the same sequence, and the consensus sequence was designated as cld6 (Figure 65). The translated amino acid sequence of cld6 (Figure 66) had 34.7% identity in 190 amino acids with HSELO1, 35.8% identity in 187 amino acids with MELO4, 45.6% identity in 160 amino acids with GLELO, and 32.9% identity in 155 amino acids with CEELO. A new primer was designed based on the 5' sequence of cld6, at the first Met. RO1160 (5' -AAG GAA CCA TGG CAA ACA GCA GCG TGT GGG ATG-3'), which has an added

NcoI site (underlined), and vector primer R0899 (5' -AGC GGA TAA CAA TTT CAC ACA GGA AAC AGC- 3') were used to amplify the T7091 cDNA. The Polymerase Chain Reaction (PCR) was carried out as described above. The PCR amplified product was run on a gel, an amplified fragment of approximately 1.2 Kb was gel purified, the termini of the fragment were digested with NcoI and HindIII (Boehringer Mannheim, Corp., Indianapolis, IN), and the fragment was cloned into pYX242 (NcoI/HindIII). The new plasmids were designated as pRAT-4-A1, pRAT-4-A2, pRAT-4-A3, pRAT-4-A4, pRAT-4-A6, pRAT-4-A7, and pRAT-4-D1. (Plasmid DNA pRAT-4-A7 was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, on June 29, 2001, under the terms of the Budapest Treaty, and was accorded deposit number ATCC PTA-3490.) The putative PUFA elongation enzyme cDNAs in these clones were sequenced using ABI 373A Stretch DNA Sequencer (Perkin Elmer, Foster City, CA). The putative PUFA elongation enzyme cDNA sequences in plasmids pRAT-4-A1 through pRAT-4-D1 are shown in Figures 67-73, and the translated sequences are shown in Figures 74-80, respectively.

The constructs pRAT-4-A1 through pRAT-4-D1 were transformed into *S. cerevisiae* 334 (Hoveland et al., supra) and screened for elongase activity. *S. cerevisiae* 334 containing the unaltered pYX242 vector was used as a negative control. The cultures were grown for 48 hours at 24°C, in selective media (Ausubel et al., supra), in the presence of 25 μ M of GLA or EPA. In this study, DGLA or ω 3-docosapentaenoic acid (DPA, 22:5n-3), respectively, was the predicted product of the elongase activity. The lipid profiles of these yeast cultures indicated that GLA was elongated to DGLA in all the samples, except for 334 (pRAT-4-A3) (Figure 81). This was expected in that the cDNA sequence of

pRAT-4-A3 had several stops at the 5' end of the sequence, which would result in a truncated version of the translated enzyme (Figure 76). Although the DGLA level was very low for 334 (pRAT-4-A2), the GLA level was the lowest in this sample; therefore, the conversion level of the fatty acid to its elongated form was significant at 28.4%. What was not expected was that there was definite substrate specificity among the expressed enzymes. The cultures of 334 (pRAT-4-A1) and 334 (pRAT-4-A2) had very low levels of DPA when EPA was added as a substrate, indicating that the expressed enzymes in these cultures preferred the elongation of the 18-carbon chain long PUFA, and not the 20-chain long PUFA, EPA. The cultures of 334 (pRAT-4-A4), 334 (pRAT-4-A6), 334 (pRAT-4-A7), and 334 (pRAT-D1) all had significant levels of DPA present, indicating that the expressed enzymes in these cultures were involved in the elongation of both 18- and 20-carbon chain long PUFAs to their respective elongated fatty acids.

The amino acid sequences of the 6 active clones were compared to determine if the substrate preferences were dictated by the translated sequences (Figure 82). The cDNA sequences of pRAT-4-A1 and pRAT-4-A2 differed from other sequences in that they had a mutation at Y377C and V371A, respectively. This must be a critical region of the enzyme for 20-carbon chain elongation. The other sequences also had mutations, pRAT-4-A4 (I475V), pRAT-4-A6 (D26G and V458A), and pRAT-4-D1 (K182R and E269V); however, these mutations do not appear to interfere with 20-carbon chain elongation. The pRAT-4-A7 cDNA had a single, silent mutation at base 726 in comparison to the consensus sequence.

The translated amino acid sequence of the consensus TELO1 sequence had 34.0% identity in 265 amino acids with HSELO1

(Figure 83), 34.1% identity in 267 amino acids with MELO4 (Figure 84), 43.4% identity in 244 amino acids with GLELO (Figure 85), and 34.3% identity in 239 amino acids with CELO (Figure 86).

The yeast cells containing the fungal elongase cDNAs also had elevated levels of the monounsaturated fatty acid 18:1n-7, compared to the control strain (Figure 81). Therefore, these results indicated that the identified fungal elongases are capable of utilizing PUFAs as well as monounsaturated fatty acids as substrates. Thus, these fungal sequences TEL01, and their encoded proteins (TELO1p), possess elongase activity independent of substrate specificity.

To further confirm the substrate specificity of the fungal elongation enzyme, described above and referred to herein as TEL01, the recombinant yeast strain 334(pRAT-4-A4), 334(pRAT-4-A6), 334(pRAT-4-A7), and 334(pRAT-4-D1) were grown in minimal media containing n-6 fatty acids GLA, AA, or n-3 fatty acids STA, or EPA, or no substrate. The lipid profiles of these yeast cultures, when examined by GC and GC-MS, indicated that there were accumulations of DGLA, ADA, ETA, ω 3-docosatetraenoic acid (DTA, C22:4n-3), and DPA, respectively (Figure 87). The levels of these fatty acids were 3.88 - 5.42% (DGLA), 0.18 - 0.75% (ADA), 2.27 - 4.01% (ETA), 0.16 - 1.10% (DTA), and 0.54 - 1.74% (DPA), respectively, of the total fatty acids in the strains containing the TEL01 sequence. These represented 64.0 - 77.2%, 1.0 - 5.0%, 79.3 - 89.6%, 3.8 - 32.6%, and 3.4 - 13.3% conversions of the substrate fatty acids, respectively, to the products elongated by two carbon atoms.

The yeast cells expressing the recombinant TEL01 sequence, compared to the control cells, also contained significantly

elevated levels of C18:1n-7 and decreased levels of C16:1n-7 (Figure 87). This finding suggested that the recombinant TEL01 protein (TELO1p) might also be involved in the elongation of monounsaturated fatty acids of 16-carbon length.

To further confirm the substrate specificity of TEL01p, the recombinant yeast strain 334(pRAT-4-A7) was grown in minimal media containing 25 μ M of various PUFAs. The lipid profiles of these various substrates revealed that TEL01p is involved in the elongation of n-6 PUFAs LA, GLA, and AA, but not DGLA (Figure 88). The lipid profiles of these yeast cultures indicated that there were accumulations of C20:2n-6, DGLA, and ADA, respectively, but not C22:3n-6. The levels of these fatty acids were 1.07% (C20:2n-6), 5.84% (DGLA), and 0.76% (ADA), respectively, of the total fatty acids in the lysates of 334(pRAT-4-A7). These represented 23.2%, 78.6%, and 3.5% conversions of the substrate fatty acids, respectively, to the products elongated by two-carbon atoms. TEL01p is also involved in the elongation of n-3 PUFAs ALA, STA, and EPA (Figure 88). The lipid profiles of these yeast cultures indicated that there were accumulations of ETrA, ETA, and DPA, respectively. The levels of these fatty acids were 2.71% ETrA, 4.19% (ETA), and 1.99% (DPA), respectively, of the total fatty acids in the strain containing the TEL01 sequence. These represented 43.3%, 85.3%, and 11.5% conversions of the substrate fatty acids, respectively, to the products elongated by two-carbon atoms. When STA was added as a substrate, there was also an accumulation of DTA in the culture. The level of this fatty acid was 0.74%, which represented 15.0% conversion of ETA, the two-carbon chain elongated product from substrate STA. All results confirmed that the expression of TEL01 from T7091 in

yeast resulted in the elongation of various long-chain PUFAs in n-6 and n-3 fatty acid pathways.

Nutritional Compositions

The PUFAs described in the Detailed Description may be utilized in various nutritional supplements, infant formulations, nutritional substitutes and other nutritional solutions.

10 I. INFANT FORMULATIONS

A. Isomil® Soy Formula with Iron:

Usage: As a beverage for infants, children and adults with an allergy or sensitivity to cows milk. A feeding for patients with disorders for which lactose should be avoided: lactase deficiency, lactose intolerance and galactosemia.

Features:

- Soy protein isolate to avoid symptoms of cow's-milk-protein allergy or sensitivity.
- Lactose-free formulation to avoid lactose-associated diarrhea.
- Low osmolality (240 mOs/kg water) to reduce risk of osmotic diarrhea.
- Dual carbohydrates (corn syrup and sucrose) designed to enhance carbohydrate absorption and reduce the risk of exceeding the absorptive capacity of the damaged gut.
- 1.8 mg of Iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.
- Recommended levels of vitamins and minerals.
- Vegetable oils to provide recommended levels of essential fatty acids.
- Milk-white color, milk-like consistency and pleasant aroma.

Ingredients: (Pareve) 85% water, 4.9% corn syrup, 2.6% sugar (sucrose), 2.1 % soy oil, 1.9% soy protein isolate, 1.4% coconut oil, 0.15% calcium citrate, 0.11 % calcium phosphate tribasic,

- 5 potassium citrate, potassium phosphate monobasic, potassium chloride, mono- and diglycerides, soy lecithin, carrageenan, ascorbic acid, L-methionine, magnesium chloride, potassium phosphate dibasic, sodium chloride, choline chloride, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic
- 10 acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D3 and cyanocobalamin.

B. Isomil® DF Soy Formula For Diarrhea:

Usage: As a short-term feeding for the dietary management of diarrhea in infants and toddlers.

Features:

- First infant formula to contain added dietary fiber from soy fiber specifically for diarrhea management.
- 25 -Clinically shown to reduce the duration of loose, watery stools during mild to severe diarrhea in infants.
- Nutritionally complete to meet the nutritional needs of the infant.
- Soy protein isolate with added L-methionine meets or exceeds an infant's requirement for all essential amino acids.
- 30 -Lactose-free formulation to avoid lactose-associated diarrhea.

- Low osmolality (240 mOsm/kg water) to reduce the risk of osmotic diarrhea.
- Dual carbohydrates (corn syrup and sucrose) designed to enhance carbohydrate absorption and reduce the risk of exceeding the absorptive capacity of the damaged gut.
- Meets or exceeds the vitamin and mineral levels recommended by the Committee on Nutrition of the American Academy of Pediatrics and required by the Infant Formula Act.
- 1.8 mg of iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.
- Vegetable oils to provide recommended levels of essential fatty acids.

Ingredients: (Pareve) 86% water, 4.8% com syrup, 2.5% sugar (sucrose), 2.1% soy oil, 2.0% soy protein isolate, 1.4% coconut oil, 0.77% soy fiber, 0.12% calcium citrate, 0.11 % calcium phosphate tribasic, 0.10% potassium citrate, potassium chloride, potassium phosphate monobasic, mono and diglycerides, soy lecithin, carrageenan, magnesium chloride, ascorbic acid, L-methionine, potassium phosphate dibasic, sodium chloride, choline chloride, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D3 and cyanocobalamin.

C. Isomil® SF Sucrose-Free Soy Formula With Iron:

Usage: As a beverage for infants, children and adults with an allergy or sensitivity to cow's-milk protein or an intolerance to sucrose. A feeding for patients with disorders for which lactose and sucrose should be avoided.

Features:

- Soy protein isolate to avoid symptoms of cow's-milk-protein allergy or sensitivity.
- Lactose-free formulation to avoid lactose-associated diarrhea (carbohydrate source is Polycose® Glucose Polymers).
- Sucrose free for the patient who cannot tolerate sucrose.
- Low osmolality (180 mOsm/kg water) to reduce risk of osmotic diarrhea.
- 1.8 mg of iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.
- Recommended levels of vitamins and minerals.
- Vegetable oils to provide recommended levels of essential fatty acids.
- Milk-white color, milk-like consistency and pleasant aroma.

Ingredients: (Pareve) 75% water, 11.8% hydrolyzed cornstarch, 4.1% soy oil, 4.1 % soy protein isolate, 2.8% coconut oil, 1.0% modified cornstarch, 0.38% calcium phosphate tribasic, 0.17% potassium citrate, 0.13% potassium chloride, mono- and diglycerides, soy lecithin, magnesium chloride, ascorbic acid, L-methionine, calcium carbonate, sodium chloride, choline chloride,

carrageenan, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine

119

120

hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D3 and cyanocobalamin.

5 D. Isomil® 20 Soy Formula With Iron Ready To Feed,

20 Cal/fl oz.:

Usage: When a soy feeding is desired.

Ingredients: (Pareve) 85% water, 4.9% corn syrup, 2.6%

10 sugar(sucrose), 2.1 % soy oil, 1.9% soy protein isolate, 1.4%

coconut oil, 0.15% calcium citrate, 0. 11% calcium phosphate

tribasic, potassium citrate, potassium phosphate monobasic,

potassium chloride, mono- and diglycerides, soy

lecithin, carrageenan, ascorbic acid, L-methionine, magnesium

15 chloride, potassium phosphate dibasic, sodium chloride, choline

chloride, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl

acetate, zinc sulfate, L-carnitine, niacinamide, calcium

pantothenate, cupric sulfate, vitamin A palmitate, thiamine

chloride hydrochloride, riboflavin, pyridoxine hydrochloride,

20 folic

acid, manganese sulfate, potassium iodide, phylloquinone,

biotin, sodium selenite, vitamin D3 and cyanocobalamin.

E. Similac® Infant Formula:

Usage: When an infant formula is needed: if the decision is made to discontinue breastfeeding before age 1 year, if a supplement to breastfeeding is needed or as a routine feeding if breastfeeding is not adopted.

Features:

-Protein of appropriate quality and quantity for good growth; heat-denatured, which reduces the risk of milk-associated enteric blood loss.

-Fat from a blend of vegetable oils (doubly homogenized),

5 providing essential linoleic acid that is easily absorbed.

-Carbohydrate as lactose in proportion similar to that of human milk.

-Low renal solute load to minimize stress on developing organs.

-Powder, Concentrated Liquid and Ready To Feed forms.

Ingredients: (-D) Water, nonfat milk, lactose, soy oil, coconut oil, mono- and diglycerides, soy lecithin, ascorbic acid, carrageenan, choline chloride, taurine, m-inositol, alpha-tocopheryl acetate, zinc sulfate, niacinamide, ferrous sulfate,

15 calcium pantothenate, cupric sulfate, vitamin A palmitate,

thiamine chloride hydrochloride, riboflavin, pyridoxine

hydrochloride, folic

acid, manganese sulfate, phylloquinone, biotin, sodium selenite, vitamin D3 and cyanocobalamin.

20 F. Similac® NeoCare Premature Infant Formula With Iron:

Usage: For premature infants' special nutritional needs after hospital discharge. Similac NeoCare is a nutritionally complete

25 formula developed to

provide premature infants with extra calories, protein, vitamins and minerals needed to promote catch-up growth and support development.

30 Features:

-Reduces the need for caloric and vitamin supplementation. More calories (22 Cal/fl oz) than standard term formulas (20 Cal/fl oz).

-Highly absorbed fat blend, with medium-chain triglycerides (MCT oil) to help meet the special digestive needs of premature infants.

-Higher levels of protein, vitamins and minerals per 100 calories to extend the nutritional support initiated in-hospital.

-More calcium and phosphorus for improved bone mineralization.

Ingredients: -D Corn syrup solids, nonfat milk, lactose, whey protein concentrate, soy oil, high-oleic safflower oil, fractionated coconut oil (medium chain triglycerides), coconut oil, potassium citrate, calcium phosphate tribasic, calcium carbonate, ascorbic acid, magnesium chloride, potassium chloride, sodium chloride, taurine, ferrous sulfate, m-inositol, choline chloride, ascorbyl

palmitate, L-carnitine, alpha-tocopheryl acetate, zinc sulfate, niacinamide, mixed tocopherols, sodium citrate, calcium pantothenate, cupric sulfate, thiamine chloride hydrochloride, vitamin A palmitate, beta carotene, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, phylloquinone, biotin, sodium selenite, vitamin D3 and cyanocobalamin.

G. Similac Natural Care Low-Iron Human Milk Fortifier Ready To Use, 24 Cal/fl oz.:

Usage: Designed to be mixed with human milk or to be fed alternatively with human milk to low-birth-weight infants.

Ingredients: -D Water, nonfat milk, hydrolyzed cornstarch, lactose, fractionated coconut oil (medium-chain triglycerides), whey protein concentrate, soy oil, coconut oil, calcium phosphate tribasic, potassium citrate, magnesium chloride, sodium citrate, ascorbic acid, calcium carbonate, mono and diglycerides, soy lecithin, carrageenan, choline chloride, m-inositol, taurine,

niacinamide, L-carnitine, alpha tocopheryl acetate, zinc sulfate, potassium chloride, calcium pantothenate, ferrous sulfate, cupric sulfate, riboflavin, vitamin A palmitate, thiamine chloride hydrochloride, pyridoxine hydrochloride, biotin, folic acid, manganese sulfate, phylloquinone, vitamin D3, sodium selenite and cyanocobalamin.

Various PUFAs of this invention can be substituted and/or added to the infant formulae described above and to other infant formulae known to those in the art.

II. NUTRITIONAL FORMULATIONS

A. ENSURE®

Usage: ENSURE is a low-residue liquid food designed primarily as an oral nutritional supplement to be used with or between meals or, in appropriate amounts, as a meal replacement. ENSURE is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets. Although it is primarily an oral supplement, it can be fed by tube.

Patient Conditions:

- For patients on modified diets
- For elderly patients at nutrition risk

- For patients with involuntary weight loss
- For patients recovering from illness or surgery
- For patients who need a low-residue diet

5 Ingredients: -D Water, Sugar (Sucrose), Maltodextrin (Corn), Calcium and Sodium Caseinates, High-Oleic Safflower Oil, Soy Protein Isolate, Soy Oil, Canola Oil, Potassium Citrate, Calcium Phosphate Tribasic, Sodium Citrate, Magnesium Chloride, Magnesium Phosphate Dibasic, Artificial Flavor, Sodium Chloride, Soy Lecithin, Choline Chloride, Ascorbic Acid, Carrageenan, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Gellan Gum, Niacinamide,

10 Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Folic Acid, Sodium Molybdate, Chromium Chloride, Biotin, Potassium Iodide, Sodium Selenate.

B. ENSURE® BARS:

20 Usage: ENSURE BARS are complete, balanced nutrition for supplemental use between or with meals. They provide a delicious, nutrient-rich alternative to other snacks. ENSURE BARS contain <1 g lactose/bar, and Chocolate Fudge Brownie flavor is gluten-free. (Honey Graham Crunch flavor contains

25 gluten.)

Patient Conditions:

- For patients who need extra calories, protein, vitamins and minerals.
- 30 -Especially useful for people who do not take in enough calories and nutrients.

- For people who have the ability to chew and swallow
- Not to be used by anyone with a peanut allergy or any type of allergy to nuts.

Ingredients: Honey Graham Crunch -- High-Fructose Corn Syrup, Soy Protein Isolate, Brown Sugar, Honey, Maltodextrin (Corn), Crisp Rice (Milled Rice, Sugar [Sucrose], Salt [Sodium Chloride] and Malt), Oat Bran, Partially Hydrogenated Cottonseed and Soy Oils, Soy Polysaccharide, Glycerine, Whey Protein Concentrate, Polydextrose, Fructose, Calcium Caseinate, Cocoa Powder, Artificial Flavors, Canola Oil, High-Oleic Safflower Oil, Nonfat Dry Milk, Whey Powder, Soy Lecithin and Corn Oil.

10 Manufactured in a facility that processes nuts.

15 Vitamins and Minerals: Calcium Phosphate Tribasic, Potassium Phosphate Dibasic, Magnesium Oxide, Salt (Sodium Chloride), Potassium Chloride, Ascorbic Acid, Ferric Orthophosphate, Alpha-Tocopheryl Acetate, Niacinamide, Zinc Oxide, Calcium Pantothenate, Copper Gluconate, Manganese Sulfate, Riboflavin, Beta Carotene, Pyridoxine Hydrochloride, Thiamine Mononitrate, Folic Acid, Biotin, Chromium Chloride, Potassium Iodide, Sodium Selenate, Sodium Molybdate, Phylloquinone, Vitamin D3 and Cyanocobalamin.

20

25 Protein: Honey Graham Crunch - The protein source is a blend of soy protein isolate and milk proteins.

Soy protein isolate	74%
Milk proteins	26%

30

Fat: Honey Graham Crunch - The fat source is a blend of partially hydrogenated cottonseed and soybean, canola, high oleic safflower, oils, and soy lecithin.

- 5 Partially hydrogenated cottonseed and soybean oil 76%
 Canola oil 8%
 High-oleic safflower oil 8%
 Corn oil 4%
 Soy lecithin 4%

10

Carbohydrate: Honey Graham Crunch - The carbohydrate source is a combination of high-fructose corn syrup, brown sugar, maltodextrin, honey, crisp rice, glycexine, soy polysaccharide, and oat bran.

15

- High-fructose corn syrup 24%
 Brown sugar 21%
 Maltodextrin 12%
 Honey 11%
 Crisp rice 9%
 Glycexine 9%
 Soy Polysaccharide 7%
 Oat bran 7%

20

25 C. ENSURE® HIGH PROTEIN:

Usage: ENSURE HIGH PROTEIN is a concentrated, high-protein liquid food designed for people who require additional calories, protein, vitamins, and minerals in their diets. It can be used as an oral nutritional supplement with or between meals or, in appropriate amounts, as a meal replacement. ENSURE HIGH PROTEIN

30

is lactose- and gluten-free, and is suitable for use by people recovering from general surgery or hip fractures and by patients at risk for pressure ulcers.

5 Patient Conditions:

- For patients who require additional calories, protein, vitamins, and minerals, such as patients recovering from general surgery or hip fractures, patients at risk
- for pressure ulcers, and patients on low-cholesterol diets

10

Features:

- Low in saturated fat
- Contains 6 g of total fat and < 5 mg of cholesterol per serving
- Rich, creamy taste
- Excellent source of protein, calcium, and other essential vitamins and minerals
- For low-cholesterol diets
- Lactose-free, easily digested

15

20 Ingredients:

- Vanilla Supreme: -D Water, Sugar (sucrose), Maltodextrin (Corn), Calcium and Sodium Caseinates, High-Oleic Safflower Oil, Soy Protein Isolate, Soy Oil, Canola Oil, Potassium Citrate, Calcium Phosphate Tribasic, Sodium Citrate,
 Magnesium Chloride, Magnesium Phosphate Dibasic, Artificial Flavor, Sodium Chloride, Soy Lecithin, Choline Chloride, Ascorbic Acid, Carrageenan, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Gellan Gum, Niacinamide,
 25 Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine

25

30

127

Hydrochloride, Riboflavin, Folic Acid, Sodium Molybdate, Chromium Chloride, Biotin, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D3 and Cyanocobalamin.

5 Protein:

The protein source is a blend of two high-biologic-value proteins: casein and soy.

Sodium and calcium caseinates 85%

10 Soy protein isolate 15%

Fat:

The fat source is a blend of three oils: high-oleic safflower, canola, and soy.

High-oleic safflower oil 40%

Canola oil 30%

Soy oil 30%

20 The level of fat in ENSURE HIGH PROTEIN meets American Heart Association (AHA) guidelines. The 6 grams of fat in ENSURE HIGH PROTEIN represent 24% of the total calories, with 2.6% of the fat being from saturated fatty acids and 7.9% from polyunsaturated fatty acids. These values are within the AHA guidelines of < 30% of total calories from fat, < 10% of the calories from saturated fatty acids, and < 10% of total calories from polyunsaturated fatty acids.

Carbohydrate:

30 ENSURE HIGH PROTEIN contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla

128

supreme, chocolate royal, wild berry, and banana), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

Vanilla and other nonchocolate flavors:

Sucrose 60%

Maltodextrin 40%

Chocolate:

Sucrose 70%

Maltodextrin 30%

D. ENSURE® LIGHT

Usage: ENSURE LIGHT is a low-fat liquid food designed for use as an oral nutritional supplement with or between meals. ENSURE LIGHT is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

Patient Conditions:

25 -For normal-weight or overweight patients who need extra nutrition in a supplement that contains 50% less fat and 20% fewer calories than ENSURE.

-For healthy adults who don't eat right and need extra nutrition.

30 Features:

- Low in fat and saturated fat
- Contains 3 g of total fat per serving and < 5 mg cholesterol
- Rich, creamy taste
- Excellent source of calcium and other essential vitamins and minerals
- For low-cholesterol diets
- Lactose-free, easily digested

Ingredients:

- French Vanilla: -D Water, Maltodextrin (Corn), Sugar (Sucrose), Calcium Caseinate, High-Oleic Safflower Oil, Canola Oil, Magnesium Chloride, Sodium Citrate, Potassium Citrate, Potassium Phosphate Dibasic, Magnesium Phosphate
- Dibasic, Natural and Artificial Flavor, Calcium Phosphate Tribasic, Cellulose Gel, Choline Chloride, Soy Lecithin, Carrageenan, Salt (Sodium Chloride), Ascorbic Acid, Cellulose Gum, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Zinc Sulfate, Niacinamide, Manganese Sulfate, Calcium Pantothenate, Cupric Sulfate, Thiamine Chloride Hydrochloride, Vitamin A Palmitate, Pyridoxine Hydrochloride, Riboflavin, Chromium Chloride, Folic Acid, Sodium Molybdate, Biotin, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D3 and Cyanocobalamin.

Protein:

The protein source is calcium caseinate.

Calcium caseinate 100%

Fat:

The fat source is a blend of two oils: high-oleic safflower and canola.

- High-oleic safflower oil 70%
- Canola oil 30%

The level of fat in ENSURE LIGHT meets American Heart

- Association (AHA) guidelines. The 3 grams of fat in ENSURE LIGHT represent 13.5% of the total calories, with 1.4% of the fat being from saturated fatty acids and 2.6% from polyunsaturated fatty acids. These values are within the AHA guidelines of < 30% of total calories from fat, < 10% of the, calories from saturated fatty acids, and < 10% of total calories from polyunsaturated fatty acids.

Carbohydrate:

ENSURE LIGHT contains a combination of maltodextrin and sucrose.

- The chocolate flavor contains corn syrup as well. The mild sweetness and flavor variety (French vanilla, chocolate supreme, strawberry swirl), plus VARI-FLAVORS® Flavor Packs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

Vanilla and other nonchocolate flavors:

- Sucrose 51%
- Maltodextrin 49%

Chocolate:

131

132

Sucrose 47.0%
Corn Syrup 26.5%
Maltodextrin 26.5%

Vitamins and Minerals:

An 8-fl-oz serving of ENSURE LIGHT provides at least 25% of the RDIs for 24 key vitamins and minerals.

10 Caffeine:

Chocolate flavor contains 2.1 mg caffeine/8 fl oz.

E. ENSURE PLUS®

Usage: ENSURE PLUS is a high-calorie, low-residue liquid food

15 for use when extra calories and nutrients, but a normal concentration of protein, are needed. It is designed primarily as an oral nutritional supplement to be used with or between meals or, in appropriate amounts, as a meal replacement. ENSURE PLUS is lactose- and gluten-free. Although 20 it is primarily an oral nutritional supplement, it can be fed by tube.

Patient Conditions:

-For patients who require extra calories and nutrients, but a 25 normal concentration of protein, in a limited volume
-For patients who need to gain or maintain healthy weight

Features:

-Rich, creamy taste
30 -Good source of essential vitamins and minerals

Ingredients:

Vanilla: -D Water, Corn Syrup, Maltodextrin (Corn), Corn Oil, Sodium and Calcium Caseinates, Sugar (Sucrose), Soy Protein Isolate, Magnesium Chloride, Potassium Citrate, Calcium Phosphate Tribasic, Soy Lecithin, Natural and Artificial Flavor, Sodium Citrate, Potassium Chloride, Choline Chloride, Ascorbic Acid, Carraegenan, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Calcium

10 Pantothenate, Manganese Sulfate, Cupric

Sulfate, Thiamine Chloride Hydrochloride, Pyridoxine

Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid,

Biotin, Chromium Chloride, Sodium Molybdate, Potassium Iodide,

Sodium Selenite, Phylloquinone, Cyanocobalamin and Vitamin D3.

15 Protein:

The protein source is a blend of two high-biologic-value proteins: casein and soy.

20 Sodium and calcium caseinates 84%

Soy protein isolate 16%

Fat:

The fat source is corn oil.

25 Corn oil 100%

Carbohydrate:

ENSURE PLUS contains a combination of maltodextrin and 30 sucrose. The mild sweetness and flavor variety (vanilla, chocolate, strawberry, coffee, buffer pecan, and eggnog), plus

133

VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

5 Vanilla, strawberry, butter pecan, and coffee flavors:

Corn Syrup	39%
Maltodextrin	38%
Sucrose	23%

10

Chocolate and eggnog flavors:

Corn Syrup	36%
Maltodextrin	34%
Sucrose	30%

15

Vitamins and Minerals:

An 8-fl-oz serving of ENSURE PLUS provides at least 15% of the RDIs for 25 key Vitamins and minerals.

20

Caffeine:

Chocolate flavor contains 3.1 mg Caffeine/8 fl oz. Coffee flavor contains a trace amount of caffeine.

25 F. ENSURE PLUS® HN

Usage: ENSURE PLUS HN is a nutritionally complete high-calorie, high-nitrogen liquid food designed for people with higher calorie and protein needs or limited volume tolerance. It may be used for oral supplementation or for total nutritional support by tube. ENSURE PLUS HN is lactose- and gluten-free.

30

134

Patient Conditions:

-For patients with increased calorie and protein needs, such as following surgery or injury.

5 -For patients with limited volume tolerance and early satiety.

Features:

-For supplemental or total nutrition

-For oral or tube feeding

10 -1.5 CaV/mL,

-High nitrogen

-Calorically dense

Ingredients:

15

Vanilla: -D Water, Maltodextrin (Corn), Sodium and Calcium Caseinates, Corn Oil, Sugar (Sucrose), Soy Protein Isolate, Magnesium Chloride, Potassium Citrate, Calcium Phosphate Tribasic, Soy Lecithin, Natural and Artificial Flavor, Sodium Citrate, Choline Chloride, Ascorbic Acid, Taurine, L-Carnitine, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Carrageenan, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate,

20

Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride,

25 Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Chromium

Chloride, Sodium Molybdate, Potassium Iodide, Sodium Selenite, Phylloquinone, Cyanocobalamin and Vitamin D3.

G. ENSURE® POWDER:

30

Usage: ENSURE POWDER (reconstituted with water) is a low-residue

135

Liquid food designed primarily as an oral nutritional supplement to be used with or between meals. ENSURE POWDER is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

5

Patient Conditions:

- For patients on modified diets
- For elderly patients at nutrition risk
- For patients recovering from illness/surgery
- For patients who need a low-residue diet

10

Features:

- Convenient, easy to mix
- Low in saturated fat
- Contains 9 g of total fat and < 5 mg of cholesterol per serving
- High in vitamins and minerals
- For low-cholesterol diets
- Lactose-free, easily digested

15

- 20 **Ingredients:** -D Corn Syrup, Maltodextrin (Corn), Sugar (Sucrose), Corn Oil, Sodium and Calcium Caseinates, Soy Protein Isolate, Artificial Flavor, Potassium Citrate, Magnesium Chloride, Sodium Citrate, Calcium Phosphate
- Tribasic, Potassium Chloride, Soy Lecithin, Ascorbic Acid,
- 25 Choline Chloride, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Calcium Pantothenate, Manganese Sulfate, Thiamine Chloride Hydrochloride, Cupric Sulfate, Pyridoxine Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Sodium Molybdate, Chromium Chloride, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D3 and Cyanocobalamin.

30

136

Protein:

The protein source is a blend of two high-biologic-value proteins: casein and soy.

5

Sodium and calcium caseinates 84%

Soy protein isolate 16%

Fat:

10 The fat source is corn oil.

Corn oil 100%

Carbohydrate:

15 ENSURE POWDER contains a combination of corn syrup, maltodextrin, and sucrose. The mild sweetness of ENSURE POWDER, plus VARI-FLAVORS® Flavor Paks in pecan, cherry, strawberry, lemon, and orange, helps to prevent flavor fatigue and aid in patient compliance.

20

Vanilla:

Corn Syrup 35%

Maltodextrin 35%

25 Sucrose 30%

H. ENSURE® PUDDING

Usage: ENSURE PUDDING is a nutrient-dense supplement providing balanced nutrition in a nonliquid form to be used with or between meals. It is appropriate for consistency-modified diets

30

137

(e.g., soft, pureed, or full liquid) or for people with swallowing impairments. ENSURE PUDDING is gluten-free.

Patient Conditions:

- 5 -For patients on consistency-modified diets (e.g., soft, pureed, or full liquid)
- For patients with swallowing impairments

Features:

- 10 -Rich and creamy, good taste
- Good source of essential vitamins and minerals
- Convenient-needs no refrigeration
- Gluten-free

15 Nutrient Profile per 5 oz: Calories 250, Protein 10.9%, Total Fat 34.9%, Carbohydrate 54.2%

Ingredients:

Vanilla: -D Nonfat Milk, Water, Sugar (Sucrose), Partially Hydrogenated Soybean Oil, Modified Food Starch, Magnesium Sulfate, Sodium Stearoyl Lactylate, Sodium Phosphate Dibasic, Artificial Flavor, Ascorbic Acid, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Choline Chloride, Niacinamide, Manganese Sulfate, Calcium Pantothenate, FD&C Yellow #5, Potassium Citrate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, FD&C Yellow #6, Folic Acid, Biotin, Phylloquinone, Vitamin D3 and Cyanocobalamin.

30 Protein:

138

The protein source is nonfat milk.

Nonfat milk

100%

5 Fat:

The fat source is hydrogenated soybean oil.

Hydrogenated soybean oil

100%

10 Carbohydrate:

ENSURE PUDDING contains a combination of sucrose and modified food starch. The mild sweetness and flavor variety (vanilla, chocolate, butterscotch, and tapioca) help prevent flavor fatigue. The product contains 9.2 grams of lactose per serving.

Vanilla and other nonchocolate flavors:

20 Sucrose

56%

Lactose

27%

Modified food starch

17%

Chocolate:

25

Sucrose

58%

Lactose

26%

Modified food starch

16%

30 I. ENSURE® WITH FIBER:

139

Usage: ENSURE WITH FIBER is a fiber-containing, nutritionally complete liquid food designed for people who can benefit from increased dietary fiber and nutrients. ENSURE WITH FIBER is suitable for people who do not require a low-residue diet. It can be fed orally or by tube, and can be used as a nutritional supplement to a regular diet or, in appropriate amounts, as a meal replacement. ENSURE WITH FIBER is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

10

Patient Conditions:

-For patients who can benefit from increased dietary fiber and nutrients

15 Features:

- New advanced formula-low in saturated fat, higher in vitamins and minerals
- Contains 6 g of total fat and < 5 mg of cholesterol per serving
- Rich, creamy taste
- Good source of fiber
- Excellent source of essential vitamins and minerals
- For low-cholesterol diets
- Lactose- and gluten-free

20

25 Ingredients:

Vanilla: -D Water; Maltodextrin (Corn), Sugar (Sucrose), Sodium and Calcium Caseinates, Oat Fiber, High-Oleic Safflower Oil, Canola Oil, Soy Protein Isolate, Corn Oil, Soy Fiber, Calcium Phosphate Tribasic, Magnesium Chloride, Potassium Citrate, Cellulose Gel, Soy Lecithin, Potassium Phosphate Dibasic, Sodium Citrate, Natural and Artificial Flavors, Choline Chloride,

30

140

Magnesium Phosphate, Ascorbic Acid, Cellulose Gum, Potassium Chloride, Carrageenan, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Zinc Sulfate,

- Niacinamide, Manganese Sulfate, Calcium Pantothenate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Folic Acid, Chromium Chloride, Biotin, Sodium Molybdate, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D3 and Cyanocobalamin.

10 Protein:

The protein source is a blend of two high-biologic-value proteins-casein and soy.

Sodium and calcium caseinates

80%

15 Soy protein isolate

20%

Fat:

The fat source is a blend of three oils: high-oleic safflower, canola, and corn.

20

High-oleic safflower oil

40%

Canola oil

40%

Corn oil

20%

25

The level of fat in ENSURE WITH FIBER meets American Heart Association (AHA) guidelines. The 6 grams of fat in ENSURE WITH FIBER represent 22% of the total calories, with 2.01 g of the fat being from saturated fatty acids and 6.7% from polyunsaturated fatty acids. These values are within the AHA guidelines of $\leq 30\%$ of total calories from fat, < 10% of the

30

141

calories from saturated fatty acids, and $\leq 10\%$ of total calories from polyunsaturated fatty acids.

Carbohydrate:

5 ENSURE WITH FIBER contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla, chocolate, and butter pecan), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

10

Vanilla and other nonchocolate flavors:

Maltodextrin 66%
 Sucrose 25%
 15 Oat Fiber 7%
 Soy Fiber 2%

Chocolate:

20 Maltodextrin 55%
 Sucrose 36%
 Oat Fiber 7%
 Soy Fiber 2%

25 Fiber:

The fiber blend used in ENSURE WITH FIBER consists of oat fiber and soy polysaccharide. This blend results in approximately 4 grams of total dietary fiber per 8-fl. oz can. The ratio of insoluble to soluble fiber is 95:5.

30

142

The various nutritional supplements described above and known to others of skill in the art can be substituted and/or supplemented with the PUFAs produced in accordance with the present invention.

5

J. Oxepa™ Nutritional Product

Oxepa is a low-carbohydrate, calorically dense, enteral nutritional product designed for the dietary management of patients with or at risk for ARDS. It has a unique combination of ingredients, including a patented oil blend containing eicosapentaenoic acid (EPA from fish oil), γ -linolenic acid (GLA from borage oil), and elevated antioxidant levels.

15 Caloric Distribution:

Caloric density is high at 1.5 Cal/mL (355 Cal/8 fl.oz), to minimize the volume required to meet energy needs.

The distribution of Calories in Oxepa is shown in Table IV.

20

Table IV. Caloric Distribution of Oxepa

	per 8 fl oz.	per liter	% of Cal
Calories	355	1,500	---
Fat (g)	22.2	93.7	55.2
Carbohydrate (g)	25	105.5	28.1
25 Protein (g)	14.8	62.5	16.7
Water (g)	186	785	---

Fat:

-Oxepa contains 22.2 g of fat per 8-fl oz serving (93.7 g/L).
 30 -The fat source is an oil blend of 31.8% canola oil, 25% medium-chain triglycerides (MCTs), 20% borage oil, 20% fish oil, and

143

3.2 % soy lecithin. The typical fatty acid profile of Oxepa is shown in Table V.

Oxepa provides a balanced amount of polyunsaturated, monounsaturated, and saturated fatty acids, as shown in Table VI.

Medium-chain triglycerides (MCTs) -- 25% of the fat blend -- aid gastric emptying because they are absorbed by the intestinal tract without emulsification by bile acids.

The various fatty acid components of Oxepa™ nutritional product can be substituted and/or supplemented with the PUFAs produced in accordance with this invention.

15

144

Table V. Typical Fatty Acid Profile

	% Total Fatty Acids	g/8 fl oz*	g/L*
Caproic (6:0)	0.2	0.04	0.18
Caprylic (8:0)	14.69	3.1	13.07
10 Capric (10:0)	11.06	2.33	9.87
Palmitic (16:0)	5.59	1.18	4.98
Palmitoleic	1.82	0.38	1.62
Stearic	1.94	0.39	1.64
Oleic	24.44	5.16	21.75
15 Linoleic	16.28	3.44	14.49
α-Linolenic	3.47	0.73	3.09
γ-Linolenic	4.82	1.02	4.29
Eicosapentaenoic	5.11	1.08	4.55
n-3-Docosapent-enoic	0.55	0.12	0.49
20 Docosahexaenoic	2.27	0.48	2.02
Others	7.55	1.52	6.72

25 Fatty acids equal approximately 95% of total fat.

145

Table VI. Fat Profile of Oxepa.

* of total calories from fat	55.2
Polyunsaturated fatty acids	31.44 g/L
Monounsaturated fatty acids	25.53 g/L
Saturated fatty acids	32.38 g/L
n-6 to n-3 ratio	1.75:1
Cholesterol	9.49 mg/8 fl oz 40.1 mg/L

Carbohydrate:

- 10 -The carbohydrate content is 25.0 g per 8-fl-oz serving (105.5 g/L).
- The carbohydrate sources are 45% maltodextrin (a complex carbohydrate) and 55% sucrose (a simple sugar), both of which are readily digested and absorbed.
- 15 -The high-fat and low-carbohydrate content of Oxepa is designed to minimize carbon dioxide (CO₂) production. High CO₂ levels can complicate weaning in ventilator-dependent patients. The low level of carbohydrate also may be useful for those patients who have developed stress-induced
- 20 hyperglycemia.
- Oxepa is lactose-free.

Dietary carbohydrate, the amino acids from protein, and the glycerol moiety of fats can be converted to glucose within the body. Throughout this process, the carbohydrate requirements of glucose-dependent tissues (such as the central nervous system and red blood cells) are met. However, a diet free of carbohydrates can lead to ketosis, excessive catabolism of tissue protein, and loss of fluid and electrolytes. These effects can be prevented by daily ingestion of 50 to 100 g of digestible carbohydrate, if caloric intake is adequate. The

146

carbohydrate level in Oxepa is also sufficient to minimize gluconeogenesis, if energy needs are being met.

Protein:

- 5 -Oxepa contains 14.8 g of protein per 8-fl-oz serving (62.5 g/L).
- The total calorie/nitrogen ratio (150:1) meets the need of stressed patients.
- Oxepa provides enough protein to promote anabolism and the maintenance of lean body mass without precipitating respiratory problems. High protein intakes are a concern in patients with respiratory insufficiency. Although
- 10 protein has little effect on CO₂ production, a high protein diet will increase ventilatory drive.
- 15 -The protein sources of Oxepa are 86.8% sodium caseinate and 13.2% calcium caseinate.
- The amino acid profile of the protein system in Oxepa meets or surpasses the standard for high quality protein set by the National Academy of Sciences.

* Oxepa is gluten-free.

Default settings for the analysis programsGCG Programs5 Fasta Search

Default parameters:

10 range of interest Begin=1 END=last protein or nucleic acid

search set all of SwissProt (protein) or GenEMBL (nucleic acid)

15 word size =(2) for protein =(6) for nucleic acid

Expected scores lists scores until E() value reaches 2.0

20 TPasta search

Default parameters:

25 range of interest Begin=1 END=last nucleic acid

search set all of GenEMBL

30 word size wordsize=(2)

Expected scores lists scores until E() value reaches 2.0

35 Pileup

Default parameters:

40 gap creation penalty gap weight = 5

gap extension penalty gap length weight = 12

plot figure one page plot density =2.7

45 Sequencher Program

Default parameters:

Automatic Assembly

Dirty data algorithm =slower contig assembly but more rigorous comparisons between the sequences

5 minimum match =85%

minimum overlap =20

10 BLAST 2 (blastp, tblastn)

Default parameters:

V=50 Lambda=.329 W=3
B=50 K=0.140 X=22
E=10 H=0.427

15 blast n

Default parameters:

V=100 Lambda=1.37 W=11
B=250 K=0.171 X1=22
E=10 H=1.31 X2=25

BLAST 2 Command Line Arguments

25 -v Hits

number of best scores to show

-b Alignments

number of best alignments to show

30 -e Expectation value (E)

[Real] default = 10.0

-m Alignment view options:

0 = pairwise.
1 = master-slave showing identities,
2 = master-slave, no identities,
3 = flat master-slave, show identities,
4 = flat master-slave, no identities,
5 = master-slave, no identities and blunt ends,
6 = flat master-slave, no identities and blunt ends [Integer]
default = 0

45 -F Filter query seq.

(DUST with blastn, SEG with others) [T/F]
default = T

-G Cost to open a gap

(zero invokes default behavior) [Integer]
default = 0

149

150

-E Cost to extend a gap (zero invokes default behavior) [Integer]
default = 0

5 -X X dropout value for gapped alignment (in bits) (zero invokes
default behavior) [Integer]

default = 0

10 -I Show GI's in defines [T/F]

default = F

-q Penalty for a nucleotide mismatch (blastn only) [Integer]
default = -3

15 -r Reward for a nucleotide match (blastn only) [Integer]
default = 1

-f Threshold for extending hits default if zero [Integer]
default = 0

20 -g Perform gapped alignment (not available with tblastx) [T/F]
default = T

25 -Q Query Genetic code to use [Integer]
default = 1

-D DB Genetic code (Integer) (for tblast[nx] only)
default = 1

30 -J Believe the query define [T/F]
default = F

35 -M Matrix [String]
default = BLOSUM62

-W Word size default if zero [Integer]
default = 0

40 -z Effective length of the database (use zero for the real size)
[Integer]

default = 0

45 -a Number of processors to use [Integer]
default = site configurable (SeqServer.conf)

Allowed and default values for gap open/gap extension cost (-G/-E)
parameters:

50

BLOSUM62

-G 9 8 7 12 11 10
-E 2 2 2 1 1 1

5 BLOSUM50

-G 12 11 10 9 15 14 13 12 18 17 16 15
-E 3 3 3 3 2 2 2 2 1 1 1 1

10 PAM250

-G 13 12 11 10 15 14 13 12 19 18 17 16
-E 3 3 3 3 2 2 2 2 1 1 1 1

15 BLOSUM90

-G 8 7 6 11 10 9
-E 2 2 2 1 1 1

20 PAM30

-G 5 4 3 7 6 5 10 9 8
-E 3 3 3 2 2 2 1 1 1

25 PAM70

-G 6 5 4 8 7 6 11 10 9
-E 3 3 3 2 2 2 1 1 1

30

151

CLAIMS:

1. An isolated nucleotide sequence corresponding to
or complementary to at least about 35% of the nucleotide
sequence comprising SEQ ID NO:5 (Figure 54).
2. The isolated nucleotide sequence of claim 1 wherein said
sequence comprises SEQ ID NO:5.
3. The isolated nucleotide sequence of claims 1 or 2
wherein said sequence encodes a functionally active
elongase which utilizes a polyunsaturated fatty acid as a
substrate.
4. The nucleotide sequence of claim 1 wherein said
sequence is derived from a mammal.
5. The nucleotide sequence of claim 4 wherein said
sequence is derived from a mouse.
6. A purified protein encoded by said nucleotide
sequence of claims 1 or 2.
7. A purified polypeptide which elongates
polyunsaturated fatty acids and has at least about 30%
amino acid similarity to the amino acid sequence of said
purified protein of claim 6.
8. A method of producing an elongase enzyme comprising the
steps of:

152

- a) isolating a nucleotide sequence comprising SEQ ID NO:5
(Figure 54) or SEQ ID NO:6 (Figure 58);
- b) constructing a vector comprising: i) said isolated
nucleotide sequence operably linked to ii) a promoter;
- c) introducing said vector into a host cell under time
and conditions sufficient for expression of said
elongase enzyme.
9. The method of claim 8 wherein said host cell is selected
from the group consisting of a eukaryotic cell or a
prokaryotic cell.
10. The method of claim 9 wherein said prokaryotic
cell is selected from the group consisting of E. coli,
cyanobacteria, and B. subtilis.
11. The method of claim 9 wherein said eukaryotic
cell is selected from the group consisting of a mammalian
cell, an insect cell, a plant cell and a fungal cell.
12. The method of claim 11 wherein said fungal cell
is selected from the group consisting of Saccharomyces
spp., Candida spp., Lipomyces starkey, Yarrowia spp.,
Kluyveromyces spp., Hansenula spp., Aspergillus spp.,
Penicillium spp., Neurospora spp., Trichoderma spp. and
Pichia spp.
13. The method of claim 12 wherein said fungal cell is a
yeast cell selected from the group consisting of
Saccharomyces spp., Candida spp., Hansenula spp. and Pichia
spp.

153

14. The method of claim 13 wherein said yeast cell is Saccharomyces cerevisiae.

15. A vector comprising: a) a nucleotide sequence comprising SEQ ID NO:5 (Figure 54) operably linked to b) a promoter.

16. A host cell comprising said vector of claim 15.

17. The host cell of claim 16, wherein said host cell is selected from the group consisting of: a eukaryotic cell or a prokaryotic cell.

18. The host cell of claim 17 wherein said prokaryotic cell is selected from the group consisting of E. coli, Cyanobacteria, and B. subtilis.

19. The host cell of claim 17 wherein said eukaryotic cell is selected from the group consisting of a mammalian cell, an insect cell, a plant cell and a fungal cell.

20. The host cell of claim 19 wherein said fungal cell is selected from the group consisting of Saccharomyces spp., Candida spp., Lipomyces starkey, Yarrowia spp., Kluyveromyces spp., Hansenula spp., Aspergillus spp., Penicillium spp., Neurospora spp., Trichoderma spp. and Pichia spp.

30

154

21. The host cell of claim 20 wherein said fungal cell is a yeast cell selected from the group consisting of Saccharomyces spp., Candida spp., Hansenula spp. and Pichia spp.

22. The host cell of claim 21 wherein said host cell is Saccharomyces cerevisiae.

23. A plant cell, plant or plant tissue comprising said vector of claim 15, wherein expression of said nucleotide sequence of said vector results in production of a polyunsaturated fatty acid by said plant cell, plant or plant tissue.

24. The plant cell, plant or plant tissue of claim 23 wherein said polyunsaturated fatty acid is selected from the group consisting of AA, ADA, GLA and STA.

25. One or more plant oils or acids expressed by said plant cell, plant or plant tissue of claim 23.

26. A transgenic plant comprising said vector of claim 15, wherein expression of said nucleotide sequence of said vector results in production of a polyunsaturated fatty acid in seeds of said transgenic plant.

27. A transgenic, non-human mammal whose genome comprises a DNA sequence encoding an elongase, operably linked to a promoter, wherein said DNA sequence comprises SEQ ID NO:5 (Figure 54).

28. A fluid produced by said transgenic, non-human mammal of claim 27 wherein said fluid comprises a detectable level of at least one elongase or products thereof.

29. A method for producing a polyunsaturated fatty acid comprising the steps of:

- a) isolating a nucleotide sequence comprising SEQ ID NO:5 (Figure 54);
- b) constructing a vector comprising said isolated nucleotide sequence;
- c) introducing said vector into a host cell under time and conditions sufficient for expression of an elongase enzyme encoded by said isolated nucleotide sequence; and
- d) exposing said expressed elongase enzyme to a substrate polyunsaturated fatty acid in order to convert said substrate to a product polyunsaturated fatty acid.

30. The method according to claim 29, wherein said substrate polyunsaturated fatty acid is selected from the group consisting of GLA, STA, AA, ADA and ALA, and said product polyunsaturated fatty acid is selected from the group consisting of DGLA, 20:4n-3, ADA, ω 6-docosapentaenoic acid and STA, respectively.

31. The method according to claim 29 further comprising the step of exposing said expressed elongase enzyme to at least one desaturase in order to convert said product polyunsaturated fatty acid to another polyunsaturated fatty acid.

32. The method according to claim 31 wherein said product polyunsaturated fatty acid is selected from the group consisting of DGLA, 20:4n-3, ADA and ω 6-docosapentaenoic acid, said another polyunsaturated fatty acid is selected from the group consisting of AA, EPA, ω 6-docosapentaenoic acid and docosahexaenoic acid respectively, and said at least one desaturase is Δ 5-desaturase with respect to production of AA or EPA, and Δ 4-desaturase with respect to production of ω 6-docosapentaenoic acid, and Δ 19-desaturase with respect to production of docosahexaenoic acid.

33. The method of claim 32 further comprising the step of exposing said another polyunsaturated fatty acid to one or more enzymes selected from the group consisting of at least one elongase and at least one additional desaturase in order to convert said another polyunsaturated fatty acid to a final polyunsaturated fatty acid.

34. The method of claim 33 wherein said final polyunsaturated fatty acid is selected from the group consisting of ADA, ω 3-docosapentaenoic acid and docosahexaenoic acid.

35. A nutritional composition comprising at least one polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 29, said another polyunsaturated fatty acid produced according to the method

of claim 31, and said final polyunsaturated fatty acid produced according to the method of claim 33.

36. The nutritional composition of claim 35 wherein said product polyunsaturated fatty acid is selected from the group consisting of DGLA, 20:4n-3, ADA, ω6-docosapentaenoic acid and STA.

37. The nutritional composition of claim 35 wherein said another polyunsaturated fatty acid is selected from the group consisting of AA, EPA, ω6-docosapentaenoic acid and docosahexaenoic acid.

38. The nutritional composition of claim 35 wherein said final polyunsaturated fatty acid is selected from the group consisting of ADA, ω3-docosapentaenoic acid and docosahexaenoic acid.

39. The nutritional composition of claim 35 wherein said nutritional composition is selected from the group consisting of an infant formula, a dietary supplement and a dietary substitute.

40. A pharmaceutical composition comprising 1) at least one polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 29, said another polyunsaturated fatty acid produced according to the method of claim 31, and said final polyunsaturated fatty acid

produced according to the method of claim 33 and 2) a pharmaceutically acceptable carrier.

41. An animal feed comprising at least one polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 29, said another polyunsaturated fatty acid produced according to the method of claim 31 and said final polyunsaturated fatty acid produced according to the method of claim 33.

42. The animal feed of claim 41 wherein said product polyunsaturated fatty acid is selected from the group consisting of DGLA, 20:4n-3, ADA, ω6-docosapentaenoic acid and STA.

43. The animal feed of claim 41 wherein said another polyunsaturated fatty acid is selected from the group consisting of AA, EPA, ω6-docosapentaenoic acid and docosahexaenoic acid.

44. The animal feed of claim 41 wherein said final polyunsaturated fatty acid is selected from the group consisting of ADA, ω3-docosapentaenoic acid and docosahexaenoic acid.

45. A cosmetic comprising a polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 29, said another polyunsaturated fatty acid

159

produced according to the method of claim 31 and said final polynsaturated fatty acid produced according to the method of claim 33.

46. A method of preventing or treating a condition caused by insufficient intake of polynsaturated fatty acids comprising administering to said patient said nutritional composition of claim 35 in an amount sufficient to effect said prevention or treatment.

47. An isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence comprising SEQ ID NO:6 (Figure 58).

48. The isolated nucleotide sequence of claim 47 wherein said sequence comprises SEQ ID NO:6.

49. A purified protein encoded by said nucleotide sequence of claims 47 or 48.

50. An isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence comprising SEQ ID NO:7 (Figure 72).

51. The isolated nucleotide sequence of claim 50 wherein said sequence comprises SEQ ID NO:7.

52. The isolated nucleotide sequence of claims 50 or 51 wherein said sequence encodes a functionally active elongase which utilizes a polynsaturated fatty acid as a substrate.

160

53. The nucleotide sequence of claim 50 wherein said sequence is derived from *Thraustochytrium aureum*.

54. A purified protein encoded by said nucleotide sequence of claims 50 or 51.

55. A purified polypeptide which elongates polynsaturated fatty acids and has at least about 30% amino acid similarity to the amino acid sequence of said purified protein of claim 54.

56. A method of producing an elongase enzyme comprising the steps of:

- a) isolating a nucleotide sequence comprising SEQ ID NO:7 (Figure 72);
- b) constructing a vector comprising: i) said isolated nucleotide sequence operably linked to ii) a promoter;
- c) introducing said vector into a host cell under time and conditions sufficient for expression of said elongase enzyme.

57. The method of claim 56 wherein said host cell is selected from the group consisting of a eukaryotic cell or a prokaryotic cell.

58. The method of claim 57 wherein said prokaryotic cell is selected from the group consisting of *E. coli*, cyanobacteria, and *B. subtilis*.

59. The method of claim 57 wherein said eukaryotic

161

cell is selected from the group consisting of a mammalian cell, an insect cell, a plant cell and a fungal cell.

60. The method of claim 59 wherein said fungal cell is selected from the group consisting of Saccharomyces spp., Candida spp., Lipomyces starkey, Yarrowia spp., Kluyveromyces spp., Hansenula spp., Aspergillus spp., Penicillium spp., Neurospora spp., Trichoderma spp. and Pichia spp.

61. The method of claim 59 wherein said fungal cell is a yeast cell selected from the group consisting of Saccharomyces spp., Candida spp., Hansenula spp. and Pichia spp.

62. The method of claim 61 wherein said yeast cell is Saccharomyces cerevisiae.

63. A vector comprising: a) a nucleotide sequence comprising SEQ ID NO:7 (Figure 72) operably linked to b) a promoter.

64. A host cell comprising said vector of claim 63.

65. The host cell of claim 64, wherein said host cell is selected from the group consisting of a eukaryotic cell or a prokaryotic cell.

66. The host cell of claim 65 wherein said prokaryotic cell is selected from the group consisting of E. coli, Cyanobacteria, and B. subtilis.

162

67. The host cell of claim 65 wherein said eukaryotic cell is selected from the group consisting of a mammalian cell, an insect cell, a plant cell and a fungal cell.

68. The host cell of claim 67 wherein said fungal cell is selected from the group consisting of Saccharomyces spp., Candida spp., Lipomyces starkey, Yarrowia spp., Kluyveromyces spp., Hansenula spp., Aspergillus spp., Penicillium spp., Neurospora spp., Trichoderma spp. and Pichia spp.

69. The host cell of claim 68 wherein said fungal cell is a yeast cell selected from the group consisting of Saccharomyces spp., Candida spp., Hansenula spp. and Pichia spp.

70. The host cell of claim 69 wherein said host cell is Saccharomyces cerevisiae.

71. A plant cell, plant or plant tissue comprising said vector of claim 63, wherein expression of said nucleotide sequence of said vector results in production of a polyunsaturated fatty acid by said plant cell, plant or plant tissue.

72. The plant cell, plant or plant tissue of claim 71 wherein said polyunsaturated fatty acid is selected from the group consisting of AA, ADA, GLA and STA.

163

73. One or more plant oils or acids expressed by said plant cell, plant or plant tissue of claim 72.

74. A transgenic plant comprising said vector of claim 63, wherein expression of said nucleotide sequence of said vector results in production of a polyunsaturated fatty acid in seeds of said transgenic plant.

75. A transgenic, non-human mammal whose genome comprises a DNA sequence encoding an elongase, operably linked to a promoter, wherein said DNA sequence comprises SEQ ID NO:7 (Figure 72).

76. A fluid produced by said transgenic, non-human mammal of claim 75 wherein said fluid comprises a detectable level of at least one elongase or products thereof.

77. A method for producing a polyunsaturated fatty acid comprising the steps of:

- a) isolating a nucleotide sequence comprising SEQ ID NO:7 (Figure 72);
- b) constructing a vector comprising said isolated nucleotide sequence;
- c) introducing said vector into a host cell under time and conditions sufficient for expression of an elongase enzyme encoded by said isolated nucleotide sequence; and
- d) exposing said expressed elongase enzyme to a substrate polyunsaturated fatty acid in order to convert said substrate to a product polyunsaturated fatty acid.

164

78. The method according to claim 77, wherein said substrate polyunsaturated fatty acid is selected from the group consisting of GLA, STA, AA, ADA and ALA, and said product polyunsaturated fatty acid is selected from the group consisting of DGLA, 20:4n-3, ADA, ω 6-docosapentaenoic acid and STA, respectively.

79. The method according to claim 77 further comprising the step of exposing said expressed elongase enzyme to at least one desaturase in order to convert said product polyunsaturated fatty acid to another polyunsaturated fatty acid.

80. The method according to claim 79 wherein said product polyunsaturated fatty acid is selected from the group consisting of DGLA, 20:4n-3, ADA and ω 6-docosapentaenoic acid, said another polyunsaturated fatty acid is selected from the group consisting of AA, EPA, ω 6-docosapentaenoic acid and docosahexaenoic acid respectively, and said at least one desaturase is Δ 5-desaturase with respect to production of AA or EPA, and Δ 4-desaturase with respect to production of ω 6-docosapentaenoic acid, and Δ 19-desaturase with respect to production of docosahexaenoic acid.

81. The method of claim 79 further comprising the step of exposing said another polyunsaturated fatty acid to one or more enzymes selected from the group consisting of at least one elongase and at least one additional

165

desaturase in order to convert said another polyunsaturated fatty acid to a final polyunsaturated fatty acid.

82. The method of claim 81 wherein said final polyunsaturated fatty acid is selected from the group consisting of ADA, ω 3-docosapentaenoic acid and docosahexaenoic acid.

83. A nutritional composition comprising at least one polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 77, said another polyunsaturated fatty acid produced according to the method of claim 79, and said final polyunsaturated fatty acid produced according to the method of claim 81.

84. The nutritional composition of claim 83 wherein said product polyunsaturated fatty acid is selected from the group consisting of DGLA, 20:4n-3, ADA, ω 6-docosapentaenoic acid and STA.

85. The nutritional composition of claim 83 wherein said another polyunsaturated fatty acid is selected from the group consisting of AA, EPA, ω 6-docosapentaenoic acid and docosahexaenoic acid.

86. The nutritional composition of claim 83 wherein said final polyunsaturated fatty acid is selected from the group consisting of ADA, ω 3-docosapentaenoic acid and docosahexaenoic acid.

166

87. The nutritional composition of claim 83 wherein said nutritional composition is selected from the group consisting of an infant formula, a dietary supplement and a dietary substitute.

88. A pharmaceutical composition comprising 1) at least one polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 77, said another polyunsaturated fatty acid produced according to the method of claim 79, and said final polyunsaturated fatty acid produced according to the method of claim 81 and 2) a pharmaceutically acceptable carrier.

89. An animal feed comprising at least one polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 77, said another polyunsaturated fatty acid produced according to the method of claim 79 and said final polyunsaturated fatty acid produced according to the method of claim 81.

90. The animal feed of claim 89 wherein said product polyunsaturated fatty acid is selected from the group consisting of DGLA, 20:4n-3, ADA, ω 6-docosapentaenoic acid and STA.

91. The animal feed of claim 89 wherein said another

167

polyunsaturated fatty acid is selected from the group consisting of AA, EPA, ω6-docosapentaenoic acid and docosahexaenoic acid.

92. The animal feed of claim 89 wherein said final polyunsaturated fatty acid is selected from the group consisting of ADA, ω3-docosapentaenoic acid and docosahexaenoic acid.

93. A cosmetic comprising a polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 77, said another polyunsaturated fatty acid produced according to the method of claim 79 and said final polyunsaturated fatty acid produced according to the method of claim 81.

94. A method of preventing or treating a condition caused by insufficient intake of polyunsaturated fatty acids comprising administering to said patient said nutritional composition of claim 83 in an amount sufficient to effect said prevention or treatment.

SUBSTITUTE SHEET (RULE 26)




FIG. 1

3/102

FIG. 2

S. cerevisiae EL02 (AA66-145) with *M. alpina* codon bias

[illegible]

FIG. 3

5/102

FIG.4B




FIG.4A




FIG.4B

pRAE-5 GAATTCAGG * * * * * *CATGGCGCGCGCAATCTTGGACAA
 pRAE-6 GAAATTCAGGCAATCTCATGGATCGCGCATGGCGCGCGCAATCTTGGACAA
 EcoRI BamHI NcoI

FIG.5

6/102

7/102

1 ATGGCCGCG CAATCTTGGA CAAGGTCAAC TTGGCATTG ATCAGCCCTT
51 CGGAATCAAG CTCGACACCT ACTTGTCTCA GGCTATGAA CTCGTACCG
101 GAAAGTCCAT CGACTCTCTC GTCTCCAGG AGGGGTGAC GGCTCTCTCG
151 ACCCAGAGAG AGGTGCGCAT GTGACTATC ACTTACTCG TCGTCATCTT
201 TGGTGGTCG CAGATCATCA AGAGCCAGGA CGCTTCAAG CTCAAGCCCC
251 TCTTCATCCT CCACAATTC CTCCTGACGA TCGGTCCGG ATCGTGTGG
301 CTCCTGTTCA TCGGAACCT GGTCCCATC CTCGCCAGAA AGGACTTTT
351 CTACGCCATC TCGGACGAG GTGCTGGAC CAGCGCCTC GAGCTCCTCT
401 ACTACCTCAA CTACTGTGTC AAGTACTGG AGTTGCCGA CACGTCCTT
451 TTGGTCTCA AGAAGAAGCC TCTTGATTC CTGACTACT TCCACCACTC
501 GATGACCATG GTTCTCTGCT TTGTCCAGCT TGGAGGATAC ACTTCAGTGT
551 CCTGGTCCC TATTACCCTC AACTGACTG TCCAGTCTT CATGTACTAC
601 TACTACATGC GCTCCGCTGC GGGTGTTCGC ATCTGGTGA AGCAGTACTT
651 GACCACTCTC CAGATGTGTC AGTTGGTCT TGACCTCGGA TTCATCTACT
701 TCTGGGCTA CACCTACTTC GCCTTCACT ACTTCCCTG GGTCCCAAC
751 GTCGGCAAGT GCGCGGTAC GAGGGTGTCT GCTCTTTG GCTGGGACT
801 CCTCTCCAGC TATCTCTGC TCTTTATCAA CTCTACCGC ATTACTACA
851 ATGCCAAGGC CAAGGACGTC AAGGACGTC GAAGCAACTT TACCCCAAG
901 ACTGTCAAGT CCGGGGATC GCCCAAGAG CCTCCAAGA GCAAGCACAT
951 CTA

FIG.6

1 HAAAILDKVN FGIDQPFGIK LDYFAQAYE LVTGKSIDSF VFQEGVTPLS
51 TOREVAHMTI TYFVWIFGGR QIMKSQAFK LKPLFILHNF LLTIASGSL
101 LLFTENLVPI LARNGLFYAI CDDGAWTQRL ELLYVLNVLV KYMELADTVF
151 LVLKKKPLEF LHYFHSHMTM VLCFVQLGGY TSVSNWPI TL NLTVHVFMY
201 YMRSAAAGVR IMMKQVLT TL QIVQFVLDLG FIYFCAYTF AFTYFPHAPN
251 VGKCACTEGA ALFGGGLSS YLLLEINFYR ITYNAKAKAA KERGSNFTPK
301 TWKSGGSPKK PSKSKHI*

FIG.7

BEST AVAILABLE COPY

1 50
 GNS1 ~~~~~MNSLVLTQYAAPLFERYPQLHDYLPITLERPFFNINISLWEHFDQV
 SUR4 MNTTSTVIAA AVADQFQSLNSSSSCFLKVHVPSTIENPFGIEJWPIFSKV
 MAELO ~~~~~MAAAAILDKVNFGIDQPF.GIKLDTYFAQA

51 100
 GNS1 VTRVTNGRFRVPSERFQFIAGELPLSTLPVLYAITAYYVITIFGGRIFLLSKS
 SUR4 FVEYFS.GYPAEQ.FEFIHNKTFLANGYHVSIIITVYITIFGGQATLRAI
 MAELO YELVT.GKSIDS.FVFQEGVTPLSTQREVAMWTITYFVVIFGGRQIMKSQ

101 150
 GNS1 KP..FKLNGLFQLHNLVLTSLSLTLLLLMVEQLVPITVQHGLYFAIGNIG
 SUR4 NHA SP LKFKLLFEIHNLF LTSLSLVLWLLMLFQLVPMVYHNGLPW S I G SKE
 MAELO DA..FKLKPLFILHNFLLTITASGSLLLFTIENLVPILARNGLFYAICDDG

151 200
 GNS1 AWTQPLVTLYYMNYIIVKFIIEFIDTFFLVLKHKKLTIFLHTIYHHGATAILLGY
 SUR4 AFA PK L V T L Y Y L N Y L T K E I V E L I D T V F L V L R R K K L L F L H T I Y H H G A T A I L L G Y
 MAELO AWTQRLELLYYLNYLVKYWELADTVFLVLKKKPLEFLHYFHHSMIMVLGF

201 250
 GNS1 TQLMGITSTTSWVPITSLNLGVHVVMYMYIFLAARGITRVVWKEWVTRFQITIQ
 SUR4 TQLIGRTSVIEWVWVILNLNLGVHVVMYMYIFLS SCGLRVVWKKQWVTRFQITIQ
 MAELO VQLGGYTSVSWVPITLNLTVHVFMYYYMRSAGVRI.WWKQYLTTLQIVQ

251 300
 GNS1 FVLDLIGFIYFAVYQKAVHLYFPIL.PHICGD CVIGSTTATFAGCAIHSYLLV
 SUR4 F E I D L V F V Y F A I Y T E Y A H K Y L D G I L P N K G T C Y G T Q A A A A Y G Y L L L T S Y L L
 MAELO FVLDLGFIFYFCAYTYFAFTYFPAW.PNVGKCAGTEGAALFGCGLLSYLL

FIG.8A

301 350
 GNS1 LFI SFYI NVYKR K G T K T S R V V K R A H G G V A A K V N E Y V N V D L K N V P T P S P S P
 SUR4 LFI SFYI QSYKKGK K K T V K K E S E V S G . S V A S G S S T G V K T S N T K V S S R K A ~
 MAELO LFI NFYRITYNAKAKAAKERGSNFTPKTVKSGGSPK.KPSKSKH I ~~~~~

351
 GNS1 KPQHRRKR
 SUR4 ~~~~~
 MAELO ~~~~~

FIG.8B

BEST AVAILABLE COPY

SCORES 10/102
Init1: 153 Initn: 199 Opt: 495
57.4% identity in 549 bp overlap





FIG.9A

FIG.9B



12/102

HOST(PLASMID)	334(pCGN7875)	334(pYES2)	334(pYX242)	334(pRAE-5)	334(pRAE-6)	334(pYX242)	334(pRAE-5)
ADDED SUBSTRATE	25 μ M OA	25 μ M OA	25 μ M GLA	25 μ M GLA	25 μ M GLA	NO SUBSTRATE	NO SUBSTRATE
FATTY ACID	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)
C16:0	11.948	23.601	35.123	92.011	85.160	16.294	25.34
C16:1	30.665	71.217	32.789	315.464	115.456	56.183	113.913
C18:0	6.185	9.704	10.515	22.628	18.879	5.535	11.092
C18:1n-9	35.340	57.429	33.989	154.386	106.881	28.388	51.538
C18:3n-6			48.856	58.084	12.434		
C20:0			0.474	0.710	0.244		
C20:1n-9	(0.375%)* 0.352	(0.309%)* 0.527		1.405	0.867		0.516
C20:3n-6	ND	ND	(0.092%)* 0.226	(0.324%)* 2.504	(0.269%)* 1.006	ND	ND
C22:0				0.460			
C22:1n-9				0.321	0.315		
C24:0					1.825		0.999
TOTAL LIPID	93.760	170.490	245.090	771.690	374.420	112.99	256.52
ND = NOT DETECTED							
*% TOTAL FATTY ACID							

FIG. 10A

13/102

HOST(PLASMID)	334(pYX242)	334(pYX242)	334(pRAE-5)	334(pRAE-5)	334(pRAE-6)
ADDED SUBSTRATE	25 μ M GLA	25 μ M GLA	25 μ M GLA	25 μ M GLA	25 μ M GLA
FATTY ACID	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)
C16:0	60.683	61.487	100.998	96.193	66.761
C16:1	79.838	79.586	359.754	220.440	87.359
C18:0	9.784	10.106	15.317	15.165	16.744
C18:1n-9	38.536	39.936	108.472	89.637	71.631
C18:3n-6	17.974	17.833	82.866	56.596	17.766
C20:0			0.510	0.570	
C20:1n-9					
C20:3n-6	(0.136%)* 0.389	(0.130%)* 0.374	(0.336%)* 3.035	(0.401%)* 2.689	(0.353%)* 1.185
C22:0			0.414		
C22:1n-9				0.383	
C24:0			1.513	1.626	
TOTAL LIPID	285.560	288.045	902.560	671.113	335.496
*% TOTAL FATTY ACID					

FIG. 10B

BEST AVAILABLE COPY

HOST(PLASMID)	334(pRAE-5/pCGR4)	334(pYX242/pYES2)		HOST(PLASMID)	334(pRAE-5/pCGR4)	334(pYX242/pYES2)
ADDED SUBSTRATE	25 μ M GLA	25 μ M GLA		ADDED SUBSTRATE	25 μ M GLA	25 μ M GLA
FATTY ACID	LIPID (μ g)	LIPID (μ g)		FATTY ACID	LIPID (μ g)	LIPID (μ g)
C16:0	41.050	37.169		C16:0	96.986	32.221
C16:1	99.393	100.552		C16:1n-7	209.667	62.757
C18:0	34.432	27.852		C18:0	80.418	14.027
C18:1	110.631	92.786		C18:1n-9	207.104	28.701
C18:3n-6	15.004	7.924		C18:3n-6	25.264	10.543
C20:0	0.643	0.574		C20:0	2.038	
C20:1	1.996	1.684		C20:1n-9	3.591	
C20:3n-6	0.542	0.607		C20:3n-6	1.284	0.326
C20:4n-6	0.579			C20:4n-6	1.394	
C22:0	1.242	2.604		C22:0	1.124	
C24:0	4.754	4.563		C24:0	3.952	
TOTAL LIPID	334	300		TOTAL LIPID	756	197

FIG. 11

HOST(PLASMID)	334(pYX242)	334(pRAE-5)	334(pRELO-1)	334(pRELO-2)
ADDED SUBSTRATE	25 μ M GLA	25 μ M GLA	25 μ M GLA	25 μ M GLA
	25°C/48HRS	25°C/48HRS	25°C/48HRS	25°C/48HRS
FATTY ACID	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)	LIPID (μ g)
C16:0	28.7	76.707	84.424	77.445
C16:1	0.729	2.513	1.532	1.056
C18:0	7.432	15.761	27.17	21.32
C18:1n-9	28.9	77.323	109.419	82.844
C18:3n-6	9.729	29.236	19.085	18.804
C20:0		0.643	0.522	0.537
C20:1n-9		0.77	0.426	0.299
C20:3n-6	(0.185%)* 0.374	(0.279%)* 1.472	(0.153%)* 0.748	(0.200%)* 0.832
C22:0		0.451		
C22:1n-9			0.224	
C24:0		0.918		
TOTAL LIPID	202	527	490	416
*% TOTAL FATTY ACID				

FIG. 12

BEST AVAILABLE COPY

16/102

SCORES Init1: 156 Initn: 215 Opt: 296
Smith-Waterman score: 296; 28.8% identity in 264 aa overlap

U61954 RTFKMMDQLGNTFYEGAKEVARGLESAKLAIVGYATIFGLKYMKORKAFDLSTPL
MAELO AQAVELVTGKSIDSFVQEGVTPLSIQREVAAMTITYFWIFGGRQIMKSQDAFKLK-PL
30 40 50 60 70 80
70 80 90 100 110 120 130
U61954 NIMWGLSTFSLGLFTF-PTLLSVIRKOGFSHTYHVSLEYTOSTSGWY-----F
MAELO FTLNELLTIASGSLLLFIENLVPILARNGL-----FYAICDDGANTQRLLELYY
90 100 110 120 130
U61954 LWITSKIPELLDTFVILKRPLIFMHWYHHALTGYALVCYHE--DAVHWVW-VWNNY
MAELO LNYLVKYMELADTVFLVKKKPLEFLYFHHSMT---NWLCFVQLGGYTSVSWNPITLNL
140 150 160 170 180 190
U61954 ITHAFWYGYLLKSLKVPISPAQAATTSQWQFA-----VAIFAQVHVSYKHVYEGVE
MAELO TVHVFYMYMRSAGVRI--NAKQYLTLQIVQFVLDLGFYFCAYTYFAFTYFPWAPN
200 210 220 230 240 250
U61954 -GLAYSFRGTAI-GFFMLTTYFYLWIOFYKEHYLKNKGKYNLAKDAQTKKAN
MAELO VGKCAGTEGAALFGCLSSYLLLFINFRITY----NAKAKAAKERGSNFTPKYKSGG
260 270 280 290 300
MAELO SPKKPSKSKHIX
310

FIG.13

SUBSTITUTE SHEET (RULE 26)

17/102

SCORES Init1: 178 Initn: 178 Opt: 318
Smith-Waterman score: 318; 33.0% identity in 188 aa overlap

Z68749 SLLTNQDEVPHIRARRFQEHFGLFYQMAJAVILVFSIKRPMRDREPEQLTTALRLW
MAELO ELVTGKSIDSFVQEGVTPLSIQREVAAMTITYFWIFGGRQIMKSQDAFKLKPLILHN
30 40 50 60 70 80 90 100
Z68749 FFLSVFSIYGSWTFPF--WVQQLRLVGLYGGCEALSNLPQDAEYMLFTILSKAVEFV
MAELO FLITIAS--GSLLLFIENLVPILARNGLFYAICDD-GANTQRLLELYYLVKYMELA
90 100 110 120 130 140 150 160
Z68749 DTFELVLRKKPLIFLHWHYHMAFVFFCSNYPSPSSQSRVGVINLVFVHAFVYYPYFTRS
MAELO DTVFLVLRKKPLEFLYFHHSMTWLCFVQLGGYTSVSWNPITLNLTVHVFYMYMRS
150 160 170 180 190 200 210 220
Z68749 MNKIVPAKISMVATVQLTQF...MCFYVGCTLHWYSLATNQARYPSNTPATLQCLSYTL
MAELO AGVRIMWK--QVLTLLQIVQFVLDLGFYFCAYTYFAFTYFPWAPNWKAGTEGAALFG
210 220 230 240 250 260 270
Z68749 HLL
280
MAELO CGLSSVLLLFINFRITYNAKAKAAKERGSNFTPKYKSGGPKKPSKSKHIX
270 280 290 300 310

FIG.14

SUBSTITUTE SHEET (RULE 26)

18/102

SCORES Initl: 30 Initn: 30 Opt: 40
Smith-Waterman score: 49; 22.1% identity in 86 aa overlap

AF003134 MLYSITRRCYTFVTSLHFYQLYVYTECLENVIFNVLVNGQSINSRWKD
MAELO MAAAILDKVNFQDPFGIKLDTYFAQA---YELVTGKSIDSFVFEQGT--PLSTQREV
50 60 70 80 90 100 110

AF003134 AEKTTTSFPFH-----PQTFEQPHILTLHLFFVFSVTLVTYFKPKCEFPHSLA
MAELO AMWTITYVWVFEGGRQIMKSQDAFKLPLFILHNFLLTIASGSLLLLFLENLVPILARNG
60 70 80 90 100 110

FIG.15

19/102

Mouse
SCORES Initl: 161 Initn: 191 Opt: 325
Smith-Waterman score: 325; 28.8% identity in 285 aa overlap

U97107 MDTSMNFSRGLKMD--LMQPYDFETFDOLRPFLEEYWSVF.....LTVW
MAELO MAAAILDKVNFQDPFGIKLDTYFAQAYELVTGKSIDSFVFEQGTPLSTQREVAMWTI
50 60 70 80 90 100 110

U97107 VYLLIIVGQTYMTRKSFSLQRPILILWSFFLAIFSILGTLRMKFMATVMTVGLKQTV
MAELO TYFVWIFGGRQIMKSQDAFKLPLFILHNFLLTIAS--GSL-LLLFLENLV-PILARNGL
110 120 130 140 150 160 170 180 190 200 210 220 230

U97107 CFATYTDADVVRMSFLFLSKV---ELGDTAFILRKRLIFVHYHST--VLLFTS
MAELO FYALCDGAGTQRLELLYLYLVKYNELADTVLVKKKPLEFLHYPHHSMTWVLCFVQ
160 170 180 190 200 210 220 230

U97107 FGYKNKYPSSGAF-MTNFEGHSVNYTYTMAAKLKHPLNLPWITSQILQWVLG...
MAELO LGGYTSV...SWPITLNLTVHFVNYHRSAGVR--IWMKQYLLTLQIVQVFLDLGF
220 230 240 250 260 270 280 290

U97107 -----TIFGILNYIMRQEG-CHTTTEHFFSMFLYGTGYFILFAHFRAYLRPKGVA
MAELO IYFCAYTYFAFTYFPWPNVCKAGTEGALFGCLLSYLLLFINFRITY-NAKAHAA
240 250 260 270 280 290

U97107 SKSQX
MAELO KERGSNFTPKTVKSGSPKPKSKKHIX
300 310

Human
SCORES Initl: 147 Initn: 147 Opt: 211
Smith-Waterman score: 211; 28.7% identity in 150 aa overlap

MAELO NLVPILARNGLFYALCDGAGTQRLELLYLYLVKYNELADTVLVKKKPLEFLHYFH
110 120 130 140 150 160

AC004050 SLIVVKDLTYLLPLCPGDTFTILRKQKLFHNVH
10 20 30

MAELO HSMTHVLCFVLGGYTSVSWPITLNLTVHFVNYHRSAGVRIMMK--QYLTTLQIV
170 180 190 200 210 220

AC004050 HITVLLYSWYSYKQHWVAGGGMFTMNYGVHAWWSYVALRAAGFRVSRKFAHFTLSQIT
40 50 60 70 80 90

MAELO QFVLDLGFYFCAYTYFAFTYFPWPNVCKAGTEGALFGCLLSYLLLFINFRITY
230 240 250 260 270 280

AC004050 QMLNG-----CWVNYLVFC---MMQH-DOCHSHFQNTFUSSLLVSLVLFCHFFEAY
100 110 120 130 140

FIG.16

20/102

SCORES Init1: 87 Initn: 218 Opt: 232
Smith-Waterman score: 272; 29.7% identity in 232 aa overlap

MAELO	40	50	60	70	80	90	
	SFVQEGVPTLSTQREAVAMKTTTFVIFGGQINMSQDAFKLPFLFHLNELLTIAGSG						
I05465	20	30	40	50	60	70	
	PRYSQRNVPVPGQLHPVCLFCVLLTCHMAGTKTTEPAAVLLPSILQLYNLGLTLLS--						
MAELO	100	110	120	130	140	150	
	LLLLFIENLVPILARNGLFYALCDDGAMTQRELLYYL--NYLVKYMELADTFVLVKKK						
I05465	80	90	100	110	120		
	-LYMFYELVTGMEGKYNFFCGQTRSGESDKIIRVLWVWYFVKLIEFMOTFFILRKN						
MAELO	160	170	180	190	200	210	
	--PLEFLHYFHH-SMTWLCFVQLGGYTSVSWPITLNLTVHVFMYYY-MRSAAGVR--						
I05465	130	140	150	160	170	180	
	NHQITVLHVYHHATMLNIWFWVWVWPCGHSYFGATLNSFTIWLWVSYGLSSIPSIRPY						
MAELO	220	230	240	250	260	270	
	IHWKQVLTLLQIVQFVLDLGFVFCAYTFYFPAWPNVKGKAGTEGAALFGCGLSS						
I05465	190	200	210	220	230		
	LWKKYITQGGQLVQFVLTII-IQTTCG-----VFNP-----CSFPLGULFFQIGYNS						
MAELO	280	290	300	310			
	YLLLFNFYRITYNAKAAKERGSNFTPKTWKSGGSPKPSKSHIX						
I05465	240	250	260	270	280	290	
	LIALFTNFYITQYNNKKGASRRKEHLKGHONGSYAAVNGHTNSFPFSLNSVKPRKQKDXQ						

FIG.17

21/102

1	HGTDOGKTTT WEELAAHNTK DOLLAIIRGR VYDVTKFLSR HPGGVDTLILL
51	GAGRDVTPVF ENYHAFGAAD AIMKKYYVGT LYSNELPIFP EPTVFKHTIK
101	TRVEGYFTDR NIDPKNRPEI WGRYALIFGS LIASYAQLF VPFVWERTWL
151	QVVFIIIMGF ACAQVGLNPL HDASHFSVTH NPTWKILGA THDFFNGASY
201	LVMYQHMILG HPHYTNIAGA DPOVSTSEPD VRRIKPNQKW FVNHINQHF
251	VPFLYGLLAF KVRIQDINIL YFVKTNDAIR VNPISTWHTV MFWGSKAFFV
301	WYRLIVPLQY LPLGKVLILL TVADMVSSYW LALTFOANHV VEEVQMPLPD
351	ENGIIOKDWA AMQVETTDQY AHDSHLMTSI TGSINYQAVH HLPFWNSQHH
401	YPOILATIKN TCSEYKVPYL VKOTFMQAFV SHLEHLRVLG LRPKEE*

FIG.18




FIG. 19

HOST (PLASMID)	334(MAD708-2)	334(MAD708-10)	334(MAD708-18)	334(MAD708-19)	334(MAD708-30)	334(pRAE5)
ADDED SUBSTRATE	25 μ M GLA	25 μ M GLA	25 μ M GLA	25 μ M GLA	25 μ M GLA	25 μ M GLA
FATTY ACID	% TOTAL LIPID					
C16:0	14.1	14.68	14.38	15.45	14.13	13.59
C16:1	42.84	43.42	42.57	38.03	43.58	43.98
C18:0	3.19	3.28	3.63	4.08	3.37	2.04
C18:1n-9	17.66	19.39	19.6	20.8	20.06	10.88
C18:3n-6	6.65	5.58	10.24	9.46	3.56	11.14
C20:0	0.26	0.3	0.32	0.4	0.46	0.57
C20:3n-6	(47.5%) 6.03	(41.2%) 3.92	(8.0%) 0.91	(21.5%) 2.59	(49%) 3.43	(3.4%) 0.24
TOTAL LIPID (μ g)	238.47	307.86	188.51	167.31	207.47	466.65
(% CONVERSION)=PRODUCT/(SUBSTRATE+PRODUCT)						


FIG. 20

25/102

1 MEAVNLYQE VKKHADPRIQ GYPUNGSPLL MTSILLTYVY FVLSGPRIM
51 ANRKPFLQRG FHIYVNFSLV ALSLYIWEF LMSGMLSTYT MRCPVDYSN
101 SPEALRMVRV AMLFESKFI ELMOTVIFIL RKKDQVTFI HVFHSVLPW
151 SWMGVKIAP GGSGSFHAMI NSSVHVIVYL YYGLSAFEPV AQPYLWKKKH
201 MTAIQLIOFV LVSLHISQYV FMSSCNQYV VIIHLIMYG TIFFMFNSNF
251 WYHSYTKGR LPRALQNGA PGIAKUKAN*

FIG.22

24/102



1 MESIAPFLPS KNPQDLFNDL ATAIGVRAAP YVDPLEAALV AQAKEYIPTI
51 VHTRGFLVA VESPLARELP LMPFHVLLI VLAYLVTVFV GQIQKNIFER
101 FEVKTFSILLE NFCLVLSISAY MCGGILYEAY QANYGLFENA ADHTFKGLPM
151 AKMTIWLIFYFS KIHEFVDTMI MULKKNNRQI SFLHVVYHSS IFTIMMLVTF
201 VAPNGEAYFS AALNSFIHVI MYGYFELSAL GFKQVSFIKF YITRSQMTQF
251 CMMSVQSSND MYAMKVLGRP GYPFFITALL WFYMTMLGL FYNFYRNKAK
301 LAKQAKADAA KEKARKLQ*

FIG.23

HOST(PLASMD)	334(PRP2)	25 μM GLA	(n=4)		
ADDED SUBSTRATE	25 μM GLA	25 μM GLA			
FATTY ACID	% TOTAL LIPID	15.65	35.2	5.68	25.55
C16:0		15.23	38.59	5.55	25.27
C16:1				6.75	
C18:0				0.36	
C18:3n-6				3.1	
C20:0				5.06	
C20:3n-6				(62.0%)	(2.6%)
TOTAL LIPID (μg)	314				247
(% CONVERSION)=(PRODUCT/(SUBSTRATE+PRODUCT))					

FIG.24

29/102

FIG. 25B

*INDICATES SUBSTRATE ADDED
% CONVERSION=(PRODUCT/(SUBSTRATE+PRODUCT))

HOST(PLASMAID)	334(pRPB2)	334(pRPB2)	334(pRPB2)
ADDED SUBSTRATE	25 μ M ALA	25 μ M STA	25 μ M EPA
FATTY ACID	% TOTAL LIPID		
C16:0	17.32	16.01	20.67
C16:1	27.68	34.31	50.7
C18:0	6.75	5.39	6.14
C18:1n-9	28.4	28.54	
C18:3n-3	*8.39		
C18:4n-3		*1.95	
C20:4n-3		(73.2%) 5.33	
C20:5n-3			*10.33
C22:5n-3			0.25
TOTAL LIPID (ug)	114	199	201

28/102

FIG. 25A

HOST(PLASMAID)	334(pRPB2)	334(pRPB2)	334(pRPB2)	334(pRPB2)	334(pRPB2)	334(pRPB2)
ADDED SUBSTRATE	25 mM SA	25 mM OA	25 mM LA	25 mM DGLA	25 mM AA	25 mM ADRENIC
FATTY ACID	% TOTAL LIPID					
C16:0	15.07	14.52	15.74	15.69	16.06	15.15
C16:1	33.7	32.37	32.23	25.65	33.65	33.39
C18:0	*9.78	5.83	5.61	8.33	4.52	5.35
C18:1n-9	31.2	*37.25	26.05	20.15	24.54	28.54
C18:2n-6			*10.4			
C18:3n-6			0.29			
C20:2n-6						
C20:3n-6				*16.5		
C20:4n-6				0.27	*11.7	
C22:4n-6						*7.46
TOTAL LIPID (mg)	132	130	171	55	225	163

30/102

HOST(PLASMD)	334(pRPB2+PRPE31)	334(pYES2+pYX242)
ADDED SUBSTRATE	25 μM GLA	25 μM GLA
FATTY ACID	% TOTAL LIPID	
C16:0	15.54	18.26
C16:1	30.16	33.51
C18:0	8.76	5.58
C18:1n-9	27	27.37
C18:3n-6	*2.6	*5.6
C20:0	0.4	0.32
C20:3n-6	(57.4%) 3.55	(2.9%) 0.17
C20:4n-6	(27.6%) 1.32	ND
TOTAL LIPID (μg)	254	258

*INDICATES SUBSTRATE ADDED
(% CONVERSION)=PRODUCT/(SUBSTRATE+PRODUCT)

FIG.26A

HOST(PLASMD)	334(pRPB2+PRPE31)	334(pYES2+pYX242)
ADDED SUBSTRATE	25 μM STA	25 μM STA
FATTY ACID	% TOTAL LIPID	
C16:0	18	16.4
C16:1	28.37	34.78
C18:0	7.42	5.71
C18:1n-9	26.44	30.15
C18:4n-3	*2.93	*4.57
C20:0	0.25	0.17
C20:4n-3	4.13	0.32
C20:5n-3	(39%) 1.87	(2.1%) .10
TOTAL LIPID (μg)	257	304

*INDICATES SUBSTRATE ADDED
(% CONVERSION)=PRODUCT/(SUBSTRATE+PRODUCT)

FIG.26B

31/102

SCORES Initl: 114 Intn: 278 Opt: 278
Smith-Waterman score: 308; 30.9% identity in 259 aa overlap

GLELO	40	50	60	70	80	90	99
	VAQEKYIPTIVHTRGFLVAVESPLARELPUNPFFHLLIVLAVLVTVFVGHQIKNKIFE						
MAELO	20	30	40	50	60	70	
	GIKLDTYFAQAYELVTGKSIDSFVQEGVTPLSLSTQREVAAMTITTVYVIFGRGRIMKSQD						
GLELO	100	110	120	130	140	150	
	RFEVKTFSLLHNFCLVSI SAYMCGEILYE--AYQANYGLFENADHTFKGLPNAKMTLWF						
MAELO	80	90	100	110	120	130	
	AFKLKPLFTLHNFLLTIASGSLLLFTENLVPILARNGLFYAICDDGAMTQRLELLYYLN						
GLELO	160	170	180	190	200	210	
	YFSKIMEFVDTMINVLKNNRQISFLHYVHSSIFTIMLVTFVAPNGEAYFSAALNSFI						
MAELO	140	150	160	170	180	190	
	YLVKYNELADTVFLVLKK--KPLEFLHYFHHS-MTNVLCFVLGGYTSVSWPITLNLTV						
GLELO	220	230	240	250	260		
	HVIMYGYFSLGKQVSKFYITRSQMTQF-----CMWSVOS-----SHDMYAM						
MAELO	200	210	220	230	240	250	
	HVFHYYYHRSAGVRI--MMKQYLTLQIVQFVLDLGFYFCATYTFATYFPWAPNVG						
GLELO	270	280	290	300	310		
	KVLRGRPGYFFTTALLWFYMTMLGLFYNYFRKNNAKAKOAKADAKEKARKLQ						
MAELO	260	270	280	290	300		
	KCAGTEGAALFGCLLSSYLL-----LFINFYR-----ITYNAKAKAAKERGSNFTPKTVKS						
MAELO							
	GGSPKPKPSKXHIX						
	310						

FIG.27

GLELO 1 - M E S I A P F L P S K M P Q D L F M D L A T A I G V R A A P Y V D P L E A A L V A Q 42
 MAELO 1 - - - - - M A A A I L D K V N F G I D Q P F G I K 20
 GNS1 1 - - - - - M N S L V T Q Y A A P L F E R Y P Q L H D Y L P T L E R P F F N I S L W 36
 SUR4 1 M N T T T S T V I A A V A D Q F Q S L N S S S S C F L K V H V P S I E N P - F G I E L 42

GLELO 43 A E K V I P T I V H H T R G F L V A V E S P L A R E L P L M N P F H V L L I V L A Y L 85
 MAELO 21 L D T V F A Q A Y E L V T G K S I D S F V F Q E G V T P L S T Q R E V A M W T I T V F 63
 GNS1 37 E H F D D V V T R V T N G R F V P S E F Q F I A G E L P L S T L P P V L Y A I T A Y V 79
 SUR4 43 W P I F S K V F E Y F S G - Y P A E Q F E F I H N K I F L A N G Y H A V S I I I V V Y 84

GLELO 86 V T V F V G M Q I M K N F E R F E V K T F S L L H N F C L V S I S A Y M C G G I L Y E 128
 MAELO 64 V V I F G G R Q I M K S Q D A - - F K L K P L F I L H N F L L T I A S G S L L L L F I 104
 GNS1 80 V I I F G G R F L L S - - K S K P F K L N G L F Q L H N L V L T S L S L T L L L L N V 120
 SUR4 85 I I I F G G Q A I L R A L N A S P L K F K L L F E I H N L F L T S I S L V L W L L M L 127

GLELO 129 - - A Y Q - - A N Y G L F E N A A D H T F K G L P M A K M I W L F Y F S K I M E F V D 167
 MAELO 105 E N L V P I L A R N G L F Y A I C D D G A W T Q R L E L L Y Y L N Y L V K Y W E L A D 147
 GNS1 121 E Q L V P I I V Q H G L Y F A I C N I G A W T Q P L V T L Y Y M N Y I V K F I E F I D 163
 SUR4 128 E Q L V P M V Y H N G L F W S I G S K E A F A P K L V T L Y Y L N Y L T K F V E L I D 170

GLELO 168 I M I M V L K K N N R Q I S F L H V Y H H S S I F T I W W L V T F V A P N G E A Y F S 210
 MAELO 148 I V F L V L K K - - K P L E F L H Y F H H S M I M V L C F - V Q L G G Y T S V S W V P 187
 GNS1 164 I F F L V L K H - - K K L T F L H T Y H H G A T A L L C Y - T Q L M G T T S I S W V P 203
 SUR4 171 I V F L V L R R - - K K L L F L H T Y H H G A T A L L C Y - T Q L I G R T S V E W V V 210

FIG.28A

GLELO 211 A A L N S F I H V I M Y G Y Y F L S A L G F K Q V S F I K F Y I T R S Q M T Q F C M M 253
 MAELO 188 I T L N L T V H V F M Y Y Y M R S A A G V R - - I W W K Q Y L I T L Q I V Q F V L D 228
 GNS1 204 I S L N L G V H V V M Y W Y Y F L A A R G I R - - V W W K E N V T R F Q I I Q F V L D 244
 SUR4 211 I L L N L G V H V I M Y W Y Y F L S S C G I R - - V W W K Q W V T R F Q I I Q F L I D 251

GLELO 254 S V Q S S W D M Y A M K V L G R P G Y P F F I T A L L W F Y M W T M L G L F Y N F Y R 296
 MAELO 229 L G F I Y F C A Y I Y F A F T Y F P W - A P N V G K C A G T E G A A L F G C G L L S S 270
 GNS1 245 I G F I Y F A V Y Q K A V H L Y F P - I L P H C G D C V G S T T A T F A G C A I I S S 286
 SUR4 252 L V F V Y F A T Y T F Y A H K Y L D G I L P N K G T C Y G T Q A A A A Y G Y L I L T S 294

GLELO 297 K N A K L A K Q A K A D A A K E K A R K L Q 318
 MAELO 271 Y L L L F I N F Y R I T Y N A K A K A A K E R G S N F T P K T V K S G G S P K K P S K 313
 GNS1 287 Y L V L F I S F Y I N V Y K R K G T K T S R V V K R A H G G V A A K V N E Y V N V D L 329
 SUR4 295 Y L L L F I S F Y I Q S Y K K G G K K I V K K E S E V S G S V A S G S S T G V K T S N 337

MAELO 314 S K H I 317
 GNS1 330 K N V P T P S P S P K P Q H R R K R 347
 SUR4 338 T K V S S R K A 345

FIG.28B

BEST AVAILABLE COPY

34/102




FIG.29

35/102




FIG.30

BEST AVAILABLE COPY

36/102

SCORES Init1: 88 Initn: 207 Opt: 223
Smith-Waterman score: 236; 30.4% identity in 191 aa overlap

MAELO LLLLFENLPIILARNGLFYAICDDGAMTQRELLYYLNYLVKYMELADTVFLVKKKP-
MM2 IYVEFLMSGMLSTYTHRCOPIDFSNSPEALRVRVAVLFWLSKVIELMDTVIFILRKQGG
MAELO -LEFLHYFHSMTWVLCF...VOLGGYTSVSWPITLNLTVHVFYMYMRSAGV...
MM2 QVTFLLHFHHSVLPMSMMGIKAPGGSFHAN...INSSVHVWVWLYYGLSALGPVQA
MAELO -RIWKKQVLTTLQIQVFL...DLGFIVE...CAYTYFAFTYFPMAPNVGKACAGTEGAL
MM2 PYLWKKKHMTAQLIQVLSLHISQYFMPSCNYQPVIIHLN.....M
MAELO FGGLLSSYLLLFINFRITYNAKAAKERSNFTPKTWKSGSPKPSKSHI
MM2 YG.....TIFFILFSNFWHSYTKGKRLPRAVQNGAPATTVKAN

FIG.31

37/102

SCORES Init1: 51 Initn: 115 Opt: 168
Smith-Waterman score: 168; 30.4% identity in 115 aa overlap

MAELO YELVTGKSDSFVFEQVTPLSLQREVAMTITTYVWIFGGRIKMSQDAFKLPLFLH
A1225632 NAFLDNMFGRDSDRVGRHFLDLSVLPFTLITTYLLSIWLGKYNKRPALSRLGILTY
MAELO NFLTTIASSGSLLLFTENLVPILARNGLFYAICDD...GANTQRELLYYLNYLVKYYE
A1225632 NLATILL SAYMLVELI.....LSSWEGGYNLQCNLDOSAGEGDVRAKVLVWYFYSKLVE
MAELO LADTVFLVKKK...PLEFLHYFHSMTWVLCFVOLGGYTSVSWPITLNLTVHVFMYYYY
A1225632 FLDTIFFVLRKKANQITFLHYHSHAFNI

FIG.32

SCORES Frame: (3) Initl: 332 Inltn: 332 Opt: 384
40.3% identity in 144 aa overlap

38/102

GLELO LIVLAYLVTVFVGHQIKNIFERFEVKTSLHNFLVSIYAYNGGILYEAYQANYGL-F
A1815960 LYNLGITLLSAYMLAELISTWEGGYNLQC
GLELO ENAADHTFKGLPKAKMTLWLFYFSKINEFVDITMIVLKKNNRQISFLHVVHSSIFTIIMWL
A1815960 ODLTSAGEADTRVAKVLWVYFYSKSVFELDTIFFVLRKTSQITFLHVVHSSMFMNIWC
GLELO VTFVAPNGEAYFSAALNSFIHVIWYGYFLSAL-GFKQVSIKFIYITRSQMTQFCMWSVQ
A1815960 VLNWIPCGGSFPGPTLNSFIHLWYSYGYLSVFPSPMKYLMKKYLTQADLVQF
GLELO SSNDMYAMKVLGRPGYPFFITALLWFMVMTMLGLFYNYRKNAKLAKQAKADAAKEKARK

FIG.33

SCORES Initl: 316 Inltn: 384 Opt: 477
Smith-Waterman score: 477: 34.2% identity in 240 aa overlap

39/102

GLELO AQAEKIPTIIVHTRGFLVAVESPLARELPWNPFHVLIVLAYLVTVFVGHQIKNIFER
HS1 MEHFDASLSTYFKALLGPROTRVKGWFLDNVYPTIFICSIVYLLIWLGPKYRNKQP
GLELO FEVKTSLHNFLVSIYAYNGGILYEAYQANYGLF-ENAADHTFKGLPKAKMTLWLFYF
HS1 FSCRGILWVYNLGLTLLSLYMFCELVTVGWEGKNYFFCGTRTAGESDMKIIRVLWVYF
GLELO SKINEFVDITMIVLKKNNRQISFLHVVHSSIFTIIMWLTVTFVAPNGEAYFSAALNSFIHV
HS1 SKLIEFMDITFFILRKNNHQITVLHVVHSSMFMNIWFMVWVPCGHSYFGATLNSFIHV
GLELO IMVGYFLSAL-GFKQVSIKFIYITRSQMTQFCMWSVQSSNDMYAMKVLGRPGYPFFITA
HS1 LMVSYGLSSVPSMRPYLMKKYITQGLLQFVLTIITQTS-----CGVWPCTFPLGLY
GLELO LLMFYMTMLGLFYNYRKNAKLAKQAKADAAKEKARKLQ
HS1 FOIGYMSLIALFTNFYITQYNNKGASRRKHLDKHONGHSHAAVNGHTNFSPLENNVYP

FIG.34

41/102

SCORES Initl: 288 Initn: 288 Opt: 399
Smith-Waterman score: 399; 34.6% identity in 211 aa overlap

GLELO LLTVLAVLVTVGVGQIKNFERFEVKTFSLHNFCLVLSISAYMCGGLTYEAYQANGLF
MM2 IYVNFSLVLSLYIWEFLMSGMLSTYTW
GLELO ENAAD--HTFKGLPMKMTLWLFYFSKIMEFVDTMIWLVKKNRQISFLHYHSSIFTIW
MM2 CDPIDFSNPEALQNRVAVMLFSLKVELMDTVIFILRKKDQGVTFELVYFHSVLQWSW
GLELO WLTVFVAPNGEAYFSAALNSFIHVIWGYFYSALGFKQVSFI--KFYITRSQNTQFMM
MM2 WNGIKIAPGGGSHFAMINSSVHVWVLYYGLSALGPVAPQPYLMMKKHMTAQLTQFLV
GLELO SVQSSNDWYAMKVLGRPGYFFITALLFYMTMLGLFYNF....YRKNKAKAKAKADA
MM2 SLHIS-QYVFHPSQNYQ-YPVIH-LIMMYGTIFFILFSHFVHSYTKGKRLPRAVQNG
GLELO 310
MM2 AKEKARKLQ
APATTKVKAN
210

FIG.36

40/102

SCORES Initl: 80 Initn: 114 Opt: 178
Smith-Waterman score: 178; 28.8% identity in 146 aa overlap

GLELO FENAADHTFKGLPMKMTLWLFYFSKIMEFVDTMIWLVKKNRQISFLHYHSSIFTIW
AC004050 DTIFILRK--QKLIFLHWYHHTVLLYSW
GLELO LVTVPNGEAYFSAALNSFIHVIWGYFYSALGFKQVSFIKFYITRSQNTQFMSVQ
AC004050 YSYKDWVAGGGHF-NTMNYGVHVMYSYALBAAGFRVSRKFAWFTLSQITQMLGCVW
GLELO SSNDWYAMKVLGRPGYFFITALLW--FYMTMLGLFYNFYRKN--AKLAKAKAKAAKE
AC004050 NYLVFCMMQ--HDQCHSHF-QNIFWSSLWVLSVLVLFCHFFFEAYTGKMRKTTKAX
GLELO KARKLQ

FIG.35

44/102

SCORES Initl: 100 Intra: 205 Opt: 271
Smith-Waterman score: 271; 30.7% identity in 218 aa overlap

GLELO TRGELVAVESPLARELPLNPFHLLIVLAYLVTVGMQIKKINFERFEWTKFSLHNF
100 70 80 90 100 110
U68749 ATHGKNIFFDAEGKFFADHFDVTIQASILYMWVFGTKWFRNRQPFQLTPLNMF
(F56H11.4) 30 40 50 60 70 80
GLELO LVLSAYMCGGILYEAQ--ANYGL...FEWAADHTKGLPMKIMVLFYFSKIMEFVD
120 130 140 150 160
U68749 LAAFSJAGAVKMTPEFFGTIANKGIVASYCKVDFDT-KG-ENGYWMLFMASKLFELV
(F56H11.4) 90 100 110 120 130 140
GLELO MIMVLKKNRQISLHYHHSSIFTIMVLTVFVAPNGEAYFSAALNSFIHVMYGYELS
170 180 190 200 210 220
U68749 IFLVLRK--RPLMELWYHHILMTIYAWYSHPLTP-GENRYGYILNFVWVHAFMYSYEL
(F56H11.4) 150 160 170 180 190
GLELO ALGFKQVSEIKFYITRSQMTQFCMWSVSSNDYAMKVLRP-GYPFFITALLWFYMTM
230 240 250 260 270 280
U68749 SHKIRVPGFIAQAITSQIVQFIISCAVLHGLMLHFTNANCDPEPSVFKLAVFDTTY
(F56H11.4) 200 210 220 230 240 250
GLELO LGLFYNYRKNKAKLAKOAKAAKEKARKLQ
290 300 310
U68749 LALFVNFQSYVLRGKKOKYKAVPKKKNN
(F56H11.4) 260 270 280

FIG.39

SUBSTITUTE SHEET (RULE 26)

45/102

SCORES Initl: 189 Intra: 264 Opt: 358
Smith-Waterman score: 358; 28.7% identity in 296 aa overlap

MAELO MAAAILDKYVFGIDQPFQIGKLDITYAQAQVELVTGKSIDSFVQEGVTPLSQREAVM-T
10 20 30 40 50 59
U68749 MAQHPLVQRLLDVKFDT---KRFVAIATHGPKNFDAEGRKFFADHFDVTIQAS
(F56H11.4) 10 20 30 40 50
MAELO ITYVVFVFGGRQIKNSQDAFKL-PLFILHNELLTIAGSLLLLFIENLPIARNGLFY
60 70 80 90 100 110
U68749 ILYVWVFGTKWFRNRQPFQLTPLNIN-NFILAASFAGAVKMTPEFFGTIANKGIVA
(F56H11.4) 60 70 80 90 100 110
MAELO AICDDGAMTORLELLYYLNLV-KYMEADTVFLVKKPLEFLHYFHSMTWVLCFVQL
120 130 140 150 160 170
U68749 SYCKVDFDKGNGYMWLFWASKLFELVDITFLVLRKPLFLHMYHHILMTIYAWYSH
(F56H11.4) 120 130 140 150 160 170
MAELO GGYTSVSWPITLNLTVHVFNY-YYNRSAGVRI--HWKQVLTTLQIVQVLDLGFYF
180 190 200 210 220 230
U68749 PLTPGFWRVGYILNFVWVHAFMYSYFLRSWK-IRVPGFIAQAITSQIVQFIISCAVLH
(F56H11.4) 180 190 200 210 220
MAELO CAYT-YFAFTYFPWAPVWVKCAGTEGAALFGGGLSSYLLLFINFRITY-----NAKAK
240 250 260 270 280
U68749 LGYLMHFTNANCDPEPSVFKLA-----VF...MDTTYLALFVNFQSYVLRGKKOKYK
(F56H11.4) 230 240 250 260 270 280
MAELO AAKERSNFTPKTVKSGGSPKPKSKKHI
290 300 310
U68749 AVPKKKNN
(F56H11.4)

FIG.40

SUBSTITUTE SHEET (RULE 26)

46/102

SCORES Init1: 77 Initn: 155 Opt: 264
Smith-Waterman score: 264; 27.2% identity in 206 aa overlap

GLELO	40	50	60	70	80	90	
	AALVAQAEYIPTIVHHTRGELVAVESPLARNPFWLLIVLAVLVTVFVGVQIWK						
DM1	10	20	30	40	50	60	
	PTKININDISVTPNYSYIFDFENDFIHQTRKMWLENMTWVYFGGIVMLVIFGGQHFHQ						
GLELO	100	110	120	130	140	150	
	NFERFEKTFSLHNFCLVSIAYMCGGILYEAYQA--NYGLFENAADHTE--KGLPMK						
DM1	70	80	90	100	110	120	
	NRPRFQLRGPLIINWTLAMFSLNGAARTAPELIHVLRHYGLFHSVCVPSYIEQDRVCGF						
GLELO	160	170	180	190	200	210	
	MINLFYFSKIMEFVDTMIWLKNNRQISFLHVVHSSIFTIMWLTVFVAPNGEAYFSAA						
DM1	130	140	150	160	170	180	
	WTWLFLVLSKLPGLGDTIFIVLRK--QPLIFLHWYHHTITVLVYSMF-SYTEYSSARFIV						
GLELO	220	230	240	250	260	270	
	LNSFIHWIMYGYFLSALGFKQVSFIKFYITRSQMTQFMHVSQSSHDYAMKVLGRPGY						
DM1	190	200	210	220	230	240	
	MNYCVHSMYSYALKAAARFNPFRFISMITSLQLAQMIIGCAINWANGFLKTHGTXC						
GLELO	280	290	300	310			
	PFFITALLWFYMTMLGLFYNFYRKNAKLAKQAKADAKEKARKLQ						
DM1	250	260	270	280			
	HISQRNINLSIAMYSYFVLFARFFYKAYLAPGGHKSRMA						

FIG.41

SUBSTITUTE SHEET (RULE 26)

47/102

SCORES Init1: 181 Initn: 279 Opt: 328
Smith-Waterman score: 328; 30.0% identity in 237 aa overlap

MAELO	40	50	60	70	80	90	
	VTGKSDSFVFEQVTPLSSTOREVAMMTITTFVIFGGRIKMSQDAFKLPLFILHNF						
DM1	30	40	50	60	70	80	
	IFDFENDFIHQTRKMWLENMTWVYFGGIVMLVIFGGQHFQNRPRFQLRGLIINWTL						
MAELO	100	110	120	130	140	149	
	LTIASGSLLLFIENLVPILARNGLFYAICDDGAWTQ-RLELLY-YLNVLKYNELADTV						
DM1	90	100	110	120	130	140	
	LAMFSLNGAARTAPELIHVLRHYGLFHSVCVPSYIEQDRVCGFMTLFLVLSKLPGLGDTI						
MAELO	150	160	170	180	190	200	
	FLVLKKPLEFLHYFHSMTWLCFVLGGYTS-VSWVPITLNLTVHVFYHYMRSAAAG						
DM1	150	160	170	180	190	200	
	FIVLRKQPLIFLHWYHHTITVLVYSWFSYTEYSSARWF-IVMNYCVHSMYSYALKAAAR						
MAELO	210	220	230	240	250	260	
	VRI--WKKQYLTLQIQVFLDLGFIYFCATYFAFTYFPWAPWGWKAGTEGAALFGCG						
DM1	210	220	230	240	250		
	FNPPRFISMITSLQLAQMIIG-----CAINWANGFLK-THGTXSCHISQRNINLSIA						
MAELO	270	280	290	300	310		
	LLSSYLLLFINFYRITYYNAKAAKAKERGSNFTPKTVKSGSPKPKSPKSKHI						
DM1	260	270	280				
	MYSSYFVLFARFFYKAYLAPGGHKSRMA						

FIG.42

SUBSTITUTE SHEET (RULE 26)

48/102

1 ATGGAACATT TTGATGATC ACTTAGTACC TATTCAAGG CATTGCTAGG
51 CCTCGAGAT ACTAGAGTAA AAGGATGGTT TCCTCTGGAC AATTATATAC
101 CCACATTTAT CTGCTCTGTC ATATATTTAC TAAITGTATG GCTGGGACCA
151 AAATACATGA GGAATAACA GCCATCTCT TCCGGGGGA TTTTAGTGGT
201 GTATAACCTT GGACTCACAC TGCTGTCTCT GTATATGTTCTG TGTGAGTTAG
251 TAACAGGAGT ATGGAAGGC AAATACAAC TCTCTGTCA GGGCACACGC
301 ACCGAGGAG AATCAGATAT GAAGATTATC CGTGTCTCT GGTGGTACTA
351 CTCTCCAAA CTCATAGAT TTAGGACAC TTCTCTCTC ATCCTGCCGA
401 AGAACACCA CCAGATCAGG GTCTGCAGG TCTACCACTA TGCCTCGATG
451 CTGAACATCT GGTGGTTTGT GATGAATGG GTCCCTGCG GCCACTCTTA
501 TTTTGGTCC ACACCTAATA GCTTCATCCA CGTCTCATG TACTCTTACT
551 ATGGTTTGTG GTCAGTCCCT TCCATGCGTC CATACCTCTG GTGGAAGAAG
601 TACATCACTC AGGGGAGCT GCTTCAGTTT GTGCTGACAA TCATCCAGAC
651 CAGCTGCGGG GTCATCTGCG GGTGCACATT CCCTCTTGGT TGGTTGATT
701 TCCAGATTGG ATACATTATT TCCCTGATTG CTCTCTTAC AACTTCTAC
751 ATTCAGACCT ACAACAAGA AGGGGCTCC GGAAGGAAG ACCACTGAA
801 GGACCACCAG AATGGGTCG TGCTGCTGT GAATGGACAC ACCAACAGCT
851 TTTACCCCT GGAACAACAT GTGAAGCCAA GGAAGCTGCG GAAGGATTGA
901 AGTCAAGAA TTGA

FIG.43

49/102

1 MEHFDASLT YFKALLGRD TRVKGWELD NYIPTFICSV IYLLIWLGP
51 KYMRNKQPF CRGILWYNL GLTLLSLMF CELVTGWEG KYNFFCQGR
101 TAGESDKII RVLWNYFSK LIEFNDTFFF ILRKNHQIT VLVVYHHASH
151 LNTWVFVNMV VPGHSYFGA TLNSTHVLW YSYVGLSSVP SMRPYLMMKK
201 YITGGQLLOF VLTIIQTCG VIWPTFPLG WLQYQIGYII SLIALFTNFI
251 IQTYNKKGAS RRKHUKDQK NGSVAVNGH TNSFSPLENN VKPRKLKRD*

FIG.44

1 ATGGCTCAGC ATCCGCTCGT TCAACGGCTT CTGGATGTCA AATTGACAC
51 GAACGATTT TGCGCTATTG CTACTCATGG GCCAAGAAT TTCCCTGAGG
101 CAGAAGGTGG CAAGTTCTTT GCTGATCACT TTGATGTTAC TATTGAGGCT
151 TCAATCCTGT ACATGGTCGT TGTGTCGGA ACAAAATGGT TCATGCGTAA
201 TCGTCAACCA TTCCAATTGA CTATTCCACT CAACATCTGG AATTTCATCC
251 TCGCGCCATT TTCCATCGCA GGAGCTGTCA AAATGACCCC AGAGTTCTTT
301 GGAACCATTT CCAACAAGG AATTGTGCA TCCTACTGCA AAGTGTTTGA
351 TTTCAGGAA GGAGAGAAG GATACTGGGT GTGGCTCTTC ATGGTTCCA
401 AACTTTTCGA ACTTGTGAC ACCATCTTCT TGGTCTCCG TAAAGTCCA
451 CTCATGTTCC TTCAGTGGTA TCACCATATT CTCACCATGA TCTAGGCCTG
501 GTACTCTCAT CCATTGACCC CAGGATTCAG CAGATACGGA ATTTATCTTA
551 ACTTGTGCT CCACGCTTC ATGTACTCTT ACTACTTCCT TGCGTCGATG
601 AAGATTGCGG TGCAGGATT CATGCGCCAA GCTATCACAT CTCITCAAT
651 CGTTCAATTC ATCATCTCTT GCGCGTCT TGCTCATCTT GGTATCTCA
701 TGCACTTCAC CAATGCCAAC TGTGATTTCG AGCCATCAGT ATCAAGCTC
751 GCAGTTTTCA TGGACACAAC ATACTGGCT CTTTTCGTCA ACTTCTCTT
801 CCAATCATAT GTTCTCCGG GAGGAAAGA CAAGTACAAG GCAGTGCCAA
851 AGAAGAAGAA CAACTAA

FIG.46

HOST (PLASMID)	334(pRX242)	334(pRAE-58-A1)	334(pRX242)	334(pRAE-58-A1)
ADDED SUBSTRATE	25 μ M GLA	25 μ M GLA	25 μ M AA	25 μ M AA
FATTY ACID	% TOTAL FATTY ACID	% TOTAL FATTY ACID	% TOTAL FATTY ACID	% TOTAL FATTY ACID
C18:3n-6	4.40	2.71	0.03	0.04
C20:3n-6	0.09	(50.34%)* 2.75	0.02	0.02
C20:4n-6			7.48	3.97
C22:4n-6			ND	(23.37%)* 1.21
C16:1n-7	41.11	34.72	41.49	35.07
C18:1n-7	1.85	11.33	2.01	11.57
C20:1n-7	0.04	1.48	0.04	1.62
C18:1n-9	15.60	15.66	15.16	14.57
C20:1n-9	0.06	0.22	0.06	0.23
C18:1n-5	0.11	0.62	0.12	0.58
TOTAL LIPID	370	969	359	514
% CONVERSION=PRODUCT/(SUBSTRATE+PRODUCT)				

FIG.45

53/102

52/102

1 MAQHPLVQRL LDWKEDTKRF VATATHGPKN FPDAGRKFF ADHFDVTIQ
51 SILYVVVFG TKWFRNRQP FQLTPLNIW NFILAAFSIA GAVKNTPEFF
101 GTIANKGIVA SYCKVEFTK GENGYNWLF MASKLFELVD TIFLVLRKP
151 LMFLLHWYHI LTHYAMYSH PLTPGFNRYG IYLNFWVHAF MYSYFLRSH
201 KIRVPGFIAQ AITSLQIVOF IISCAVLAHL GYLMHFTNAN CDFEPSVKL
251 AVFHDTTYLA LFWNFLOSY VLRGKDKYK AVPKKKNN

FIG.47

FIG.48

HOST(PLASMAID)	334(pYX242)	334(pRET-21)	334(pRET-22)
ADDED SUBSTRATES	50 μ M GLA + 50 μ M AA	50 μ M GLA + 50 μ M AA	50 μ M GLA + 50 μ M AA
FATTY ACID	% TOTAL FATTY ACID	% TOTAL FATTY ACID	% TOTAL FATTY ACID
C16:0	9.22	12.46	9.9
C16:1	0.09	0.18	0.13
C18:0	1.46	2.41	1.49
C18:1n-9	4.03	4.92	3.91
C18:3n-6	10.02	11.89	8.69
C20:3n-6	(1.28%)*	0.13	(11.1%)*
C20:4n-6	46.98	28.87	35.25
C20:4n-6	0	0	0
TOTAL LIPID (mg)	212	174	187
% CONVERSION=PRODUCT/(SUBSTRATE+PRODUCT)			

54/102

1 ATGAACATGT CAGTGTGTGAC TTACAGAA TATGAATTG AAAAGCAGTT
51 CAACGAGAAT GAAGCCATCC AATGGATGCA GGAAGAACTGG AAGAAATCTT
101 TCCTGTTTTC TGCTCTGTAT GCTGCCCTTTA TATTGGGTGG TCGGCACCTA
151 ATGAATAAAC GAGCAAAGTT TGAAC TGAGG AAGCCATTAG TGCTCTGGTC
201 TCTGACCCCT GCAGCTTCA GTATATTGG TGCTCTCGA ACTGGTCTT
251 ATATGGTGTA CATTITGATG ACCAAAGGCC TGAAGCAGTC AGTITGTGAC
301 CAGGGTTTTT ACAATGGACC TGTACGAAA TTCTGGGCTT ATGCATTGT
351 GCTAAGCAAA GCACCCGAAC TAGGAGATAC AATATTCAAT ATTCTGAGGA
401 AGCAGAAAGCT GATCTTCTG CACTGGTATC ACCACATGAC TGTGCTCTG
451 TACTCTTGGT ACTCCTACAA AGACATGGTT GCCGGGGAG GTTGGTTTCA
501 GACTATGAAC TATGGGTGC ACGCCGTGAT GTACTCTTAC TATGCTTGC
551 GGGCGGCAGG TTTCGGATC TCCGGAAGT TTGCCATGTT CATCACCTTG
601 TCCAGATCA CTCAGATGCT GATGGGCTGT GTGGTTAACT ACCTGGTCTT
651 CTGCTGGATG CAGCATGACC AGTGTCACTC TCACCTTTCAG AACATCTTCT
701 GGTCTCTCACT CATGTACCTC AGTACCTTG TGCTCTTCTG CCAITTTCTC
751 TTGAGGCCT ACATCGGCAA AATGAGGAAA ACAACGAAAG CTGAATAG

FIG.49

55/102

1 MNWSVLTQE YEFKQFNEN EAQMWQENW KKSFLFSALY AAFIFGRHL
51 MNKRAKFE LR KPLVLNSLT AVFSIFGALR TGAYWVYILM TKGLKQSVCD
101 QGFYNGPVSK FMAVAFVLSK APELGDTIFI ILRKQKLIFL HWYHHTITVLL
151 YSWSYKDMV AGGGNFMTHN YGVHAWWYSY YALRAAGFRV SRKFAMFTTL
201 SQITQMLMG VVNYLVFCMM QHQQCHSHFQ NTFWSSLMYL SYLVLFCHFF
251 FEAYIGKHKR TTKAE*

FIG.50

HOST	PLASMID	SUBSTRATE	% TOTAL LIPID									
334	pYX242	LA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pRAE-58	LA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pYX242	GLA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pYX242	GLA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pYX242	DGLA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pYX242	DGLA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pRAE-58	DGLA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pYX242	AA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pRAE-58	AA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pYX242	ADA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
334	pRAE-58	ADA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
C18:1n-9	15.27	16.83	14.85	15.58	13.62	16.24	15.08	15.64	16.18	13.98		
C18:1n-7	1.21	13.53	1.22	11.80	1.16	12.63	1.18	11.70	1.30	10.67		
C18:1n-5	0.13	0.95	0.20	0.73	0.12	0.72	0.14	0.59	0.12	0.70		
C18:2n-6	4.09	4.85	0.09	0.07	0.07	0.04	0.04	0.04	0.03	0.07		
C18:3n-6	ND	ND	4.66	2.33	ND	ND	ND	ND	ND	ND		
C20:1n-9	0.07	2.60	0.07	0.33	0.07	0.33	0.04	0.27	0.08	0.33		
C20:1n-7	0.10	0.18	0.14	1.65	0.08	1.68	0.12	1.58	0.12	1.85		
C20:2n-6	ND (13.2%)	0.74	ND	ND	ND	ND	ND	ND	ND	ND		
C20:3n-6	ND	ND	ND (51.4%)	2.46	6.37	7.86	ND	0.03	ND	ND		
C20:4n-6	ND	ND	ND	ND	ND	0.09	6.49	5.77	ND	ND		
C22:4n-6	ND	ND	ND	ND	ND	ND (27.1%)	2.14	10.91	15.57	1.26		
C24:0	0.59	1.61	0.64	1.12	0.69	0.79	0.52	0.77	0.54	1.26		
TOTAL LIPID	333	373	260	392	260	672	553	690	706	440		

HOST	PLASMIID	SUBSTRATE	CONCENTRATION
334	pYX242	PA	25µM
334	pRAE-58	PA	25µM
334	pYX242	SA	25µM
334	pRAE-58	SA	25µM
334	pYX242	ARA	25µM
334	pRAE-58	ARA	25µM
334	pYX242	BA	25µM
334	pRAE-58	BA	25µM
334	pYX242	PTA	25µM
334	pRAE-58	PTA	25µM
334	pYX242	OA	25µM
334	pRAE-58	OA	25µM
334	pYX242	EA	25µM
334	pRAE-58	EA	25µM
% TOTAL UPID			
C16:0	24.17	17.23	11.22
C16:1n-7	39.83	33.83	30.62
C16:1n-5	0.30	0.74	0.29
C18:0	1.90	1.50	35.82
C18:1n-9	15.36	14.11	11.52
C18:1n-7	1.36	11.44	0.90
C18:1n-5	0.11	0.78	0.08
C20:0	0.15	0.17	0.09
C20:1n-9	0.09	0.45	0.05
C20:1n-7	0.20	2.84	ND
C22:0	0.43	0.56	0.29
C24:0	0.59	1.39	0.36
TOTAL UPID	297	272	573
ND = NOT DETECTED			

62/102

1 MEQLKAFDNE VNAFLDNHFG PROSRVRGMF LLDSVLPFTI LTITTYLLSTW
51 LGNKYMKNRP ALSRLGTLT YNLAITLLSA YMLVELTLSS NEGGSYULQCC
101 NLDASAGEDV RYAKVLWMMY FSKLVEFLDT IFFVLKKTW QITFLHVYHH
151 ASHFNIWMCV LNWIPCGQSF FGPTLNSFIH ILWYSYGLS VFPSSHKYLW
201 WKKYLTQAKL VOFVLITHTT LSAVVKPGCF PFGCLIFQSS YMWTLVILFL
251 NFYIQTQRKK PIVKKELOEKE WKNGFPKAHL IYVAINGTDKK AQ*

FIG. 55

63/102

HOST	PLASMOD	CONCENTRATION	Σ TOTAL L/PD											
J34	px242	GA	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
J34	pAE-84	px242	px242	pAE-84	px242	pAE-84	px242	pAE-84	px242	pAE-84	px242	pAE-84	px242	pAE-84
J34	14.63	15.94	14.16	12.30	15.67	11.77	11.41	14.81	17.92	15.91	16.33	15.04	1.57	1.38
C18-in-9	4.53	4.21	NO	NO	NO	NO	NO	NO	2.70	NO	NO	NO	NO	NO
C18-in-7	1.25	1.21	1.10	1.50	1.13	1.18	1.19	1.38	1.33	1.49	1.57	14.63	1.57	1.38
C18-in-6	4.53	4.21	NO	NO	NO	NO	NO	NO	2.70	NO	NO	NO	NO	NO
C18-in-3	NO	NO	NO	NO	NO	NO	NO	NO	0.03	NO	0.05	NO	NO	NO
C20-in-6	0.10	0.57	NO	NO	NO	NO	NO	NO	0.05	NO	NO	NO	NO	NO
C20-in-3	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
C20-in-5	NO	NO	NO	NO	NO	NO	NO	NO	(14%)0.44	NO	NO	NO	NO	NO
C20-in-3	NO	NO	NO	NO	NO	NO	NO	NO	NO	9.68	3.02	NO	NO	NO
C20-in-6	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
C22-in-3	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
C22-in-5	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
C22-in-6	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
C22-in-3	NO	NO	NO	NO	NO	NO	NO	NO	(42.3%)0.33	NO	NO	NO	NO	NO
C22-in-5	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
C24-in-6	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
C24-in-3	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
C24-in-3	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
TOTAL L/PD	126	208	126	115	189	158	149	124	433	221	271	127	126	126

(% CONVERSION)=(PRODUCT/(SUBSTRATE+PRODUCT))
ND = NOT DETECTED

FIG. 56

67/102

1	ATGGAACATT	TGATGCGCTC	ACTCAGTACC	TATTTCGAAG	CCTTCCTGGG
51	CCCCCGAGAT	ACAAGAGTCA	AAGGATGGTT	CCTCTCTGGAC	AATTACATCC
	CTACGTTTGT	CTGTTCTGTT	ATTACTTAC	TACTGTATG	CTGGBGACCA
151	AATATCATGA	AGAACCGGCA	CGCTTCTCT	TGCGGAGCA	TCTTCGAAAT
201	GTATTAACATT	GGACTCACC	TGCTGTCTCT	CTACATGTTCT	TATGATGTGG
251	TGACAGGTGT	TGGGAGGGC	AAATACAAC	TTTTCTGCCA	GGGAACACGC
301	AGCCGCGGAG	AATCCGATC	GAAGATCATC	CGGTCCTCT	GGTGCTACTA
351	CTTCTCCAAA	CTCATGGAT	TGATGGACAC	TTTTTCTTC	ATCCTCGCA
401	AGAACACCAA	CCAGATACCC	GTGCTCCATG	TCACACCA	CGCTACGATG
451	CTCAACATCT	GCTGGTTTGT	GATGAACGTGG	GTTCCTTGG	GCCATTTCAT
501	TTTTGTGGG	ACACTCAACA	GCCTCATCCA	TGTCCTCATG	TACTGGTACT
551	ATGTGTCCTC	CTCCATCCCG	TGATGGGTC	CTTACTCTG	TGTGAAAAG
601	TACATCACTG	AAGGGCAGCT	CCGTCAGTT	CTGTGACAA	TCATCCGAC
651	GACCTCGGGG	GTCTCTTGGC	CAATGCTCCT	CCCTCTCGGG	TGGGTGTCT
701	TCCAGATTGG	ATACATGATT	TCCTTGATTG	CTCTCTTCAC	AAACTTCTAC
751	ATTCCAGACT	ACAACAAGAA	AGGGGCGCTCT	CGAGGGAAC	ACCCATCTGA
801	GGGCGACCAAC	ACAAGGCTCTG	TGGGCGCCGT	CAAGGACAC	ACCAACAGCT
851	TCCCTCCCTC	TGTGAAGGCCA	CGAGGACGCG	GAAGGATTGA	

FIG. 58

FIG. 57C

(% CONVERSION)=(PRODUCT/(SUBSTRATE+PRODUCT))
ND = NOT DETECTED

HOST	PLASMOD	SUBSTRATE	CONCENTRATION	% TOTAL LIPID											
				ALA	PRF-84	PRX242	SIA	PRF-84	PRX242	SIA	EPA	PRF-84	PRX242	DPA	PRF-84
				25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM	25µM
C18:1n-9	16.69	16.38	18.24	15.95	14.07	15.16	16.05	15.06	17.47	17.15	1.73	1.75	0.13	0.18	0.15
C18:1n-7	1.37	1.43	1.71	1.40	1.37	1.47	1.67	1.51	1.75	1.73	0.08	0.12	0.17	0.13	0.15
C18:2n-6	4.47	4.28	ND	ND	ND	0.06	0.11	0.18	0.13	0.15	ND	ND	ND	ND	ND
C18:3n-3	ND	ND	2.28	2.39	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
C20:3n-3	(1.3%)0.06	(3.6%)0.16	ND	ND	ND	0.26	ND	ND	ND	ND	ND	ND	ND	ND	ND
C20:4n-3	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
C20:5n-3	0.07	0.07	ND	ND	9.97	3.84	ND	ND	ND	ND	ND	ND	ND	ND	ND
C22:4n-3	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
C22:5n-6	ND	ND	ND	ND	ND	ND	ND	0.55	ND	ND	ND	ND	ND	ND	ND
C22:5n-3	ND	ND	ND	ND	ND	ND	ND	3.57	ND	ND	ND	ND	ND	ND	ND
C24:0	0.65	0.43	1.41	0.58	1.38	0.78	1.45	1.35	0.89	0.67	ND	ND	ND	ND	ND
C24:3n-3	ND	ND	ND	ND	ND	(73.6%)3.38	ND	(46.4%)3.09	ND	ND	ND	ND	ND	ND	ND
TOTAL LIPID	362	384	173	393	124	280	137	151	190	200					

66/102

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

73/102

HOST(PLASMD)	334(pRET-22+pCCR-4)	334(pY242+pYES2)
ADDED SUBSTRATE	50 μ M GLA	50 μ M GLA
FATTY ACID	% TOTAL LIPID	
C16:0	15.92	15.07
C16:1n-7	24.97	19.48
C18:0	8.52	6.48
C18:1n-7	3.9	1.61
C18:1n-9	18.48	12.71
C18:3n-6	*7.0	*10.54
C20:0	0	0
C20:3n-6	(27.81%) 4.36	(1.58%) 0.17
C20:4n-6	(27.55%) 4.32	0
TOTAL LIPID (μ g)	508	168

FIG.63A

HOST(PLASMD)	334(pRET-22+pCCR-4)	334(pY242+pYES2)
ADDED SUBSTRATE	50 μ M STA	50 μ M STA
FATTY ACID	% TOTAL LIPID	
C16:0	18.74	16.21
C16:1n-7	21.35	26.09
C18:0	6.78	7.57
C18:1n-7	1.97	1.7
C18:1n-9	20.73	22.41
C18:4n-3	*6.05	*13.43
C20:0	0	0.45
C20:4n-3	(15.88%) 1.68	(4.73%) 0.69
C20:5n-3	(26.93%) 2.85	(3.22%) 0.47
TOTAL LIPID (μ g)	335	161

FIG.63B

*INDICATES SUBSTRATE ADDED
 (% CONVERSION)=PRODUCT/(SUBSTRATE+PRODUCT)

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

72/102

HOST(PLASMD)	334(pRET22)	334(pRET22)	334(pRET22)	334(pRET22)
ADDED SUBSTRATE	50 μ M ALA	50 μ M PA	50 μ M EPA	50 μ M STA
FATTY ACID	% TOTAL LIPID			
C16:0	13.91	15.06	16.92	20.08
C16:1	14.74	31.77	23.57	20.17
C18:0	4.06	*4.85	4.94	6.02
C18:1n-9	6.65	13.59	10.46	9.29
C18:3n-3	*38.66			
C18:4n-3				*20.45
C20:4n-3				(12.57%) 2.94
C20:5n-3				
C22:5n-3			*15.48	
TOTAL LIPID (μ g)	80	84	81	60

FIG.62B

*INDICATES SUBSTRATE ADDED
 (% CONVERSION)=PRODUCT/(SUBSTRATE+PRODUCT)

FIG. 64B

244	MELO4	208	HSLE01	LQFVLTIIQTS	CGVIMP	-C-	-	-	-	TFPLGWL	YQI	-	GYMIS	LIA	244
247	MELO4	211	GLLE0	VQFCMTLTI	THLSAV	KP	-C-	-	-	GFPGCL	IFQS	-	SYM	TLVI	247
249	GLLE0	248	GLLE0	VQFCMTSV	QSSWDM	VYAM	KVLGR	PGY	PF	-	FI	ALLW	MT	MLG	249
250	CELE0	218	CELE0	VQFII	ISCA	VL	AHL	GL	YLMH	FTN	ANC	DFEP	SVFK	LAV	250
251	CELE0	261	CELE0	LFTNF	YIQTY	NKKG	ASR	KDHL	KDHQ	NGS	MAA	VNG	HTNS	FS	251
252	GLLE0	290	GLLE0	LFTNF	-	-	-	-	-	YRKN	AKLAK	QAKA	DAKE	KAR	252
253	CELE0	261	CELE0	LFTNF	FFQL	SVL	RGG	KDKY	KAVP	KKKN	N				253
254	HSLE01	288	HSLE01	ENNV	KPKR	KLD									254
255	MELO4	283	MELO4	ANG	MTD	KK	Q								255

FIG. 64A

[illegible]

76/102

77/102

1 ACAGGCGACT TTCTGTTGAA TTTGTTGCAG GCACAGCAAG GAAGGATGGC
51 AAACAGCAGC GTGTGGATG ATGTGGTGGG CCGGTGGAG ACCGGCGTGG
101 ACCAGTGGAT GGATGGCGCC AAGCGTAGC CACTACCGA TGGGCTCCCG
151 ATGATGGACG TGTCCACCAT GCTGGCATTG GAGGTGGGAT ACATGGGCAT
201 GCTGCTCTTC GGCATCCCGA TCATGAAGCA GATGGAAG CCCTTTGAGC
251 TCAAGACCAT CAAGCTCTTG CACAACCTGT TTCTTCGG ACTTTCCTTG
301 TACATGTGCG TGGAGACCAT CCGCAGGCT ATCCTGGAG GCTACAAAGT
351 GTTTGGAAC GACATGGAGA AGGCCAACCA GTCTCATGCT CAGGGCATGT
401 CTCGCATCGT GTACGTGTTT TAGGTGTCCA AGGCATACGA GTTCTTGGAT
451 ACCGCCATCA TGATCCTTTG CAAGAAGTTC AACCAGGTTT CTTCTTTGCA
501 TGTGTACCAC CATGCCACCA TTTTGGCCAT CTGGTGGGCT ATCGCCAAGT
551 ACGCTCCAGG AGGTGATCG TACTTTTCAG TGATCCTAAA CTCCTTCATC
601 CACGTTATCA TGTACTCTTA CTACCCCTGAA

FIG.65

1 TGDFLLNLLQ AQQGRMANSS VMDVVGRVE TGVDQIMDGA KPYALTDGLP
51 MMDVSTMLAF EVGYHMLLF GIPINKQMEK PFELKTIKLL HNLFLGLSL
101 YMCVETIRQA ILGGYKIVFGN DNEKGNESHA QGHSRIVYVF YVSKAVEFLD
151 TAIMLCKKF NQVSLHVVH HATIFAIWMA IAKYAPGGDA YFSVILNSFI
201 HVIMWSSYPE

FIG.66

78/102

1 ATGGCAACA GCAGCGTGTG GGATGATGTG GTGGCCGCG TGGAGACCGG
51 CGTGGACCAG TGGATGGATG GCGCAAGCC GTACGCACTC ACCGATGGGC
101 TCCCGATGAT GGAGGTGTCC ACCATGCTGG CATTGAGGT GGGATACATG
151 GCCATGCTGC TCTTGGCAT CCCGATCATG AAGCAGATGG AGAAGCCTTT
201 TGAGCTCAAG ACCATCAAGC TCTTGCACAA CTGTGTTCTC TTGGACTTT
251 CTTGTACAT GTGCGTGGAG ACCATCCGCC AGGCTATCCT CGGAGGCTAC
301 AAAGTGTGTTG GAAACGACAT GGAGAAGGGC AACGAGTCTC ATGCTCAGGG
351 CATGCTCGC ATGCTGTACG TGTTCTGCGT GTCCAAGGCA TACGAGTTCT
401 TGGATACCG CATCATGATC CTTTGCAGA AGTTCAACCA GGTTCCTTC
451 TTGCATGTGT ACCACCATGC CACCATTTT GCCATCTGGT GGGCTATCGC
501 CAAGTACGCT CCAGGAGGTG ATGCGTACTT TTCAGTGATC CTCAACTCTT
551 TCGTGACAC CGTCATGTAC GCATACTACT TCTTCTCCTC CCAAGGTTTC
601 GGGTTCGTGA AGCCAATCAA GCCGTACATC ACCACCTTC AGATGACCCA
651 GTTCATGGCA ATGCTTGTGC AGTCTTGTA CGACTACCTC TTCCCATGG
701 ACTACCCACA GGCTCTTGTG CAGCTTCTTG GAGTGTACAT GATCACCTTG
751 CTGGCCCTCT TCGGCAACTT TTTTGTGCAG AGCTATCTTA AAAAGCCAAA
801 AAAGAGCAAG ACCAACTAA

FIG.67

79/102

1 ATGGCAACA GCAGCGTGTG GGATGATGTG GTGGCCGCG TGGAGACCGG
51 CGTGGACCAG TGGATGGATG GCGCAAGCC GTACGCACTC ACCGATGGGC
101 CCCCATGAT GGAGGTGTCC ACCATGCTGG CATTGAGGT GGGATACATG
151 GCCATGCTGC TCTTGGCAT CCCGATCATG AAGCAGATGG AGAAGCCTTT
201 TGAGCTCAAG ACCATCAAGC TCTTGCACAA CTGTGTTCTC TTGGACTTT
251 CTTGTACAT GTGCGTGGAG ACCATCCGCC AGGCTATCCT CGGAGGCTAC
301 AAAGTGTGTTG GAAACGACAT GGAGAAGGGC AACGAGTCTC ATGCTCAGGG
351 CATGCTCGC ATGCTGTACG CGTTCACGT GTCCAAGGCA TACGAGTTCT
401 TGGATACCG CATCATGATC CTTTGCAGA AGTTCAACCA GGTTCCTTC
451 TTGCATGTGT ACCACCATGC CACCATTTT GCCATCTGGT GGGCTATCGC
501 CAAGTACGCC CCAGGAGGTG ATGCGTACTT TTCAGTGATC CTCAACTCTT
551 TCGTGACAC CGTCATGTAC GCATACTACT TCTTCTCCTC CCAAGGTTTC
601 GGGTTCGTGA AGCCAATCAA GCCGTACATC ACCACCTTC AGATGACCCA
651 GTTCATGGCA ATGCTTGTGC AGTCTTGTA CGACTACCTC TTCCCATGG
701 ACTACCCACA GGCTCTTGTG CAGCTTCTTG GAGTGTACAT GATCACCTTG
751 CTGGCCCTCT TCGGCAACTT TTTTGTGCAG AGCTATCTTA AAAAGCCAAA
801 AAAGAGCAAG ACCAACTAA

FIG.68

80/102

1 ATGGCAACAG CAGCGTGTGG GATGATGTGG TGGGCCGCGT GGAGACCAGC
51 GTGGACCAAGT GGATGGATGG CGCCAAGCGG TAGGCACTCA CCGATGGGCT
101 CCCGATGATG GAGGTGTCCA CCATGCTGGC ATTCGAGGTG GGATACATGG
151 CCATGCTGCT CTTGGCAGC CCGATCATGA AGCAGATGGA GAAGCCTTTT
201 GAGCTCAAGA CCATCAAGCT CTTGCACAAC TTGTTCTCT TGGGACTTTC
251 CTTGTACATG TGGTGGAGA CCATCGGCA GGTATCTCTC GGAGGCTACA
301 AAGTGTTTGG AAACGACATG GAGAAGGGCA ACGAGTCTCA TGCTCAGGEC
351 ATGTCTCGCA TCGGTACGT GTTCTACGTG TCCAAGGCAT ACGAGTCTT
401 GGATACCGCC ATCATGATCC TTGCAAGAA GTTCAACCAG GTTTCCTTCT
451 TGCAGTGTA CCACCATGCC ACCATTTTGG CCATCTGGTG GGTATCGCC
501 AAGTACGCTC CAGGAGTGA TCGGTACTTT TCAGTGATCC TCAACTCTTT
551 CGTGCACACC GTCATGTAGG CATACTACTT CTCTCCTCC CAAGGTTGG
601 GGTTCGTGAA GCCAATCAAG CCGTACATCA CCAGCCTTCA GATGACCCAG
651 TTCATGGCAA TGCTTGTGCA GTCTTGTAC GACTACCTCT TCCCATGCGA
701 CTACCCACAG GCTCTTGTGC AGCTTCTTGG AGTGTACATG ATCACTTGC
751 TTGCCCTCTT CGGCAACTTT TTTGTGCAGA GCTATCTTAA AAAGCCAAAA
801 AAGAGCAAGA CCAACTAA

FIG. 69

SUBSTITUTE SHEET (RULE 26)

81/102

1 ATGGCAACA GCAGCGTGTG GGATGATGTG GTGGGCCGCG TGGAGACCGG
51 CGTGGACCAAG TGGATGGATG GCCCAAGCC GTACGCACTC ACCGATGGGC
101 TCCCGATGAT GGACGTGTCC ACCATGCTGG CATTGAGGT GGGATACATG
151 GCCATGCTGC TCTCGGCAT CCGATCATG AAGCAGATGS AGAAGCCTTT
201 TGAGCTCAAG ACCATCAAGC TTTGCACAA CTTGTTTCTC TTGGACTTTT
251 CCTTGTACAT GTGCGTGGAG ACCATCCGCC AGGTATCTCT CGGAGGCTAC
301 AAAGTGTTTG GAAACGACAT GGAGAAGGGC AACGAGTCTC ATGCTCAGGG
351 CATGTCTGCG ATCGGTAGC TGTCTACGT GTCCAAGGCA TACGAGTTCT
401 TGGATACCGC CATCATGATC CTTTGAAGA AGTTCAACCA GGTTCCTTC
451 TTGCATGTGT ACCACCATGC CACCGTTTTT GCCATCTGTT GGGCTATCGC
501 CAAGTACGCT CCAGGAGGTG ATGCTACTTT TTAGTGATC CTCAACTCTT
551 TCGTGCACAC CGTCATGTAC GCATCTACT TCTTCTCCTC CCAAGGGTTC
601 GGGTTCGTGA AGCCAATCAA GCGGTACATC ACCACCTTTC AGATGACCCA
651 GTTCATGGCA ATGCTTGTGC AGTCTTGTGA CGACTACCTC TTCCCATGCG
701 ACTACCCACA GGTCTCTGTG CAGCTTCTTG GAGTGTACAT GATCACCTTG
751 CTTGCCCTCT TCGCAACTT TTTTGTGCAG AGCTATCTTA AAAAGCCAAA
801 AAAGAGCAAG ACCAACTAA

FIG. 70

SUBSTITUTE SHEET (RULE 26)

82/102

1 ATGGCAACA GCAGGTGTG GGATGGTGTG GTGGCCGCG TGGAGACCGG
51 CGTGGACCAG TGGATGGATG GCGCAAGCC GTACGCACCTC ACCGATGGGC
101 TCCCGATGAT GGAGGTGTCC ACCATGCTGG CATTGAGGT GGGATACATG
151 GCATGCTGC TCTTCGGCAT CCCGATCATG AAGCAGATGG AGAAGCCTTT
201 TGAAGTCAAG ACCATCAAGC TCTTGACAA CTGTGTTCTC TTGGACTTT
251 CCTTGTACAT GTGGTGGAG ACCATCCGCC AGGCTATCCT CGGAGGCTAC
301 AAGTGTGTTG GAAAGACAT GGAGAAGGCC AACGAGTCTC ATGCTCAGGG
351 CATGTCTCGC ATCGTGTACG TGTTCTAGT GTCCAAGGCA TAGAGTTCT
401 TGGATACCGC CATCATGATC CTTTGCAAGA AGTTCAACCA GGTTCCTTC
451 TTGCATGCGT ACCACCATGC CACCATTTTT GCCATCTGGT GGGCTATCGC
501 CAAGTACGCT CCAGGAGTG ATGGGTACTT TTCAGTGATC CTCAACTCTT
551 TCGTGACAC CGTCATGTAC GCATACTACT TCTTCTCCTC CCAAGGTTTC
601 GGGTTCGTGA AGCCAATCAA GCCGTACATC ACCACCCTTC AGATGACCCA
651 GTTCATGGCA ATGCTTGTGC AGTCTTGTGA CGACTACCTC TTCCCATGGG
701 ACTACCCACA GGCCTTGTG CAGCTTCTTG GAGTGTACAT GATCAGCTTG
751 CTGGCCCTCT TCGGCAACTT TTTTGTGCAG AGCTATCTTA AAAGCCAAA
801 AAAGAGCAAG ACCAACTAA

FIG.71

83/102

1 ATGGCAACA GCAGGTGTG GGATGATGTG GTGGCCGCG TGGAGACCGG
51 CGTGGACCAG TGGATGGATG GCGCAAGCC GTACGCACCTC ACCGATGGGC
101 TCCCGATGAT GGAGGTGTCC ACCATGCTGG CATTGAGGT GGGATACATG
151 GCATGCTGC TCTTCGGCAT CCCGATCATG AAGCAGATGG AGAAGCCTTT
201 TGAAGTCAAG ACCATCAAGC TCTTGACAA CTGTGTTCTC TTGGACTTT
251 CCTTGTACAT GTGGTGGAG ACCATCCGCC AGGCTATCCT CGGAGGCTAC
301 AAGTGTGTTG GAAAGACAT GGAGAAGGCC AACGAGTCTC ATGCTCAGGG
351 CATGTCTCGC ATCGTGTACG TGTTCTAGT GTCCAAGGCA TAGAGTTCT
401 TGGATACCGC CATCATGATC CTTTGCAAGA AGTTCAACCA GGTTCCTTC
451 TTGCATGTTT ACCACCATGC CACCATTTTT GCCATCTGGT GGGCTATCGC
501 CAAGTACGCT CCAGGAGTG ATGGGTACTT TTCAGTGATC CTCAACTCTT
551 TCGTGACAC CGTCATGTAC GCATACTACT TCTTCTCCTC CCAAGGTTTC
601 GGGTTCGTGA AGCCAATCAA GCCGTACATC ACCACCCTTC AGATGACCCA
651 GTTCATGGCA ATGCTTGTGC AGTCTTGTGA CGACTACCTC TTCCCATGGG
701 ACTACCCACA GGCCTTGTG CAGCTCTTGG GAGTGTACAT GATCAGCTTG
751 CTGGCCCTCT TCGGCAACTT TTTTGTGCAG AGCTATCTTA AAAGCCAAA
801 AAAGAGCAAG ACCAACTAA

FIG.72

84/102

85/102

1 ATGGCAACA GCAGCGTGTG GGATGATGTG GTGGCGCGG TGGAGACCGG
51 CGTGGACCAG TGGATGGATG GCGCAAGCC GTACGCACTC ACCGATGGG
101 TCCGATGAT GGACGTGTCC ACCATGCTGG CATTGAGGT GGGATACATG
151 GCCATGCTGC TCTCGGCAT CCCGATCATG AGCAGATGG AGAAGCCTTT
201 TGAGCTCAAG ACCATCAAGC TCTTGCAAA CTTGTTCTC TTCGGACTTT
251 CCTTGTACAT GTGCGTGGTG ACCATCCGCC AGGCTATCCT TGGAGGCTAC
301 AAAGTGTTTG GAAACGACAT GGAGAAGGSC AAGGAGTCTC ATGCTCAGGG
351 CATGTCTCGC ATCGTGTACG TGTCTACGT GTCCAAGGCA TACGAGTTCT
401 TGGATACCGC CATCATGATC CTTTGAAGA AGTCAACCA GGTTCCTTC
451 TTGCATGTGT ACCACCATGC CACCATTITT GCCATCTGGT GGGCTATCGC
501 CAAGTAGGCT CCAGGAGGTG ATGCGTACTT TTCAGTGATC CTCAACTCTT
551 TCGTGACAC CGTCATGTAC GCATACTACT TCTTCTCCT CCAAGGGTTC
601 GGGTTGTTGA AGCCAATCAA GCGGTACATC ACCACCTTC AGATGACCCA
651 GTTCATGGCA ATGCTTGTGC AGTCTTGTGA CGACTACCTC TTCCCATGGC
701 ACTACCCACA GGTCTTGTG CAGCTTCTTG GAGTGTACAT GATCACCTTG
751 CTGGCCCTCT TCGGCACTT TTTTGGCAG AGCTATCTTA AAAAGCCAAA
801 AAAGAGCAAG ACCAACTAA

FIG.73

1 MANSSVDDV VGRVETGVQQ WMDGAKPYAL TDGLPMWDVS TMLAFEVGYM
51 AMLLFGIPIM KOMEKPFELK TIKLHLNLF FGLSLYMCVE TIRQAILGGY
101 KVFQNDMEKG NESHAQGHSR IVVYFCVSKA YEFDTATMT LCKKFNQVSF
151 LHVYHATIF AIWMAIAKYA PGDAYFSVI LNSFVHTVMY AYYFFSSQGF
201 GFVKPIKPYI TTLQMTQFMA MLVQSLYDYL FPCDYPQALV QLLGWYMITL
251 LALFENFFVQ SYLKKPKKSK TN*

FIG.74

86/102

87/102

1 MANSSVDDV VGRVETGVDQ WMDGAKPYAL TDGPPMDVS TMLAFEVGYM
51 AMLFGIPIM KQMEKPFELK TIKLLHNLFL FGLSYMCVE TIRQATLGYY
101 KIVFGNDMEKG NESHAQMSR IYAFYWSKA YEFLDTAIMI LCKKFNQVSF
151 LHVYHHATIF AIWMAIAKYA PGEDAYFSVI LNSFVHTVMY AYYFSSQGF
201 GFVKPIKPYI TTLQMTQFMA MLVOSLYDYL FPCDYPQALV QLLGVYMITL
251 LALFGNFFVQ SYLKKPKKSK TN*

FIG.75

1 MATAACGMMW WAAWRPAMTS GMMAPSRTHS PMGSR*WTCB PQWHSRWDTW
51 PCCSSASRS* SRMRSLLSSR PSSSCTTCFS SDFPCTCAMR PSARLSSEAT
101 KCLETTWRA TSLMLRACLA SCTCSTCPRH TSSWIPPS*S FARSSSTREPS
151 CKCTTNPPFL PSGGLSPSTL QEVMRTFQ*S STLCTPSCT HTTSSPPKGS
201 GS*SQSSRTS PPFR*PSSMQ CLCSPCTTS SHATTHRLLC SFLECT*SPC
251 LPSSATFLCR AILKSQKRAR PT

FIG.76

88/102

1 MANSSWDDV VGRVETGVDQ WMDGAKPYAL TDGLPMDVS TMLAFEVGYM
51 AMLLFGIPIM KQMEKPFELK TIKLLHNLFL FGLSLYMCVE TIRQAILGGY
101 KVFNDMEKG NESHAQHSR IYVYFYVSKA YEFLOTAIMI LCKKFNQVSF
151 LHVYHHATVF AIMMAIAKYA PGDAYFSVI LNSFVHTVMY AYYFFSSQGF
201 GFVKPIKPYI TTLQMTQFMA MLVQSLYDYL FPCDYPQALV QLLGYVMITL
251 LALFGNFFVQ SYLKKPKKSK TN*

FIG.77

89/102

1 MANSSWDDGV VGRVETGVDQ WMDGAKPYAL TDGLPMDVS TMLAFEVGYM
51 AMLLFGIPIM KQMEKPFELK TIKLLHNLFL FGLSLYMCVE TIRQAILGGY
101 KVFNDMEKG NESHAQHSR IYVYFYVSKA YEFLOTAIMI LCKKFNQVSF
151 LHAYHHATIF AIMMAIAKYA PGDAYFSVI LNSFVHTVMY AYYFFSSQGF
201 GFVKPIKPYI TTLQMTQFMA MLVQSLYDYL FPCDYPQALV QLLGYVMITL
251 LALFGNFFVQ SYLKKPKKSK TN*

FIG.78

90/102

1 MANSSWDDV VGRVETGVDQ WMDGAKPYAL TDGLPMDVS TMLAFEVGYM
51 ANLLFGIPIM QMEKPFELK TIKLLHNLFL FGLSLYMCVE TIRQAILGGY
101 KVFGNDMEKG NESHAGMSR IVYFYVSKA YEFLDTAIMI LCKKFNQVSF
151 LHVYHHATIF AIWMAIAKYA PGDAYFSVI LNSFVHTVMY AYYFSSQGF
201 GFVKPIKPYI TTLQMTQFMA MLVQSLYDYL FPCDYPQALV QLLGVYMITL
251 LALFGNFFVQ SYLKKPKKSK TN*

FIG.79

91/102

1 MANSSWDDV VGRVETGVDQ WMDGAKPYAL TDGLPMDVS TMLAFEVGYM
51 ANLLFGIPIM QMEKPFELK TIKLLHNLFL FGLSLYMCVW TIRQAILGGY
101 KVFGNDMEKG NESHAGMSR IVYFYVSKA YEFLDTAIMI LCKKFNQVSF
151 LHVYHHATIF AIWMAIAKYA PGDAYFSVI LNSFVHTVMY AYYFSSQGF
201 GFVKPIKPYI TTLQMTQFMA MLVQSLYDYL FPCDYPQALV QLLGVYMITL
251 LALFGNFFVQ SYLKKPKKSK TN*

FIG.80

95/102

PRAT-4-A1 189 MYAYYFFSSQGFFVKPIKPYITTLQMTQFMAMLVQSLYDYLFPCDY 235
PRAT-4-A2 189 MYAYYFFSSQGFFVKPIKPYITTLQMTQFMAMLVQSLYDYLFPCDY 235
PRAT-4-A4 189 MYAYYFFSSQGFFVKPIKPYITTLQMTQFMAMLVQSLYDYLFPCDY 235
PRAT-4-A6 189 MYAYYFFSSQGFFVKPIKPYITTLQMTQFMAMLVQSLYDYLFPCDY 235
PRAT-4-A7 189 MYAYYFFSSQGFFVKPIKPYITTLQMTQFMAMLVQSLYDYLFPCDY 235
PRAT-4-D1 189 MYAYYFFSSQGFFVKPIKPYITTLQMTQFMAMLVQSLYDYLFPCDY 235
PRAT-4-A1 236 PQALVQLLGVYMITLLALFGNFFVQSYLKKPKKSKTN 272
PRAT-4-A2 236 PQALVQLLGVYMITLLALFGNFFVQSYLKKPKKSKTN 272
PRAT-4-A4 236 PQALVQLLGVYMITLLALFGNFFVQSYLKKPKKSKTN 272
PRAT-4-A6 236 PQALVQLLGVYMITLLALFGNFFVQSYLKKPKKSKTN 272
PRAT-4-A7 236 PQALVQLLGVYMITLLALFGNFFVQSYLKKPKKSKTN 272
PRAT-4-D1 236 PQALVQLLGVYMITLLALFGNFFVQSYLKKPKKSKTN 272

FIG.82B

94/102

PRAT-4-A1 48 GYAMALLFGIPIMKQMEKPFELKTIKLLHNLFLFLGSLYMCVETIRQ 94
PRAT-4-A2 48 GYAMALLFGIPIMKQMEKPFELKTIKLLHNLFLFLGSLYMCVETIRQ 94
PRAT-4-A4 48 GYAMALLFGIPIMKQMEKPFELKTIKLLHNLFLFLGSLYMCVETIRQ 94
PRAT-4-A6 48 GYAMALLFGIPIMKQMEKPFELKTIKLLHNLFLFLGSLYMCVETIRQ 94
PRAT-4-A7 48 GYAMALLFGIPIMKQMEKPFELKTIKLLHNLFLFLGSLYMCVETIRQ 94
PRAT-4-D1 48 GYAMALLFGIPIMKQMEKPFELKTIKLLHNLFLFLGSLYMCVETIRQ 94
PRAT-4-A1 95 AILGGYKVF GNDMEKGNESHAGMSRIYVAFVSKAYEFLDTAIMIL 141
PRAT-4-A2 95 AILGGYKVF GNDMEKGNESHAGMSRIYVAFVSKAYEFLDTAIMIL 141
PRAT-4-A4 95 AILGGYKVF GNDMEKGNESHAGMSRIYVAFVSKAYEFLDTAIMIL 141
PRAT-4-A6 95 AILGGYKVF GNDMEKGNESHAGMSRIYVAFVSKAYEFLDTAIMIL 141
PRAT-4-A7 95 AILGGYKVF GNDMEKGNESHAGMSRIYVAFVSKAYEFLDTAIMIL 141
PRAT-4-D1 95 AILGGYKVF GNDMEKGNESHAGMSRIYVAFVSKAYEFLDTAIMIL 141
PRAT-4-A1 142 C K K F N Q V S F L H V Y H H A T I F A I W M A I A K Y A P G G D A Y F S V I L N S F V H T V 188
PRAT-4-A2 142 C K K F N Q V S F L H V Y H H A T I F A I W M A I A K Y A P G G D A Y F S V I L N S F V H T V 188
PRAT-4-A4 142 C K K F N Q V S F L H V Y H H A T I F A I W M A I A K Y A P G G D A Y F S V I L N S F V H T V 188
PRAT-4-A6 142 C K K F N Q V S F L H V Y H H A T I F A I W M A I A K Y A P G G D A Y F S V I L N S F V H T V 188
PRAT-4-A7 142 C K K F N Q V S F L H V Y H H A T I F A I W M A I A K Y A P G G D A Y F S V I L N S F V H T V 188
PRAT-4-D1 142 C K K F N Q V S F L H V Y H H A T I F A I W M A I A K Y A P G G D A Y F S V I L N S F V H T V 188

FIG.82A

96/102

```

SCORES      Init1: 259      Initn: 259      Opt: 509      Z-score: 86.5      E(): 0.28
>>EN:HSEL01      in1tn: 259      in1t: 259      opt: 509      Z-score: 86.5      expect(): 0.28
Smith-Waterman score: 511:      34.0% identity in 255 aa overlap
(4-265:9-257)

```

[illegible]

TELO1
GIPIKQMEKPFELTKILKLHNLFLGLSLVMCVETIRQATLGGYVFGNDMEKGNSHA

HSEL01
GPKYNRN-KQPFCRGLVYVNLGLTLLSLMYMCELVGWMEGYNFFCCGTTRTAGESDM

[illegible]

	180	190	200	210	220	230
TELO1	YFSVTLNSFVHTWYAYYFFSQSGFGVKP	I---KPYITTLQTFNAMLVQSLVDYLP				
HSELO1	YFGATLNSFTHVLWYSYGLSS---	VPSNRPLYLWKKYITQGQLQFLVLT	TIQTSCGVTP			

[illegible]

FIG. 83

97/102

SCORES Init1: 278 Initn: 278 Opt: 515 Z-score: 86.1 E(): 0.3
 >>EN:MELO4
 Smith-Waterman score: 517; 34.1% identity in 267 aa overlap
 (8-270:16-265)

TELO1 MANSSWDVGVGVETGVQWDGAKPVALTDGLPMNDVSTHLAFEVGYNAM
MELO4 MEQLKAFQNEVNAFLDNMFGRDPSVRGM.....FLDLSYLP-----FILTITYLLS

TELO1
LLFGPIPKQWEKP-FELKTIKLLHNLFLGLSLNYCVETTRQAILGGYKVFQNDWEKGN 60 70 80 90 100 110

MELO4
IWLGNKYKNK-RPALSRLGILTLNYLAITLLSAYMLVELTSSWEGGYNLCQNLDSAG 50 60 70 80 90 100

	120	130	140	150	160	170
TELO1	ESHAQGRSIVVYFYYSKAYEFLDTAIMLCKKNQVSFLHVYHHATIFAINWATAKYAP					
	:	:	:	:	:	:
MEL04	EDGVR-VAKVLWNYYFSKLVEEFLTIFFVLRRKTQTITFLHVYHHASMFNIMCVLNWIP					
	:	:	:	:	:	:

	180	190	200	210	220
TELO1	GGDAYFSYLNSFVHTVMYYFFSSQGFVKPI...	KPVITTLQMTQMAMLVQSLYD			
MEL04	I::: I::: I::: I::: I::: I::: I::: I:::	I::: I::: I::: I::: I::: I::: I::: I:::			
	CQGSGFGPTLNSFIHILWYSYGLSV..PFSHHKYLMMKKYLTOAQLVQFVLTIHTLSA				
	170	180	190	200	210
					220

TELO1
YLFPCDYPQALVQLLGGVYMITLLALFGNFFVQSYLKKPKKSKTXNXCNCLHMPLAGVRIDS
230 233 236 239 242 245 248 251 254 257 260 263 266 269 272 275 278 280

MEL04
VKVKGPFPGCLFQSSYMMTLVTLFLNFYITQTRKPKVKKELOEKVKNKGFPAHLIVA
230 233 236 239 242 245 248 251 254 257 260 263 266 269 272 275 278 280

FIG. 84

98/102

SCORES Initl: 412 Initn: 541 Opt: 628 Z-score: 102.7 E(): 0.035
>>EN:GLELO
Initn: 541 Initl: 412 opt: 628 Z-score: 102.7 expect(): 0.035
Smith-Waterman score: 628; 43.4% identity in 244 aa overlap
(34-272:69-308)

TELO1	SSVNDVVGRTGVQMDGAKPYALTGGLPMNDVSTMLAFEVGYMALLFGIPINQKM	10	20	30	40	50	60
GLELO	LVAQAEKYIPTIVHTRGFLVAVESPLAREPLMNPHVLLIVLVTVFVQIKNF	40	50	60	70	80	90
TELO1	EKFELTKTIKLLHNLFLFGLSLYMCVETIROATLGGYKVFQNDMEKGNESHQAQKSRIVY	70	80	90	100	110	120
GLELO	ER-FEVKTFSLLHNFCLVSIYAMCGGILVEAYQANYGLFENAAD--HTFKGLPMAKNIW	100	110	120	130	140	150
TELO1	VFYYSKAYEFLDTAIMILCKFNQVSFLHYVHHATIFAIMAIKAYAPGGDAYFSVLNS	130	140	150	160	170	180
GLELO	LFYFSKIMEFVDTMIWLVKNNRQISFLHYHSSIFTIMLVTFVAPNGEAYFSAALNS	160	170	180	190	200	210
TELO1	FWHTVMYAYFFSSQGFGEVFKPKPYITTLQMTQFMALVQSLYO-YLFFPC-...DYPQA	190	200	210	220	230	
GLELO	FIHVIMYGYFLSALGFKQVSFKFYITRSQMTQFCMMSVQSSMDWYAMKYLGRGPFF	220	230	240	250	260	270
TELO1	LVQLLGVMYITLLALFGNFFVQSYLKKPKKSKTNXNCLHDMPLAGVRIDSESELRRHANS	240	250	260	270	280	290
GLELO	ITALLWFYMTMLGLFYNFYRKNA-KLAKQAKADAKEKARKLQ	280	290	300	310		

FIG.85

SUBSTITUTE SHEET (RULE 26)

99/102

SCORES Initl: 94 Initn: 220 Opt: 302 Z-score: 61.6 E(): 6.5
>>EN:CEELO
Initn: 220 Initl: 94 opt: 302 Z-score: 61.6 expect(): 6.5
Smith-Waterman score: 312; 34.3% identity in 239 aa overlap
(49-270:54-278)

TELO1	DQMDGAKPYALTGGLPMNDVSTMLAFEVGYMALLFGIPINQKMEKPFELTKL-LHN	20	30	40	50	60	70
CEELO	ATHGPKNFPDAGRKKFFADHFDVTIQASILYM-VVVFQKMFMRNRQPFQL-TIPLNIW	30	40	50	60	70	80
TELO1	LFLFGLSLYMCVE-----TI-RQATLGGY-KVFGNDMEKGNESHQAQKSRIVYVFWYS	80	90	100	110	120	
CEELO	FILAAFSIAGAVKMTPEFFGTIANKGIVASYCKVF--DFTKGENGYM-----VWLFMAS	90	100	110	120	130	
TELO1	KAYEFLDTAIMILCKFNQVSFLHYVHHATIFAIMAIKAYAPGGDAYFSVLNSFVHTV	130	140	150	160	170	180
CEELO	KLFEVDITFLVLRKR--PLMFLHMYHHILMTIYAWYSHPLTPGNRY-GIYLNFWHAF	140	150	160	170	180	190
TELO1	MYAYYFSSQGFGEVFKPKPYITTLQMTQFM---AMLVQSLYDYLFP---CDYPQALVQL	190	200	210	220	230	240
CEELO	MYSYFRLSRWKIRVPGFTAQAITSLQIVQFIISCAVLHGLYLMHFTNANDCFEPSFKL	200	210	220	230	240	250
TELO1	LGVMY-ITLLALFGNFFVQSYLKKPKKSKTNXNCLHDMPLAGVRIDSESELRRHANSIFF	250	260	270	280	290	300
CEELO	-AVFMDTTYLALFVNFFLQSYVLGGKQKYKAVPKKKN	260	270	280			

FIG.86

SUBSTITUTE SHEET (RULE 26)

334(PLASMID)	pRAT-4-A4	pRAT-4-A6	pRAT-4-A7	pRAT-4-D1	pYX242	pRAT-4-A4	pRAT-4-A6	pRAT-4-A7	pRAT-4-D1	pYX242	pRAT-4-A4	pRAT-4-A6	pRAT-4-A7	pRAT-4-D1	pYX242
ADDED SUBSTRATE	GLA	GLA	GLA	GLA	GLA	AA	AA	AA	AA	AA	STA	STA	STA	STA	STA
% TOTAL LIPID															
C16:1n-7	36.29	39.18	38.58	38.84	45.68	30.36	35.19	33.47	33.70	45.06	34.43	39.63	38.03	38.74	45.94
C18:0	2.78	3.13	2.73	3.05	1.76	2.51	2.78	2.56	2.72	1.65	4.01	3.13	3.06	3.76	1.82
C18:1n-9	15.89	16.55	15.92	16.34	13.23	14.60	15.14	15.39	15.26	13.01	16.05	16.51	17.37	19.07	14.10
C18:1w7	5.91	2.01	3.44	2.06	0.93	5.72	1.94	3.75	2.22	1.03	4.92	1.78	3.78	2.52	0.95
C18:3w6	2.10	1.96	1.60	2.19	5.29										
C18:4w3											0.83	0.88	0.53	1.09	3.42
C20:3w6	4.56	4.23	5.42	3.88					0.04						
C20:4w6						16.53	13.61	14.21	17.13	7.54					
C20:4w3											2.27	3.25	3.95	4.01	0.06
C22:4w6						0.57	0.20	0.75	0.18						
C22:4n-3											1.10	0.19	0.63	0.16	
% CONVERSION* OF C18	68.4%	68.4%	77.2%	64.0%							80.3%	79.6%	89.7%	79.3%	
% CONVERSION* OF C20						3.4%	1.5%	5.0%	1.0%		32.6%	5.5%	13.8%	3.8%	

100/102

FIG.87A

334(PLASMID)	pRAT-4-A4	pRAT-4-A6	pRAT-4-A7	pRAT-4-D1	pYX242	pRAT-4-A4	pRAT-4-A6	pRAT-4-A7	pRAT-4-D1	pYX242
ADDED SUBSTRATE	EPA	EPA	EPA	EPA	EPA	NONE	NONE	NONE	NONE	NONE
% TOTAL LIPID										
C16:1w7	31.51	33.92	34.31	34.74	47.12	39.54	41.51	41.44	43.02	46.45
C18:0	2.76	3.09	2.78	2.77	1.79	2.45	3.21	2.59	3.07	2.05
C18:1w9	15.69	15.79	16.49	15.22	13.95	18.56	19.08	17.98	18.80	14.03
C18:1w7	6.07	1.97	3.72	1.89	1.05	8.77	2.57	4.86	2.77	1.07
C20:1w7	0.22	0.08	0.13	0.07		0.61	0.07	0.14	0.07	
C20:5w3	11.88	15.20	11.32	13.91	6.41					
C22:5n-3	1.49	0.54	1.74	0.54						
% CONVERSION*	11.1%	3.4%	13.3%	3.7%						

101/102

*% CONVERSION=PRODUCT/(SUBSTRATE+PRODUCT)

FIG.87B

SUBSTITUTE SHEET (RULE 26)

334(PLASMOD)	pYX242	pRAT-4-A7	pYX242	pRAT-4-A7	pYX242	pRAT-4-A7	pYX242	pRAT-4-A7	pYX242	pRAT-4-A7	pYX242	pRAT-4-A7	pYX242	pRAT-4-A7	pYX242	pRAT-4-A7
ADDED SUBSTRATE	LA	LA	ALA	ALA	GLA	GLA	STA	STA	DGLA	DGLA	ETA	ETA	AA	AA	EPA	EPA
	% TOTAL UPID															
C16:1n-7	38.73	27.71	39.05	26.97	35.28	30.13	34.75	30.95	35.96	28.51	34.91	31.45	34.71	24.76	40.02	24.75
C16:1n-5	0.37	0.17	0.32	0.20	0.25	0.21	0.27	0.18	0.33	0.22	0.31	0.21	0.32	0.20	0.40	0.21
C18:0	2.21	2.80	2.14	3.27	2.12	3.14	2.44	3.28	2.15	2.86	2.55	3.52	2.42	2.71	2.75	3.26
C18:1n-9	11.14	12.79	11.73	15.73	10.14	14.24	11.13	14.79	11.17	14.59	11.33	16.32	11.63	13.85	12.86	15.99
C18:1n-7	0.85	3.19	0.73	3.84	0.64	3.31	0.78	3.01	0.96	3.71	0.95	3.89	1.06	3.49	1.11	3.87
C18:2n-6	3.04	3.54														
C18:3n-6					4.49	1.59										
C18:3n-3			3.55	3.56												
C18:4n-3							3.09	0.85								
C20:1n-7		0.10		0.09		0.24		0.24		0.09		0.10		0.22		0.27
C20:2n-6		1.07								0.08						
C20:3n-6						5.84			9.08	14.13				0.06		
C20:4n-6													14.60	20.89		
C20:3n-3				2.71						0.10						
C20:4n-3								4.19			5.06	8.49				
C20:5n-3											0.16	0.25			6.47	15.32
C22:4n-7				0.11	0.19	0.14	0.18	0.13	0.14	0.13	0.24	0.14	0.22		0.27	
C22:4n-6														0.76		
C22:4n-3								0.74				1.04				
C22:5n-3																1.99
% CONVERSION* OF C18	23.2%		43.3%		78.6%		85.3%									
% CONVERSION OF C20							15.0%				10.9%		3.5%		11.5%	

*% CONVERSION=PRODUCT/(SUBSTRATE+PRODUCT)

FIG.88

102/102

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.